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Abstract 
	  
Blastic plasmacytoid  dendritic cel  neoplasm (BPDCN) is an incurable malig- 
nancy for which disease mechanisms are unknown. Here, we identify the NR3C1 gene 
(5q31), encoding the glucocorticoid receptor (GCR), and a long, intergenic, non-coding 
RNA gene (named here lincRNA-3q), respectively, as targets for genetic alteration or 
transcriptional deregulation in BPDCN. NR3C1 translocation/deletion was associated 
to criticaly short survival in  BPDCN and to abnormal activity  of  GCR,  EZH2, and 
FOXP3 gene regulatory networks. LincRNA-3q, was found to encode a nuclear, non- 
coding RNA that is ectopicaly activated in BPDCN and high-risk AML. Depletion of 
lincRNA-3q in myeloid cancer cels induced cel cycle arest, coincident to suppression 
of E2F1/Rb and leukemia stem cel-specific gene expression signatures. BET bromod- 
omain protein inhibition could selectively suppress lincRNA-3q indicating a treatment 
strategy for counteracting oncogenic activity of this non-coding RNA. Thus, this work 
defines a new framework for understanding disease pathogenesis and treatment resis- 
tance in BPDCN. 
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Chapter 1   
Dendritic cels 
1.1 Hematopoiesis - General principles 
	  
	  
Blood cels are divided into three lineages erythroid (erythrocytes), lymphoid (B and 
T cels), and myeloid (granulocytes, megakaryocytes, and macrophages).  These cels 
are produced and constantly regenerated in the bone marow from  hematopoietic stem 
cels (HSCs) through a series  of progenitor stages (by a  process caled 
hematopoiesis) (Figure  1).  The curent “deterministic  model” for  hematopoiesis 
proposes that  Long- Term-Hematopoietic Stem  Cels (LT-HSCs)  which  display a 
unique ability for life-long self-renewal give rise to Short-Term-Hematopoietic Stem 
Cels (ST-HSCs), which produce multipotential progenitors (MPPs) that have lost al 
self-renewal potential but are stil able to  generate al  hematopoietic lineages.  From 
these derive the common lymphoid progenitors (CLPs), which give rise to T, B, NK 
and certain  dendritic cel (DC) cel subsets, and common  myeloid progenitors 
(CMPs)(which give rise to granulocyte/macrophage  progenitors (GMPs), 
megakaryocyte/erythroid progenitors (MEPs), mast cel and basophil progenitors. This 
process is tightly controled by lineage and differentiation stage specific 
transcription factors that  modulate gene expression  programs to 
permanently  generate the corect  number  of specific cel types at a  given time and 
place.  
 
1 
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FIGURE 1: Hierarchical model of hematopoiesis in the adult bone marow. From 
(Wang et Wagers, Nat Rev Mol Cel Biol, 2011) 
	  
	  
A comprehensive analysis  of the  molecular control and the precise interplay of 
these cell fate  decisions are crucial for a ful  understanding  of  normal and 
malignant hematopoiesis (Rieger and Schroeder, 2012).  Disruptions of these cel fate 
decisions underlie hematological disorders including blood cancers. 
	  
	  
	  
1.2 Dendritic cel lineage 
	  
	  
Dendritic cels (DCs) were first described in 1973 by Ralph M. Steinman and Zanvil 
A. Cohn (Steinman and Cohn, 1973).  DCs are antigen-presenting cels (APCs) of the 
mammalian immune system and they play a critical role in the regulation of the adap- 
tive immune response. These cels are recognized as the  most important  APCs with 
the ability to migrate in lymphatic system and to prime naive T cels in secondary lym- 
phoid organs (SLOs) (Banchereau and Steinman, 1998). Therefore, they constitute a 
front-line  defense against invading  pathogens.  DCs are located throughout the  body 
and form a sophisticated and complex network that alows them to communicate with 
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diferent populations of lymphocytes, thereby forming an interface between the external 
environment and the adaptive immune system (Belz and Nut, 2012). 
	  
	  
	  
1.3 Dendritic Cel development 
	  
In the bone marow (BM) a fraction of CMP expresses FMS-related tyrosine kinase 3 
(FLT3) and diferentiates into more-restricted macrophage and DC progenitors (MDPs). 
MDPs are thought to be the direct precursor to common DC progenitors (CDPs) and 
give rise to the DC lineages. CDPs produce precursor DCs (pre-DCs) and plasmacytoid 
DCs (pDCs), which then exit the bone marow and travel through the blood and migrate 
toward the secondary lymphoid organs and non-hematopoietic tissues.  A limited pro- 
portion of DCs may also derive from CLPs in the bone marow and from early T cel 
progenitors in the thymus (Belz and Nut, 2012).  The only subsets found in the spleen 
are lymphoid tissue-resident  DCs, which under steady-state conditions arise from 
pre-DCs.  This population is composed  of three conventional DC subsets,  namely 
cluster  of diferentiation  4+ (CD4+)  DCs, CD8α+ DCs and CD8α−CD4− double-
negative (DN) DCs (Figure 2). 
Peripheral lymph nodes contain CD8α+ and CD8α− DC populations but are also 
populated by two groups of migratory DCs; the dermal DC population which is broadly 
composed of CD11b+ and CD103+ DCs, and, migrate through the lymphatic to the 
lymph node and Langerhans cels that develop in the epidermis and migrate through the 
basement membrane to the lymph nodes via terminal lymphatic vessels that arise in the 
dermis. Monocytes arive at tissues from the blood and in response to inflammation 
they can develop into monocyte-derived DCs, which adopt many of the characteristics 
of conventional DCs (Figure 2). 
	  
In order to provide their protective function, specialized DCs subsets have evolved 
and this segregation was initialy based on their distinct paterns of cel-surface molecule 
expression. 
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FIGURE 2: Organization of the dendritic cel (DC) network and key surface pheno- 
type markers of different DC subsets, delineated on the basis of their localization in 
secondary lymphoid tissues. From (Belz and Nut, Nat Rev, Immunol, 2012) 
	  
	  
Diferent subsets of DCs are composed of: plasmacytoid DCs (pDCs), conven- 
tional DCs (cDCs), monocyte-derived inflammatory DCs and Langerhans cels (LCs) 
(Belz and Nut, 2012). 
	  
	  
	  
1.4 Dendritic Cel Subsets 
	  
	  
1.4.1 Plasmacytoid Dendritic Cels 
	  
	  
Plasmacytoid dendritic cels (pDCs) are quiescent cels that are broadly distributed in 
the body. From their initial identification as “lymphoblasts” by Lennert and Remmele in 
1958 (Lennert and Remmele, 1958), pDCs were given a number of diferent names that 
suggested a possible cel origin and were exclusively based on their immunophenotype 
(e.g., plasmacytoid  T cels, plasmacytoid monocytes) (Faccheti et al.,  1988). Under 
physiological conditions, pDCs present plasma-like cel morphology, but once activated 
a radical morphological transformation occurs; the round plasmacytoid cels acquire a 
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typical dendritic morphology (from the Greek word dendron, for ’tree’) that is tightly 
associated with the specialized efector functions  of DC in  T cel stimulation (Naik 
et al., 2005). 
pDCs account for <0.1% of peripheral blood mononuclear cels and accumulate 
in inflammatory sites to contribute to inflammatory and immune response.  pDCs are 
characterized as Lin− MHC-I+ CD123 (IL3R)+ CD4+ CD303(BDCA2)+ CD304(BD- 
CA4;  Neuropilin-1)+ and are known for their capacity for type  1 interferon alpha 
and beta (IFN α	  and β	  ) secretion folowing  viral infection  by signaling through the 
nu- cleic acid-sensing Tol-like receptor  7 (TLR7) and  TLR9 (TLR7/9) (Mathan et 
al., 2013). They are also known for their antigen presentation capacity (Ginhoux et 
al., 2009,  Sasaki et al.,  2012),  which is  of increasing interest for anti-tumoral 
vaccination strategies. 
	  
They express several other characteristic markers, including sialic acid-binding 
immunoglobulin-like lectin H (SIGLEC-H) and bone marow stromal antigen 2 (BST2) 
in mice and  blood DC antigen  2 (BDCA2; also known as  CLEC4C) and leukocyte 
immuno-globulin-like receptor, member 4 (LILRA4; also known as ILT7) in humans 
(Belz and Nut, 2012).  Other surface markers, such as maturation markers appear on 
mouse  pDC as they  mature in  bone marow and in the  peripheral tissues.  Such 
markers include Ly6C (Vremec et al., 2007), Ly49Q (Toyama-Sorimachi et al., 2005), 
CD4, and CD8 (O’Keefe et al., 2002).  Human pDCs are usualy distinguished from 
other DC by the lack of expression of CD11c (Dzionek et al., 2000). 
More recently, a subset of normal pDCs were shown to express CD56, a minor 
subpopulation of Lin− DR+ CD56+ CD123+ CD11c− cels were designated as pDC- 
like cels (pDLCs). These cels constitute 0.03% of peripheral blood mononuclear cels 
(PBMCs), and express BDCA2, BDCA4, and myeloid antigens, which are frequently 
expressed  by the  malignant counterpart  of  pDC (BPDCN).  pDLCs exhibited  modest 
expression of Tol-like receptors and produced less interferon-α	  after CpG stimulation 
(Osaki et al., 2013). 
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1.4.2 Conventional Dendritic Cels 
	  
Conventional DCs (cDCs) specialized for antigen processing and presentation.  Based 
on their localization in tissues and their  migratory pathways, cDCs can  be  grouped 
into two main classes.  The first category of conventional DCs is generaly refered to 
as the migratory DCs, which develop from early precursors in the peripheral tissues, 
where they act as antigen-sampling sentinels, and then they migrate from the peripheral 
tissues to the lymph nodes.  Migratory DCs can be broadly divided into CD11b+ DCs 
(also known as dermal or interstitial DCs) and CD11b− DCs, which have more recently 
been shown to express CD103 (also known as integrin αE). 
Lymphoid tissue-resident DCs are the second major category of conventional DCs 
that are found in the  major lymphoid  organs, such as the lymph  nodes, spleen and 
thymus. They can  be classified  by their expression  of the surface markers; CD8α+ 
DCs are noted for their major role in priming cytotoxic CD8+ T cel responses, CD4+ 
DCs and CD4−CD8α− DCs can also present major histocompatibility complex (MHC) 
class I-restricted antigens and more efficiently present MHC class I-associated antigens 
to CD4+ T cels (Belz and Nut, 2012). 
	  
	  
	  
1.4.3 Inflammatory Monocytes 
	  
During inflammation, circulating blood monocytes can be rapidly mobilized and can 
diferentiate into cels that possess many prototypical features of DCs, this subset has 
been described as inflammatory DCs. These cels arise from MDP and are recruited to 
the site of inflammation where they can present antigens to both CD4+ and CD8+ T 
cels (Leon et al., 2007). 
	  
	  
Similar to macrophages these cels express a number of markers including macrop- 
hage colony-stimulating factor receptor (M-CSFR) (or  CD115),  which is expressed 
in monocytes-macrophages and their progenitors, and drives growth and development 
of this blood cel lineage (Bourete and Rohrschneider, 2000), and respond to growth 
factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) (Segura 
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et al., 2013). GM-CSF is an important hematopoietic growth factor and immune mod- 
ulator, which is produced localy by T cels, macrophages, endothelial cels and fibrob- 
lasts  upon receiving immune stimuli and it can act in a  paracrine fashion to recruit 
circulating neutrophils, monocytes and lymphocytes to enhance their functions in host 
defense (Shi et al., 2006). 
	  
	  
1.4.4 Langerhans Cels 
	  
	  
These cels are skin-resident subset  of  DCs and arise from a  bone marow-derived 
myelomonocytic precursor that migrates to the lymph nodes to present antigens. They 
share similarities with  macrophages in their  gene expression  profiles and are devel- 
opmentaly dependent on signaling through the macrophage colony-stimulating factor 
receptor (Miler et al.,  2012).  When activated, however,  LCs acquire features  more 
in line with cDCs such as their migratory ability and they also share the cDC specific 
transcription factors (Meredith et al., 2012). 
These diferent populations of DC arise from common lymphoid progenitor (CLP) 
in the  bone marow and are restricted to  macrophage-DC  progenitors (MDPs).  The 
MDP is a common precursor that gives rise in vivo to monocytes, macrophages, and the 
two main subsets of DCs: cDC and pDCs (Aufray et al., 2009). 
Dendritic cel development is tightly controled both by cytokines such as FLT3 
(Onai et al., 2007), M-CSF and GM-CSF (Fancke et al., 2008) and transcription factors, 
which wil be further described in the section 1.6. 
	  
	  
	  
1.5 NK lineage 
	  
Natural kiler (NK) cels survey host tissues for signs of infection, transformation or 
stress and, true to their name, kil target cels that have become useless or are detrimen- 
tal to the host. NK cels, like cytotoxic CD8+ T cels (also known as CTLs) are defined 
based on their cytolytic machinery and the kiling of their targets is mediated predom- 
inantly via perforin and granzymes.  Theses cels originate from a common lymphoid 
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progenitor (CLP) and during infection they become activated through antigen-specific 
receptors and by pro-inflammatory cytokines (such as interleukin-12 (IL-12) and type I 
interferons (IFNs), and produce large amounts of IFNγ	  (Sun and Lanier, 2011). During 
viral infection, homeostasis is perturbed and mature NK cels become activated, prolif- 
erate robustly (Raulet, 2004). cDC and pDCs contribute to NK cel-mediated protection 
by secreting large amounts of type I IFNs folowing the triggering of Tol-like receptors 
(TLRs) and intracelular sensors of viral nucleic acids; indeed, specific pDC ablation 
leads to decreased NK cel activity (Sun and Lanier, 2011, Swiecki et al., 2010). 
	  
	  
	  
1.6 Transcriptional control of Plasmacytoid Dendritic 
Cel development 
	  
The transcription factors (TFs) determining the development of DC subsets have been 
the subject  of intense investigation in recent  years.  The emerging  paradigm is that 
distinct TFs act at discrete stages to determine or commit distinct lineage choices and 
cel identities (Figure  3).  Some transcription regulators such as  Pu.1 (Carota et al., 
2010), Gfi-1 (growth factor independent 1) a transcriptional repressor, and interferon 
regulatory factor 8 (IRF 8) are broadly required for DC development and they make 
their specific efects at the level of the DC progenitors. Other transcription factors such 
as E2-2 for example have more specific efects within the pDC population (Seilet and 
Belz, 2013). 
	  
	  
	  
1.6.1 Ikaros 
	  
	  
It has been shown in numerous studies that Ikaros is required at multiple steps in DC 
development and influences both the earliest DC progenitors and mature DCs to main- 
tain pDC identity (Alman et al., 2006, Onai et al., 2007). Mice expressing low levels 
of Ikaros lack peripheral pDCs, but no other DC subsets. Loss of pDCs is associated 
with an inability to produce type I IFN after chalenge with Tol-like receptor-7 and 
-9 ligands. Additionaly BM cels of these mice contain a pDC population that appears 
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FIGURE 3: Growth factors and transcription factors regulating DC differentiation; the 
development of both DCs and monocytes depends on high concentrations of PU.1, 
which regulates the expression of the cytokine receptors FMS-related tyrosine kinase 
3 (FLT3), macrophage colony-stimulating factor receptor (M-CSFR) and granulocyte- 
macrophage colony-stimulating factor receptor (GM-CSFR). The plasmacytoid DC 
(pDC) lineage requires IRF8, a low level of PU.1 and the absence of ID2. The difer- 
entiation of pDCs from an immature precursor requires E2-2 and Ikaros, with induced 
loss of E2-2 converting pDCs into cels that closely resemble CD8α+ conventional 
DCs. CDP, common DC progenitor; CLP, common lymphoid progenitor; CMP, com- 
mon myeloid progenitor; FLT3L, FLT3 ligand; GFI1, growth factor independent 1; 
LMPP, lymphoid-primed multipotent progenitor; MDP, macrophage and DC progeni- 
tor, (From Belz and Nut, Nature reviews, Immunology, 2012) 
	  
blocked at the Ly-49Q- stage of diferentiation and fails to terminaly diferentiate in re- 
sponse to Flt-3L (Alman et al., 2006). Ikaros (~50 kDa) encoded by IKZF1 (IKAROS 
family zinc finger 1) the gene of same name localized to 7p12, is a member of the Krup- 
pel family of zinc finger DNA-binding proteins and is a transcription factor implicated 
in self-renewal activity in HSC, as wel as priming of the B lymphoid transcriptional 
program (Nichogiannopoulou et al., 1999). Interestingly a number of these genes are 
also expressed in pDC. The precise downstream targets for Ikaros have not been identi- 
fied in the pDC lineage. 
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1.6.2   E2-2 
	  
As  discussed above,  pDCs are a  distinct lineage separated from the cDCs, at a late 
development stage, by diferential regulation of discrete gene expression programs by 
distinct transcription factors, in particular E2-2 (Cisse et al., 2008, Ghosh et al., 2010). 
E2-2 (~71k Da), encoded by Tcf4, located on 18q21 locus, is a member of E-box (or 
E) proteins that belong to the basic helix-loop-helix (bHLH) transcription factor family. 
The members of this family bind to regulatory E-box sequences (CATATG/CACCTG) 
on target  genes and activate transcription  by forming either  heterodimers  or  homod- 
imers (Kee, 2009). E2-2 is highly expressed in pDC, at lower levels in B cels, and is 
almost undetectable in other immune cels. pDCs are very sensitive to E2-2 expression; 
in E2-2+/− mice as in human patients with Pit-Hopkins syndrome who have E2-2 hap- 
loinsuficiency, pDC numbers and IFN-α	  secretion are profoundly impaired (Cisse et 
al., 2008). 
	  
E2-2  binds  directly to the  promoter regions  of Spi-B, Irf8, and Irf7 genes, 
which are important factors for  pDC development (Cisse et al.,  2008,  Ghosh et al., 
2010). Induced deletion of E2-2 in mature pDC is associated with the loss of pDCs 
markers, increased MHC class I expression and T cel priming capacity, acquisition of 
dendritic  morphology, and cDC  phenotype accompanied  by increased expression  of 
Id2 (an antagonist E protein, which is abundantly expressed in al cDC) and the loss 
of pDC lineage identity (Ghosh et al., 2010). 
	  
	  
	  
1.6.3 SPI-B 
	  
SPI-B (~29 kDa), is encoded from SPI-B gene located at 19q13 locus, and is an ETS- 
domain transcription-factor family member and is closely related to PU.1, with 70% 
sequence identity in their DNA-binding  domain (DBD) (Chrast et al.,  1995). SPI-B- 
deficient  pDCs  present  defects in  TLR7/9-induced type I IFN  production,  Sasaki et 
al.  demonstrated that pDCs were decreased in BM of Spi-B−/− mice whereas periph- 
eral pDCs were increased; this uneven distribution suggested the defective retention of 
mature non-dividing pDCs in the BM. Therefore Spi-B seems to be involved in pDC 
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function and development in mice (Sasaki et al., 2012).  Knock down experiments in 
CD34+ precursor cels demonstrated that the ability of these cels to develop pDCs in 
both in vitro and in vivo assays was strongly inhibited (Schote et al., 2004). 
	  
	  
	  
1.6.4 Interferon regulatory factor 8 
	  
Interferon regulatory factor 8 (IRF8) (~48 kDa) belongs to the IRF transcription fac- 
tor family. IRF8 encoding gene is located at 16q24.1 locus and is particularly highly 
expressed in common dendritic cel precursor (CDP), pDCs, and CD8a DCs (Becker 
et al., 2012). 
The function of IRF8 in DC development appears to be conserved across humans 
and mice. In vivo experiments have shown that IRF8 plays an important role in regu- 
lation of proliferation and diferentiation of hematopoietic progenitor cels. IRF8 was 
recently found to  promote  CDP development and the initial commitment to the DC 
lineage by inhibiting granulopoiesis (Becker et al., 2012).  pDCs and CD8a DCs help 
to establish antiviral and antimicrobial responses by producing type I IFN and IL-12, 
respectively.  These functions are impaired in Irf8−/− mice, which are more suscepti- 
ble to viral infection, a phenotype shared by the human patients with IRF8 mutations 
(Hambleton et al., 2011). 
	  
	  
	  
1.6.5 RUNX2 
	  
The Runx family of transcription factors in vertebrates consists of three proteins (Runx1- 
3). Runx1 (~55 kDa) and Runx3 (~48 kDa) have been extensively studied within the 
hematopoietic system, where they often act as transcriptional regulators that direct cel 
fate choices. Runx1  and  Runx3 are critical regulators  of  T cel diferentiation but 
Runx2 has  been specificaly identified as a master regulator  of  bone development. It 
has  been recently shown that  pDCs specificaly express  Runx2 (~57  kDa) in an E2- 
2–dependent manner. Runx2, located at  6p21 locus, is required for the expression  of 
several pDC-enriched genes, including the chemokine receptors Ccr2 and Ccr5. Ma- 
ture pDCs express high levels of Ccr5 at the cel surface, and Ccr5-deficient pDCs are 
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greatly reduced in the periphery relative to the bone marow.  pDCs in Runx2-deficient 
mice developed normaly in the bone marow but are greatly reduced in the periphery 
(caused by the retention of mature Ly49Q+ pDCs in the bone marow). These data 
indicate that Runx2 facilitates pDC homing to peripheral lymphoid organs in a Ccr5 
dependent manner (Sawai et al., 2013). 
	  
	  
	  
1.6.6 L-Myc 
	  
MYC genes encode nuclear factors that criticaly regulate stem cel and metabolic func- 
tions, cel proliferation and apoptosis.  Their deregulation contributes to the genesis of 
many human tumors. In mammals, there are four related genes in the family, encoding 
4 factors: c-MYC (~67  kDa),  N-MYC (~49  kDa),  L-MYC (~40  kDa) and  S-MYC 
(~50 kDa). It is very well known now that the enhanced expression of Myc proteins 
contributes to almost every aspect of tumor cel biology. 
	  
The c-MYC gene is located at 8q24.21 locus and is the most studied member of 
this family. Deregulated expression of c-MYC occurs in a broad range of human cancers 
and is often associated with poor prognosis, indicating a key role for this oncogene in tu- 
mor progression. c-MYC regulates celular proliferation, metabolism and maintenance 
of progenitor populations. MYC proteins bind cognate DNA sequences in cooperation 
with DNA binding partners (MAX) through a conserved basic helix loop helix leucine 
zipper. At least c-MYC  has  been shown to  directly regulate the transcription  of 
numerous genes but also to control the speed at  which transcription  proceeds.  The 
third  member of  myc family  of  proto-oncogenes is L-MYC,  which is located at 
1p34.2 locus and is also required for  normal embryonic development. Forced 
expression of L-Myc exerts weaker efects than c-MYC for cel growth, apoptosis and 
transformation (Wasylishen et al.,  2011) but is  more efficient in reprogramming 
fibroblasts towards induced pluripotent stem cels (Nakagawa et al., 2010). 
Interestingly it has been recently shown that L-Myc is selectively expressed in 
pDCs and its expression is initiated in common DC progenitor.  The knockout experi- 
ments in mice have shown that the loss of L-Myc in DCs causes a significant decrease 
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in in vivo T-cel priming during infection. It has been shown likewise that some subsets 
of DCs such as migratory CD103+ conventional DCs in the lung and liver are greatly 
reduced at steady state, when c-Myc is replaced by L-Myc in immature DCs (Kc et al., 
2014). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Chapter 2 
	  
	  
Blastic plasmacytoid dendritic cel neoplasm 
	  
	  
2.1 Classification and clinical features 
	  
Others and we identified leukemic derivatives of pDC in the early 2000s (Chaperot et al., 
2001). Folowing on from this, intense clinical, pathology analysis and bio- logical and 
functional investigations led to pDC-derived leukemic disorders being classified as a 
new entity  blastic plasmacytoid  dendritic cel  neoplasm (BPDCN) (formerly caled 
CD4+/CD56+ hematodermic  neoplasm  or plasmacytoid  dendritic cel leukemia) 
within AML, in the curent WHO classification of hematological malignancies. A char- 
acteristic of BPDCN is a clinicaly aggressive course with a median survival of 12-14 
months irespective of the initial patern of disease (Facheti, 2008).  BPDCN is a rare 
disease representing <1% of acute leukemia cases (Jacob et al., 2003), predominantly 
afects males, with a sex ratio of 3:1, with an average of 67 years old, although some 
pediatric cases have also been reported (Feuilard et al., 2002). This aggressive disease 
presents a milder clinical course in children than in adults (Jegalian et al., 2010). 
	  
	  
Clinical presentation, consisting at the time of diagnosis of a solitary cutaneous 
lesion that rapidly disseminates in multiples sites including lymph nodes, bone marow, 
blood or central nervous system (CNS) (Jardin et al., 2011). BPDCN cutaneous nodules 
15 
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are present in 90% of patients (the most common feature; including nodules, plaques, 
or bruise-like areas) with or without bone marow, peripheral blood (PB) (60-90%) and 
lymph nodes (40-50%) involvement. Lymphadenopathy or spleen enlargement or both 
and cytopenia is frequent (Facheti, 2008). 
Morphologicaly  BPDCN is  usualy  pleomorphic with cel size varying from 
smal to large, with iregular nuclei, fine chromatin and one to several smal nucleoli. 
The cytoplasm is non-granular but displays a heterogeneous structure and cytoplasmic 
membrane often exhibits pseudopods (Facheti, 2008, Garnache-Otou et al., 2007). 
As mentioned before, leukemic plasmacytoid dendritic cels have been classified 
as  blastic NK-cel, lymphoma/leukemia  or agranular CD4+,  CD56+ and/or  hemato- 
dermic  neoplasm  of  myeloid  precursors (Brody et al.,  1995, Faccheti et al.,  1990). 
Chaperot and coleagues were the first to report and recognize that this disease is a ma- 
lignancy of the pDC lineage (Chaperot et al., 2001). They performed an immunophe- 
notypic study on the leukemic cels of 7 patients (6 men and 1 woman from 8 to 86 
years of age, mean = 63 years) and identified that these cels presented expression of 
the folowing markers: CD4+, CD56+, CD3−, CD13−, CD33−, and CD19−. They 
completed these findings with functional studies and demonstrated that, as reported for 
normal pDCs, in the same culture conditions, leukemic cels became powerful inducers 
of T-cel proliferation. In addition tumor cels from peripheral blood and lymph nodes 
of two of these patients produced IFN-α	  in response to inactivated influenza virus, a 
distinct feature of pDCs and as such refered to as “natural interferon-producing cels”. 
On the  basis  of these observations  Chaperot et al.  proposed that  BPDCN is derived 
from a plasmacytoid  dendritic cel interleukin-3α	  (IL-3Rα/CD123+) precursor.  Be- 
sides they confirmed that these cels shared also some markers with T (CD4) and NK 
cels (CD56), suggesting a relation to lymphoid lineage origin of these neoplastic cels 
(Chaperot et al., 2001, Facheti, 2008). 
Jacob et al. have documented, through an analysis of published cases in litera- 
ture that an important number of malignant cases showing similar features as explained 
for BPDCN. They assessed then the expression of more specific pDC-related markers 
and confirmed that these cels to be HLA-DR+, CD123 high, CD116 low, CD45RA+, 
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BDCA2+ or  BDCA4+ (Jacob et al.,  2003). In addition, in a study  of  45 cases  of 
BPDCN  neoplasms and their  potential cutaneous mimics, some immunohistochemi- 
cal markers, such as SPIB, BDCA-4, IRF-8, BCL11A and CD2AP, have been reported 
as tools for BPDCN diagnosis (Montes-Moreno et al., 2013). 
To date the etiology of BPDCN is unclear but its association with myelodysplasia 
in some cases may suggest a related pathogenesis (Facheti, 2008). It has been reported 
that some  BPDCN  patients  presented a  prior  history  of myelodysplastic syndromes 
(MDS) (Feuilard et al., 2002). MDS is a clonal disorder of hematopoietic stem cels 
characterized  by inefective  hematopoiesis,  morphologic  dysplasia,  peripheral  blood 
cytopenias, and propensity to transformation to acute myeloid leukemia (AML) (Mufti 
et al., 2003). The genetic features of MDS wil be discussed in the folowing section. 
BPDCN, categorized previously as a type of NK-cel lymphoma, is now classified 
as a rare subgroup of AML and related precursor myeloid neoplasms in the 2008 World 
Health Organization (WHO) classification 4th edition nomenclature, (Facheti, 2008) 
because the origin of the malignancy has been identified as precursor of pDCs (Chaperot 
et al., 2001). 
	  
	  
	  
2.2 Molecular pathogenesis of BPDCN 
	  
	  
2.2.1 Chromosomal aberrations 
	  
In  2002  Leroux et al. have  documented for the first time the cytogenetic features  of 
BPDCN, by using conventional and Fluorescence in situ hybridization (FISH) on 18 
adults and 3 children with CD4+, CD56+ DC2 acute leukemia. Clonal, mostly complex 
chromosome aberations were found in 14 patients (66%). The aberant cytogenetic fea- 
tures represented important genomic imbalances, a combination/accumulation of chro- 
mosomal anomalies and both lymphoid and myeloid lineage-associated rearangements 
(Leroux et al., 2002, Sapienza et al., 2014). This is suggestive of complex multistep tu- 
morigenic mechanisms and is supportive of the hypothesis that BPDCN may arise from 
an undiferentiated progenitor (Leroux et al., 2002). Leroux et al. showed that two 
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thirds of patients with BPDCN presented complex karyotypes and documented six ma- 
jor recurent specific chromosomal abnormalities; 5q21 or 5q34 (72%), 12p13 (64%), 
13q13-21 (64%), 6q23-qter (50%), 15q (43%) and loss of chromosome 9 (28%).  Re- 
curent deletions of chromosomal regions such as 4 (4q34), 9 (9p13-p11 and 9q12-q34) 
and 13 (13q12-q31) have been also observed (Leroux et al., 2002). 
In addition to  FISH,  other approaches have  been employed to characterize the 
genetic landscape of BPDCN. For example, comparative genomic hybridization (CGH) 
aray studies in skin biopsies from 11 cases (5 cases with BPDCN and 6 cases with 
AML) coupled to Gene expression profiling (GEP), has demonstrated recurent deletion 
of regions  on chromosome  4 (4q34), chromosome  9 (9p13-p11 and  9q12-q34), and 
chromosome 13 (13q12-q31) are recurent in BPDCN (Dijkman et al., 2007) that are 
distinctive of BPDCN compared to AML with cutaneous lesions.  BPDCN was found 
to show a distinct gene expression profile comprising expression of both myeloid and 
lymphoid genes compared to AML. 
In another study Jardin et al. used aray CGH to delineate novel candidate regions 
and disease-related genes in BPDCN. They studied 9 cases in which the most frequent 
findings were the loss of chromosome 9 (four cases) or chromosome 13 (five cases). 
The most frequent partial chromosomal losses afected 5q (four cases), 7p (two cases), 
8q (two cases), 9p (two cases), 12p (six cases), 13q (two cases) and 17p (three cases) 
(Jardin et al., 2009). 
Taken together these observations demonstrated that 5q deletion is a frequent phe- 
nomenon in BPDCN and it is mostly associated with “lymphoid type” anomalies (up 
to 70% of cases with abnormal karyotypes) in this disease (Jardin et al., 2009, Leroux 
et al., 2002, Petrela et al., 2005). 
It is wel known that deletions involving the long arm of chromosome 5 (chr5), 
del(5q), are the most common cytogenetic abnormalities in MDS and secondary AML. 
These chromosomal losses are especialy prevalent in AML arising after  prodromal 
MDS  or in MDS and AML arising after previous cancer treatment with alkylating 
agents or radiotherapy (approximately 40% of patients) (Ebert, 2009). 
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As mentioned briefly before, MDS comprises a heterogeneous spectrum of myeloid 
malignancies, and the frequent cytogenetic alterations in this  disease consists  of (-
5/5q-, -7/7q-,  +8,  20q-, and -Y) (Haase,  2008).   Besides  5q- syndrome,  which is a 
hematologic disorder with isolated 5q deletion and blast count of <5% that is associ- 
ated with specific MDS clinical features and favorable prognosis (Ebert, 2009) a large 
proportion of del(5q) patients have bone marow (BM) blasts exceeding 5%, complex 
cytogenetic, and extremely  poor prognosis and are refractory to available treatments 
(Byrd et al., 2002, Giagounidis et al., 2006, Grimwade et al., 2001). 
Chromosome  5q alterations have already been associated to haploinsufficiency 
mechanisms caused  by critical  5q target  gene(s) that in cooperation with additional 
signaling  net- works drives  malignant transformation and clonal evolution in these 
disorders (Ebert, 2011). It has recently been demonstrated that the deletion of miR-
146a in  del(5q) MD- S/AML cels is associated with increasing cel survival and 
proliferation of the propa- gating cels trough the TRAF6/p62/NF-κB complex (Fang 
et al., 2014). 
Until the present work, no study has addressed identification of 5q driver genes 
in BPDCN. A significant proportion of BPDCN cases with normal karyotypes are also 
described but have not undergone detailed molecular investigations either by molecular 
cytogenetic, sequencing or GEP. 
	  
	  
	  
2.2.2 Recurrent gene mutations in BPDCN 
	  
	  
2.2.2.1 Tumor suppressor genes 
	  
	  
Despite the findings on ontogenetic origin of BPDCN tumors, the genetic causes and 
oncogenic signaling events involved in the  malignant transformation  of this  disease 
are stil unknown.  Preliminary results from molecular studies suggested the presence 
of abnormalities in  genes known to confer a  poor  prognosis in  other  hematopoietic 
malignancies.  BPDCN cels display recurent alterations leading to a combination of 
deletions of several tumor suppressor genes including: RB1, CDKN1B, CDKN2A, or 
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TP53 (Jardin et al., 2009), indicating that deletion events altering G1/S regulation are 
crucial for BPDCN oncogenesis. 
	  
	  
	  
TP53 
	  
	  
TP53 (tumor protein 53 or the human p53 gene) is one of the most commonly mutated 
tumor suppressor genes in human cancer. Many of these mutations lead to expression 
of mutant p53 proteins that dominantly interact with normal p53 activity and thereby 
drive genome instability, abnormal proliferation and cel survival and treatment resis- 
tance (Muler and Vousden, 2013). It has been shown that tp53 inactivation strongly 
cooperates with oncogenic Kras to induce aggressive AML: myeloid progenitor cels 
expressing oncogenic Kras and lacking p53 become leukemia-initiating cels, resem- 
bling cancer stem cels capable of maintaining AML in vivo.  These results suggested 
the ability of tp53 to limit aberant self-renewal and contribute to its tumor suppressor 
activity (Zhao et al., 2010). In order to determine the mutational status in BPDCN Jardin 
et al. performed polymerase chain reaction (PCR) assays folowed by direct sequencing 
on thirteen  patients with  BPDCN. Five cases  displayed TP53 mutations (38%), 
leading to changes in its functional domain (Jardin et al., 2011), indicating that TP53 
mutation is a recurent genetic anomaly in BPDCN. 
	  
	  
	  
RB protein families 
	  
	  
The retinoblastoma (RB)  gene family is composed  of RB1, located at chromosome 
13q14.2, and two other RB-related genes designated as retinoblastoma-like 1 (RBL1) 
and retinoblastoma-like 2 (RBL2) located respectively at chromosome 20q11.2, a re- 
gion of special interest because of its association with some myeloid disorders (Claudio 
et al., 2002) and chromosome 16q12.2 in which deletions or loss of heterozygosity have 
been reported in several human neoplasms respectively (Di Fiore et al., 2013).  These 
evolutionary conserved genes are structuraly related, and play a key role in regulating 
advancement  of the cel division cycle from the G1 to  S-phases. They regulate neg- 
atively cel cycle entry, by controling E2F transcription factors and cyclin dependent 
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kinases.  Stimulation of cel cycle entry by growth factor signaling leads to activation 
of cyclin dependent kinases, resulting in phosphorylation and inactivation of the RB 
family proteins, and finaly E2F activation and DNA synthesis (Figure 4) (Henley and 
Dick, 2012). 
 
	  
	  
FIGURE 4: The central role of the retinoblastoma protein (pRb) in cel-cycle pro- 
gression. Entrance into S phase is characterized by phosphorylation of pRb by cyclin 
D1–cyclin-dependent kinase (CDK)-4, cyclin D1–CDK6 and cyclin  E–CDK2 com- 
plexes. The phosphorylation of pRb is associated with release  of the E2F1–3 tran- 
scription factors, which then activate genes that are required for cel-cycle progression. 
From (Hilary A. Coler, Nat Rev Mol Cel Biol, 2007) 
	  
	  
	  
It  has  been  demonstrated that  mutational inactivation  of RB1 causes the  pedi- 
atric cancer retinoblastoma, while deregulation of the pathway in which it functions is 
common in most types of human cancer (Goodrich, 2006). Inactivation of RB tumor- 
suppressor gene has been already reported in lymphoid malignancies (Hangaishi et al., 
1996). By using Gene expression profile (GEP) on 11 cases (5 cases with BPDCN and 
6 cases with AML), Djikman et al. demonstrated that there is a diminished expression 
in oncosuppressor genes such as RB1 and LATS2. LATS2 is also an important factor for 
implicated in cel cycle control (Dijkman et al., 2007). 
In order to establish corelations with disease outcome and by combining clinico- 
pathologic findings and genetic data, Lucioni et al.  utilized aray CGH on 21 cases of 
BPDCN and they found monosomy of chromosome 13 in 52.4% of samples, they also 
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detected a common deleted region (CDR) on 13q13.1-q14.3 involving RB1 (Lucioni 
et al., 2011). 
	  
	  
2.2.2.2 Gene mutations afecting cel signaling 
FLT3 
The FMS-like tyrosine kinase 3 (FLT3) gene, located on 13q12, encodes a membrane- 
bound receptor tyrosine kinase (~140 kDa) that has a crucial role in normal hematopoi- 
esis. It contains five extracelular immunoglobulin-like domains (E), a transmembrane 
domain (TM), a juxtamembrane domain (JM) and two tyrosine-kinase domains (K) that 
are linked through the tyrosine-kinase insert (KI) (Figure 5). Cytoplasmic FLT3 under- 
goes glycosylation, which promotes its localization to the membrane, where it remains 
as a  monomeric, inactive  protein  on the cel surface until FLT3 ligand (L)  binds the 
receptor and induces receptor dimerization. Its dimerization promotes phosphorylation 
(P) of the tyrosine-kinase domains, thereby activating the receptor and downstream ef- 
fectors. FLT3 is normaly only expressed in primitive hematopoietic precursors within 
the bone marow (Stirewalt and Radich, 2003). 
Clinical and experimental evidence both indicate that FLT3 is a proto-oncogene 
with the capacity to enhance survival and proliferation of leukemia blast cels (Stirewalt 
and Radich, 2003). There are two broad categories of activating mutations of FLT3. The 
JM domain of FLT3 often has an autoinhibitory function, therefore mutations disrupt- 
ing this domain and causing the deformation of the secondary structure of FLT3, result 
in constitutive activation of the tyrosine kinase domain of this receptor (the so-caled 
FLT3-ITD  “internal tandem  duplication  mutations”).  Other  major FLT3-activating 
mutation consists  of  point  mutations  within the tyrosine  kinase  domain (TKD), par- 
ticularly  on the activation loop at aspartate  835 (D835) (Grunwald and Levis,  2013) 
(Figure 5).  The constitutive activation of FLT3 promotes ligand-independent cel pro- 
liferation and blocks myeloid diferentiation of early hematopoietic cels (Stirewalt and 
Radich, 2003).  Mutations in the FMS-like tyrosine kinase gene characterize more than 
30 % of AML cases. FLT3 internal tandem duplication (ITD) mutations, accounting for 
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FIGURE 5: A schematic diagram of the FLT3 receptor tyrosine kinase showing the 
location of the internal tandem duplication of genes within the juxtamembrane domain 
and point mutations and gene insertions in the second kinase domain. Ilustration by 
Kenneth Probst. From (Mark R. Litzow, Blood, 2005) 
	  
	  
approximately 23 % of AML cases, are associated with a particularly poor prognosis 
(Grunwald and Levis, 2013). 
Pagano et al. have  done  molecular analysis  on  14  BPDCN  patients and found 
that three (21%) of these patients had FLT3-ITD mutations (Pagano et al., 2013). Gene- 
expression profiling on 8 BPDCN patient biopsies also demonstrated that there is a high 
expression of FLT3 in some of these samples, and it was paradoxicaly associated with 
monoalelic deletion of the locus containing this proto-oncogene (Dijkman et al., 2007). 
	  
	  
	  
BRAF 
	  
	  
The RAF-MEK-ERK signal transduction pathway is a conserved RAS-activated protein 
kinase cascade that regulates cel growth, proliferation, and diferentiation in response 
to growth factors, cytokines, and  hormones with  RAF as the first efector identified 
downstream of RAS (Malumbres and Barbacid, 2003). 
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RAF activation initiates by RAS-GTP association with the N-terminal RAS bind- 
ing domain (RBD), which is associated by concomitant conformational changes and re- 
cruitment to the cel membrane, promoting changes in RAF phosphorylation, stimulat- 
ing its serine/threonine kinase activity. This results in the triggering sequential phospho- 
rylation and activation of MEK and extracelular signal-regulated kinase (ERK) (Wan 
et al., 2004). Constitutive activation of the RAS-ERK signaling pathway is common 
to numerous cancers. Almost 90% of BRAF mutations result in a Val600Glu (V600E) 
amino acid substitution leading to constitutive kinase activation (Hoeflich et al., 2006). 
	  
	  
Recently Go et al. examined BRAF mutation  by  using  Sanger sequencing and 
peptide nucleic acid clamp real-time polymerase chain reaction (PNAcqPCR) in a series 
of  129 cases  of histiocytic,  dendritic cel and  other related lesions. PNAcqPCR is a 
sensitive method for detection of mutations in the presence of a large excess of wild- 
type DNA. PNA is a synthetic DNA analogue, in which the ribose/phosphate backbone 
of the DNA has  been replaced  by  N-(2-aminoethyl)-glycine  units linked  by  peptide 
bonds. PNA  binds strongly to complementary DNA  by Watson-Crick  base  pairing, 
whereas one single mismatch wil severely destabilize the complex. 
This analysis detected BRAF V600E mutations, and Histiocytic sarcoma exhib- 
ited the highest rate of BRAFV 600E (62.5%, five of eight), folowed by Langerhans cel 
tumors (25%, seven of 28), folicular dendritic cel sarcoma (18.5%, five of 27) and 
giant cel tumor (6.7%, two of 30) (Go et al., 2014). 
	  
	  
2.2.2.3 Transcription factors 
Ikaros 
By using a whole-exome sequencing (WES), Menesez et al. provide the first mutational 
profiling of BPDCN. They identified recuring mutations for a group of newly identi- 
fied genes, such as IKZF3 (Ikaros family of zinc-finger protein hematopoietic-specific 
transcription factors involved in the regulation of lymphocyte development) and ZEB2 
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(Zinc finger E-box-binding homeobox 2, is a transcription factor implicated in develop- 
ment), with prevalence range of 12-16% in BPDCN. It is of note that Ikaros mutations 
are also described in B-ALL (Kastner et al., 2013, Menezes et al., 2014). 
	  
	  
2.2.2.4 Epigenetic regulators 
	  
	  
Beside recurent mutations that confer a growth advantage by activating downstream 
efectors  of various signaling pathways and  mutations that impact the expression  of 
key transcriptional targets in myelopoiesis, emerging genetic data suggest that there are 
additional classes of mutations that commonly occur in patients with myeloid malignan- 
cies.  The most prominent examples are from recent genome-wide and candidate-gene 
studies that have identified somatic alterations in genes that encode proteins regulat- 
ing DNA methylation and post-translational histone modifications. These data suggest 
that somatic alterations in epigenetic regulators are a common genetic event in cancer 
including myeloid malignancies and contribute to hematopoietic transformation (Shih 
et al., 2012). 
In the folowing section I briefly introduce epigenetics deregulation, which is an 
important emerging halmark of cancer, and wil discuss specificaly the mutations af- 
fecting epigenetic factors that have been demonstrated to be associated to BPDCN and 
similar hematological malignancies. 
	  
	  
	  
Epigenetics: an emerging halmark of cancer 
	  
	  
As normal cels evolve progressively to a neoplastic state, they acquire a succession of 
capabilities that help them to become tumorigenic and ultimately malignant. Tumors are 
complex tissues composed of multiple distinct cel types that interact with one another, 
and tumor microenvironment contributes actively to their development. As it proposed 
by Hanahan and Weinberg (Hanahan and Weinberg, 2011), the halmarks of cancer con- 
sist of the folowing biological capabilities; sustaining proliferative signaling, evading 
growth suppressors, resisting cel death, enabling replicative immortality, genome insta- 
bility and mutation, tumor-promoting inflammation, inducing angiogenesis, activating 
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invasion and metastasis. They have also  proposed two emerging  halmarks  based  on 
recent research, comprising; the deregulation of celular energetics and the capability 
of avoiding immune destruction in their last model (Figure 6). 
 
	  
	  
FIGURE 6: The halmarks of cancer. From (Hanahan and Weinberg, Cel, 2011) 
	  
	  
	  
In the past decade a remarkable acceleration has been made in the validation of the 
concept as wel as genetic anomalies that result in tumor formation and progression, 
cancer is an epigenetic disease (Baylin and Jones, 2011). Folowing the discoveries of 
DNA methylation abnormalities, learning about chromatin covalent modifications, their 
organization and relevance to gene expression, brought us to the emerging view of what 
is now caled “the cancer epigenome”.  This comprises alterations in epigenetic 
information as  opposed to DNA sequence changes.  By  definition epigenetic 
alterations are heritable and somaticaly reversible  making them ideal targets for 
treatment intervention in cancer. 
	  
	  
	  
General overview on epigenetics 
	  
	  
The  genetic code resides  within a negatively charged DNA polymer. The  binding  of 
the DNA fiber around basic histone proteins results in neutralizing the negative charges 
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and alows the DNA to be folded into chromosomes and compacted up to 10,000 times 
within the  nucleus. Wrapping DNA around  histone core,  which is composed  of two 
copies of each of the histone proteins H2A, H2B, H3 and H4, forms the most basic unit 
of eukaryotic chromatin: the nucleosome (Dawson and Kouzarides, 2012) (Figure 7). 
Histones are not merely DNA-packaging proteins, but molecular structures that 
participate in the regulation  of  gene expression. They store epigenetic information 
through post-translational modifications on their amino-terminal histone “tails”, as ly- 
sine acetylation, arginine and lysine methylation, and serine  phosphorylation. These 
modifications afect gene transcription and DNA repair (Jiang and Pugh, 2009). 
 
	  
	  
FIGURE 7: Overal structure of the epigenome in human cels.  From (Baylin and 
Jones, Nat Rev Cancer, 2011) 
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Today we know that nucleosome positions are dynamic and change during cel 
replication and gene expression (Kely et al., 2010). Active gene promoters are usualy 
characterized by CpG-rich without DNA methylation and having nucleosome-depleted 
regions (NDRs) upstream of their transcription start sites (TSSs).  The flanking nucle- 
osomes of these NDRs are marked by the histone modifications such as H3 trimethy- 
lated on lysine 4 (H3K4me3), H3 acetylated on lysine 27 (H3K27ac), extensive lysine 
acetylation and  harbor the  histone variant  H2A.Z and  H3.3,  which may  destabilize 
nucleosomes to facilitate transcriptional initiation.  Gene  bodies  of active  genes also 
show enrichment  of specific covalent  marks, such as  H3K36me3,  which may facil- 
itate transcriptional elongation (Guenther et al.,  2007).  By contrast, DNA methyla- 
tion in promoter regions, in  general enhances epigenetic  gene silencing, with  nucle- 
osomes positioned over the TSS  harboring repressive  histone  modifications, such as 
H3K9me2,  H3K9me3,  H4K20me3 and H3K27me3 marks and preventing gene tran- 
scription (Baylin and Jones,  2011) (Figure  7).  Highly compacted, transcriptionaly 
silent chromatin is known as heterochromatin, whereas more accessible chromatin is 
known as euchromatin.  Heterochromatin can  be divided into i) constitutive,  which 
designates genomic regions in the nucleus of a eukaryotic cel that have the opportunity 
to adopt open or compact conformations within temporal and spatial contexts (Trojer 
and Reinberg, 2007) or i) facultative that mainly comprises repetitive genetic elements, 
such as telomeres and centromeres, that localize to the nuclear periphery (Oberdoerfer 
and Sinclair, 2007). 
	  
	  
	  
Epigenetic readers, writers and erasers 
	  
	  
As mentioned above, epigenetic modifications of DNA and histones, and/or alterations 
in chromatin-remodeling processes, determine active and repressive chromatin states of 
genes and thus operate as switches either to turn gene expression “on” or “of”.  These 
alterations can  be as important for tumorigenesis as the altered  genome itself. Each 
of these epigenetic pathways involves enzymes that transfer modifications (“writers”), 
which establish a mark on either DNA or the histone tail.  These modifications can be 
removed or modified by enzymes reverting modifications (“editors”), and the third class 
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of enzymes is composed of “readers” of epigenetic marks, which mediate the interaction 
of these  marks with a  protein complex and thus influence transcription (“readers”) 
(Figure 8). Readers recognize modifications on histone tails and subsequently translate 
the information into  distinct transcriptional  profiles through alterations  of chromatin 
states. They determine whether a chromosomal region is accessible for the binding of 
transcription factors or other regulatory molecules. The modification paterns are estab- 
lished by histone acetyltransferases (HATs) or histone methyltransferases (HMTs) and 
can be removed by histone deacetylases (HDACs) or histone demethylases (HDMs). 
These enzymes are usualy specific to particular amino acid motifs on N-terminal his- 
tone tails, core histones and histone variants (Plass et al., 2013). 
As mentioned earlier, it is wel known now that mutations in genes encoding epi- 
genetic regulators are a common genetic event in myeloid malignancies and contribute 
to hematopoietic transformation. These mutations target al major classes of epigenetic 
regulator including tet methylcytosine dioxygenase 2 (TET2), isocitrate dehydrogenase 
1 (IDH1), IDH2, additional sex combs-like 1 (ASXL1), enhancer of zeste homologue 2 
(EZH2) and DNA methyltransferase 3A (DNMT3A), which have recently been shown 
to have biological, clinical and potential therapeutic relevance in myeloid malignancies 
(Shih et al., 2012). Some of these somatic alterations of epigenetic regulators genes wil 
be specificaly discussed in the folowing section because of their relevance to BPDCN 
pathogenesis. 
	  
	  
2.2.2.5 Mutations afecting DNMT3A, TET2 and IDH2 
DNMT3A 
DNA methylation is  one  of the  best-characterized epigenetic modifications. It is an 
essential process for normal development and is associated with a number of key pro- 
cesses including genomic imprinting, X-chromosome inactivation, suppression of repet- 
itive elements and carcinogenesis (Jones and Takai, 2001). DNA methylation consists 
of addition a methyl group (CH3) on carbon 5 (C5) of cytosine (5-metrhylCytosine) on 
DNA fiber. In mammals, DNA methylation occurs on a cytosine folowed by a guanine 
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FIGURE 8: Enzymes involved in DNA and histone modification pathways. The 
top panel depicts DNA modifications, such as DNA methylation and demethyla- 
tion, and the enzymes involved; the botom panel shows histone modifications and 
the enzymes involved. Examples for each class of enzyme are  given. 5hmC, 5-
hydroxymethylcytosine; 5mC,  5-methylcytosine;  BAZ1B, tyrosine protein kinase 
BAZ1B; BRCT, BRCT domain-containing protein; CHD, chromodomain helicase 
DNA-binding protein; DIDO1, death-inducer obliterator 1; DNMT, DNA methyl- 
transferase; HAT, histone acetyltransferase; HDAC, histone deacetylase; HMT, histone 
methyltransferase; KDM, lysine-specific histone demethylase; MECP2, methyl-CpG- 
binding protein2; PPP, serine/threonine; RPS6K, ribosomal protein S6 kinase; SAM, 
S-adenosyl-l-methionine; TAF3, transcription initiation factor TFIID subunit 3; TET, 
TET 5mC hydroxylase. From (Plaas C. et al., Nat Rev Genet, 2013) 
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(CpG) through the DNA sequence and about 70-80% of CpGs are methylated. CpGs are 
not found frequently in human genome and they are mostly present on gene promoter 
regions in clusters that are caled  CpG islands (Weber et al.,  2007). Levels  of DNA 
methylation corelates with chromatin accessibility, and acquired abnormal methyla- 
tion, which can be due to mutation in genes controling the DNA methylation factors 
(Figure 9) is a common event in divers diseases including cancer.  This results in tran- 
scriptional disorders and can be inherited by daughter cels (Jones and Takai, 2001). It 
is wel known that 5mC is associated with a transcriptionaly repressed chromatin state, 
and DNA methylation at specific genomic loci, including lineage-specific genes, can 
help to shape the celular identity during development (Kohli and Zhang, 2013). 
The enzymes responsible for this modification, DNMTs, are grouped in two cat- 
egories:  de novo and  maintenance DNMTs. Initialy the DNA methylation  paterns 
are established by the de novo DNA methyltransferases:  DNMT3A, (~102 kDa), and 
DNMT3B, (~96  kDa),  during embryonic development (Law and Jacobsen,  2010). 
These methyl marks are then maintained during cel divisions through the action of the 
maintenance methyltransferase,  DNMT1, (~183  kDa),  which  preferentialy methy- 
lates the unmethylated strand of hemimethylated DNA during DNA replication. These 
mechanisms are crucial for development, since mice deficient in DNMT3B or DNMT1, 
located respectively on 20q11 and 19p13 loci, are embryonicaly lethal and DNMT3A-
nul mice die at 4 weeks of age (Wu and Zhang, 2010). 
	  
Ley and coleagues performed whole-genome sequencing on AML samples with 
normal cytogenetic and identified for the first time somatic  mutation  of DNMT3A. 
DNMT3A gene, located on 2p23 locus, was found mutated in 22%, (62 of 281) of AML 
cases, and these mutated cases were associated with a poor outcome (Ley et al., 2010). 
In another study, the direct sequencing demonstrated also that DNMT3A was mutated 
in 87 (17.8%) of 489 patients with AML (Thol et al., 2011). 
Exome sequencing in M5 subtype of AML demonstrated that (20.5%) 23 of 112 
cases presented DNMT3A mutations and these mutants showed reduced enzymatic ac- 
tivity  or aberant affinity to  histone H3 in vitro.  The  majority  of somatic DNMT3A 
mutations result either in  premature truncation  of the  protein  product (nonsense  or 
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frameshift mutations), or occur at a single amino acid, R882 (60% of mutated cases, 
37 of 62 mutations) and has been shown to decrease catalytic activity and DNA binding 
affinity (Gowher et al., 2006).  These findings suggest a contribution of aberant DNA 
methyltransferase activity to the pathogenesis of acute monocytic leukemia (Yan et al., 
2011). 
DNMT3A mutations have also been observed in BPDCN patients, Menez et al. 
have assessed whole-exome sequencing (WES) on 3 BPDCN cases and on the basis of 
these data, they designed a resequencing approach to identify mutations in 38 selected 
genes in  25  BPDCN  patients. They observed that  half  of the tumors  had  mutations 
afecting either the DNA methylation or chromatin-remodeling pathways, with mutated 
DNMT3A, observed in BPDCN cases. DNMT3A mutations were then corelated with a 
poor prognosis in these patients (Menezes et al., 2014). 
	  
	  
	  
TET2 
	  
	  
TET2 coding gene is located on 4q24 locus and codes for TET2 protein (~220 kDa), 
one of the three proteins of the TET (Ten-Eleven Translocation) family, which are evo- 
lutionarily conserved dioxygenases that catalyze the conversion of 5-methyl-cytosine 
(5-mC) to 5-hydroxymethyl-cytosine (5-hmC) (Figure 9) and promote DNA demethy- 
lation. In addition to their hydroxylase activity, TET proteins recruit the O-linked β	  - 
D-N-acetylglucosamine (O-GlcNAc) transferase (OGT) enzyme to chromatin,  which 
promotes post-transcriptional modifications of histones and facilitates gene expression 
(Tahiliani et al., 2009). Pathways for active DNA demethylation include the oxidation 
of 5mC by TET 5mC hydroxylases. 
	  
Alternative  mechanisms to oxidative demethylation  of cytosines are  based  on 
deamination and subsequent base-excision repair (BER) or nucleotide-excision repair. 
These demethylation pathways are replication-independent mechanisms alowing rapid 
conversions from methylated to unmethylated states. 
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During the development  of a  neoplasm, the degree  of hypomethylation  of  ge- 
nomic DNA increases as the lesion progreses from benign proliferating cels to an in- 
vasive cancer. Three abnormalities are caused by DNA hypomethylation in cancer cels: 
the  generation  of chromosomal instability, the reactivation  of transposable elements 
and loss of imprinting. Hypomethylation of DNA can also favor mitotic recombination, 
leading itself to deletions and translocations, and it can also promote chromosomal rear- 
rangements.  This mechanism was seen in experiments in which the depletion of DNA 
methylation  by the disruption  of DNMTs caused aneuploidy. Activation  of intrage- 
nomic endoparasitic DNA, such as L1 (long interspersed nuclear elements), and Alu 
(recombinogenic sequence) repeats is another consequence of undermethylated DNA. 
These hypomethylated transposons can be translocated to other genomic regions and 
cause further disruption in the genome (Esteler, 2008). 
TET2 gene mutations are recurent in myeloid and lymphoid malignancies and 
accumulate with age. It has been recently demonstrated that alterations of TET2 may 
represent an important and early event in the pathogenesis of various myeloid malig- 
nancies including MDS, chronic myelomonocytic leukemia (CMML), or de novo/sec- 
ondary AML (Mulighan, 2009). 
It has been also shown that acquired TET2 mutations could be detected at a low 
level in CD3+ cels  of MDS  patients, indicative therefore  of a very early event dur- 
ing hematopoiesis (Smith et al., 2010).  Missense, frameshift and nonsense mutations 
in TET2 also  occur in  7.6%  of AML samples.  Mutation rates in myeloproliferative 
neoplasms are higher (>20%), but these rates may be biased, as the number of tested 
samples is smaler (Plass et al., 2013). 
	  
	  
In another study  direct sequencing  on a cohort  of  190  peripheral  T-cel lym- 
phomas (PTCL) demonstrated that TET2 mutations were presented in 40 of 86 (47%) 
cases of angioimmunoblastic T-cel lymphoma (AITL) and in 22 of 58 (38%) cases of 
peripheral  T-cel lymphoma, but were absent in al  other  PTCL entities, with the 
exception of 2 of 10 cases of enteropathy-associated T-cel lymphoma (Lemonnier et 
al., 2012). 
Interestingly TET2 mutations have been described in BPDCN. Briefly, by direct 
sequencing on thirteen patients with BPDCN, TET2 mutations were detected in (7/13) 
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cases (53%) (Jardin et al.,  2011). Menez et al. by  using next  generation sequencing 
(NGS) analyzed 42 BPDCN patients and found that 36% of these patients presented 
TET1/2 mutations. 
Also in a recent study and by using NGS on a panel of recurently mutated genes 
in AML, it has been suggested that an appreciable subset of BPDCN cases have TET2 
mutations (Alayed et al., 2013). In this study NGS were performed on 5 of these pa- 
tients and TET2 mutations were found in 4 cases (80%). This raises the possibility that 
perturbations in DNA methylating modifying enzymes,  here TET2 mutations,  play a 
role in the pathogenesis of BPDCN (Alayed et al., 2013). 
The major functional consequence of TET2 mutation is a hypermethylation phe- 
notype thus indicating that TET2 mutated cancers should respond to hypomethylating 
agents (Shih et al., 2012). 
	  
	  
	  
IDH2 
	  
	  
The homodimeric enzymes, Isocytrate dehydrogenases 1 and 2 (IDHs 1 and 2), IDH1 
(~235 kDa) and IDH2 (~51 kDa), both catalyze the oxidative decarboxylation of isoc- 
itrate to α-ketoglutarate (α-KG) and reduce NADP+ to NADPH, but they have diferent 
subcelular locations: IDH1 in the cytoplasm and IDH2 in mitochondria.  Their enzy- 
matic activity is then folowed by a series of additional enzymes, which further process 
2-ketoglutarate to produce energy in cels. IDH1 and IDH2 genes are located on 2q33.3 
and 15q26.1 loci respectively. IDH1 mutations were discovered in patients with acute 
myeloid leukemia (AML) through whole genome sequencing (Mardis et al., 2009, Ward 
et al., 2010).  Sanger sequencing and Sequenom MassAR- RAY platform (Sequenom) 
have demonstrated that IDH2 mutations were present in angioimmunoblastic lymphoma 
cases (Cairns et al., 2012). Mutations are heterozygous and occur at the arginine residue 
of the enzyme’s active site and cause both loss of normal enzyme function and gain  of 
function (McKenney and Levine,  2013). IDH mutations induce a  neomorphic 
function to  produce the  oncometabolite  2-hydroxyglutarate (2HG),  which can
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FIGURE 9: Associated mutations in the DNA methylation and demethylation path- 
way. The process of DNA methylation and the enzymes involved are shown. En- 
zymes affected by somatic mutations in myeloid leukaemia, are marked with an 
asterisk. AID, activation-induced cytidine deaminase; BER, base-excision repair; 
DNMT3A, DNA methyltransferase 3A; IDH, isocitrate dehydrogenase; NADP+, 
nicotinamide adenine dinucleotide phosphate; SAH, S-adenosylhomocysteine; SAM, 
S-adenosylmethionine; TDG, thymine DNA glycosylase, 5fC (5-formylcytosine), 
5caC (5-carboxylcytosine). From (Shih et al., Nat Rev Cancer, 2012) 
	  
	  
alter the epigenetic landscape. IDH mutations are most common in patients with cyto- 
geneticaly normal AML (CN-AML), and the prevalence of IDH1 and IDH2 missense 
mutations among patients with AML is between 5% and 20% (McKenney and Levine, 
2013). By using WES, Menez et al. analyzed a total of 25 BPDCN patients and reported 
(1/25) 4% and (3 of 25) 12% of these cases were mutated for IDH1 and IDH2 genes 
respectively (Menezes et al., 2014). 
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2.2.2.6 Mutations afecting histone-modulating factors 
MLL 
Mixed lineage leukemia (MLL) gene is located at chromosome 11, band q23 and en- 
codes a  histone methyltransferase that  directly  binds DNA and positively regulates 
gene transcription, and particularly regulates the expression of homeobox (HOX) genes. 
MLL is a member of Trithorax group (TrxG) of proteins and is known because of its 
involvement in leukemia (Schuetengruber et al., 2011). 
MLL (~180  kDa) is a large  multi-domain  protein,  ubiquitously expressed in 
hematopoietic cels including stem and  progenitor  populations.  Rearangements  of 
MLL, the human homolog of the Drosophila gene trithorax, are associated with aggres- 
sive lymphoid and myeloid acute leukemias in both children and adults. MLL mutations 
are found as a fusion protein that has no H3K4 methylation function (Krivtsov and Arm- 
strong, 2007). MLL fusions are highly efficient oncoproteins that transform hematopoi- 
etic progenitors and cause aggressive leukemia (Slany, 2009). Approximately 10% of 
human acute leukemias harbor MLL translocations and MLL is also afected by abnor- 
malities such as partial tandem duplications (PTDs) of exons encoding the N terminus 
of MLL in about 10% of normal cytogenetic AML cases (Muntean and Hess, 2012). 
	  
Depending on the fusion partner, they seem to either afect chromatin-associated 
processes or, more frequently, specificaly stimulate transcriptional elongation (Maeth- 
ner et al., 2013). “Eleven Nineteen Leukemia” protein (ENL) originaly discovered as 
an MLL fusion partner in the recurent translocation t(11;19) (Maethner et al., 2013). 
ENL belongs to a  protein complex caled EAP as “elongation assisting  proteins”. It 
has been demonstrated that EAP  has also the capacity to accommodate MLL fusion 
proteins.  Therefor the constitutive recruitment of EAP to MLL target loci is responsi- 
ble for persistent target transcription through stimulation of transcriptional elongation. 
This mechanism resists diferentiation stimuli and therefore causes a maturation arest 
(Mueler et al., 2009).  The MLL rearangements have been also reported in a BPDCN 
case with MLL-ENL fusion gene, suggesting its implication in the development of this 
disease (Toya et al., 2012). Two BPDCN cases with 11q23 abnormalities were also 
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reported in another study on 5 cases of DC malignancy, which caried t(9;11)(p21; q23) 
and 11q23 deletion (Bueno et al., 2004). 
	  
	  
	  
Mutations afecting the Polycomb repressive complex PRC2 
	  
	  
Celular memory is provided by two counteracting groups of chromatin proteins termed 
Trithorax group (TrxG) and Polycomb group (PcG) proteins. The antagonistic activ- 
ities of the PcG and the trithorax families of  proteins culminate in the  maintenance, 
throughout development and adulthood, of the appropriate paterns of homeotic gene 
expression in a spatialy defined manner. TrxG proteins activate transcription and PcG 
complex is implicated in gene repression (Schuetengruber et al., 2011). In mammals, 
two main PcG complexes exist, Polycomb repressive complex 1 (PRC1) and 2 (PRC2). 
The PRC2 complex is responsible for the methylation (di- and tri-) of Lys 27 of histone 
H3 (H3K27me2/3) through its enzymatic subunits enhancer of zeste homologue, EZH1 
and  EZH2,  whereas the  PRC1 complex  monoubiquitylates Lys  119  of  histone  H2A 
(H2AK119ub) via the ubiquitin ligases RING1A and RING1B. It has been suggested 
that PRC1 functions downstream of PRC2, and both are often required to maintain gene 
repression (Margueron and Reinberg, 2011). 
The core PRC2 complex, which is conserved from Drosophila to mammals, com- 
prises four components: EZH1/2, SUZ12, EED and RbAp46/48 (also known as RBBP7 
/4) (Figure 10). It has been demonstrated that besides the EZH2 methyltransferase ac- 
tivity through its SET (Su(var)3-9/enhancer of zeste/trithorax) domain, SUZ12 is also 
important for H3-K27 methylation and gene silencing (Cao and Zhang, 2004) and HM- 
Tase activity requires a minimum of three components-EZH2, EED, and SUZ12-while 
AEBP2 is required for optimal enzymatic activity (Cao and Zhang, 2004).  The PRC2 
component EED, can bind H3K27me3, and PRC2 enzymatic activity is stimulated by 
the presence of H3K27me3, thus generating a positive-feedback loop. H3K27me2 and 
H3K27me3 marks are associated with facultative heterochromatin: a subdivision of het- 
erochromatin that is regulated in a developmental-specific manner.  Acetylated H3K27 
is thought to be antagonistic to PcG-mediated silencing and is enriched in the absence 
of PRC2. 
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A model predicting the recruitment of PRC2 to chromatin has been proposed: first 
the interaction of JARID2 and AEBP2 with DNA, next the interaction of the histone 
chaperones RbAp46 or 48 with histones H3 or H4, then the interaction of EED with the 
product of PRC2 catalysis, H3K27me3 and the interaction of PRC2 components with a 
long non coding RNA (ncRNA). The binding specificity could be modulated by the vari- 
ation in the composition of the PRC2 holoenzyme and postranslational modifications 
(PTMs)  of its components.  The ncRNA is thought to  be a  major  player in the cel- 
specific recruitment of PRC2 (Figure 10). A large pool of long ncRNA may function to 
direct the complex to defined target genes and this targeting may not necessarily entail 
linear base pairing with target sequences, but instead the tertiary structure of the RNA 
may be the key to specific target gene recognition (Margueron and Reinberg, 2011). 
 
	  
	  
FIGURE 10: Schematic representation of the PRC2 holoenzyme at chromatin. Puta- 
tive interactions with either DNA or histones that could explain PRC2 recruitment are 
highlighted. From (Raphaël Margueron and Danny Reinberg, Nat Rev, 2011) 
	  
	  
	  
	  
	  
PRC2 catalytic unit: EZH2 
	  
	  
EZH2 gene located on 7q36 locus, encodes for a protein (~95 kDa), which is the cat- 
alytic subunit of the PRC2. EZH2 is a highly conserved histone methyltransferase that 
methylates lysine 27 of histone 3. It contains conserved regions including cysteine-rich 
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amino acid stretch that precedes the carboxy-terminal SET domain with HMTase ac- 
tivity (Xiao, 2011). EZH2-mediated methylation is a potential independent mechanism 
for epigenetic silencing  of tumor suppressor  genes in cancer.  Oncogenic activity  of 
overexpressed EZH2 has been shown in a wide range of cancers such as those of the 
prostate and breast (Deb et al., 2013, Yu et al., 2007). 
EZH2 has been reported to harbor various heterozygous mutations at tyrosine 641 
(Y641) in the C-terminal SET domain (Morin et al., 2010) resulting in a gain of func- 
tion.  Although initialy reported to be a loss-of-function mutation, subsequent studies 
have shown that the Y641 mutation actualy results in a gain of function (Yap et al., 
2011). These mutants have enhanced catalytic efficiency for dimethylated H3K27me2, 
comparing to the wild type showing substrate preference for unmethylated H3K27 and 
monomethylated H3K27me1, therefore both the wild type and the Y641 mutants can 
work together to increase the levels of H3K27me3. It has been reported that such mu- 
tations are found in 7% of folicular lymphomas and 22% of germinal center B-cel and 
difuse large B-cel lymphomas (DLBCLs) (Tan et al., 2014). 
Unlike in B-cel lymphomas, EZH2 mutations in myeloid malignancies are inac- 
tivating/hypomorphic (Khan et al.,  2013). In a recent study,  Khan et al. studied the 
mutational status by Sanger sequencing in myeloid malignancies and found EZH2 mu- 
tations in  8%  of cases (n=469 cases examined). In addition, they observed reduced 
EZH2 expression in 78% of cases with hemizygous deletion (-7/del7q cases involving 
EZH2 locus), and 41% of cases with diploid chromosome 7 (Khan et al., 2013). 
Another study suggested that in patients with myeloid disorders, EZH2 mutations 
were found most commonly in patients with myelodysplastic/myeloproliferative neo- 
plasms (27 out of 219 individuals, or 12%) and in those with myelofibrosis (4 out of 30 
individuals, or 13%) (Ernst et al., 2010). 
In addition to its role as a transcriptional repressor, several studies have shown that 
EZH2 may also function in target gene activation. It has been recently found that a sub- 
set of EZH2-bound genes did not bind the PRC2 subunit SUZ12 or display H3K27me3. 
Many of these genes were down regulated upon EZH2 knockdown, suggesting that the 
role of EZH2 as an activator was independent of the PRC2 complex (Xu et al., 2012). 
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They found that the oncogenic function of EZH2 in resistant prostate cancer cels is 
independent of its role as a transcriptional repressor, but it involves the ability of EZH2 
to act as a coactivator for critical transcription factors such as androgen receptor. 
	  
	  
	  
PRC2 accessory sub-unit: ASXL1 
	  
	  
The Additional sex combs like 1 (Asxl1) gene, located on 20q11 locus, is 1 of 3 mam- 
malian homologs of the Additional sex combs (Asx) gene of Drosophila. Asx genes are 
unusual because they belong to both PcG genes, which silence their targets, and trxG 
proteins that maintain transcriptional activation. These proteins that are capable of both 
activation and silencing are grouped in the Enhancer of trithorax and Polycomb (ETP) 
proteins (Katoh, 2013). 
Al mammalian ASXL  proteins have conserved sequence features: an amino- 
terminal ASX homology (ASXH) region and a carboxy-terminal plant homeodomain 
(PHD) domain (Fisher et al., 2010). ASXL1 (~165 kDa) functions autonomously as a 
transcriptional activator in human cancer cel lines that are retinoic acid (RA) sensitive. 
It enhances recruitment of RA receptors to their chromatin targets, and in the presence 
of the ligand RA, it interacts with the activation domain core of RA receptors to in- 
crease their activity. However, in other cancer cel lines that are RA resistant, ASXL1 is 
a co-repressor  of retinoic acid receptor (RAR) activity, supporting the  dual 
activator/repressor functions for mammalian ASXL  proteins  depending  on celular 
context (Cho et al., 2006). 
	  
Asxl1 is expressed in al hematopoietic cel fractions and Asxl1 knockout mice ex- 
hibit defects in frequency of diferentiation of lymphoid and myeloid progenitors, but 
not in multipotent progenitors. In addition no efects have been detected on hematopoi- 
etic stem cels, or in peripheral blood. These observations suggest that Asxl1 is needed 
for normal hematopoiesis (Fisher et al., 2010). 
ASXL1 interacts with components of PRC2, including EZH2 and SUZ12, and 
it has been shown that ASXL1 mutations result in loss of PRC2-mediated histone H3 
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lysine 27 tri-methylation; the re-expression of ASXL1 promotes H3K27me2/3 to par- 
tialy inhibit the aberant expression of the HOXA-cluster genes in ASXL1-nul leukemic 
cels and loss of ASXL1 in vivo promotes myeloid leukemogenesis (Abdel-Wahab et al., 
2012). It remains unclear whether ASXL1 binds directly to a PRC2 component, how- 
ever ASXL1 recruits PRC2 to specific genomic loci, where it adds the H3K27me3 to 
further recruit PRC1 for transcriptional repression (Katoh, 2013). 
It has been widely demonstrated that recurent somatic ASXL1 mutations occur 
in patients with myelodysplastic syndrome, myeloproliferative neoplasms, and acute 
myeloid leukemia, and these mutations are associated with adverse outcome. These 
mutations cause truncation of the protein downstream of the ASXH domain with con- 
sequent loss or translocation of the PHD domain in leukemic cels (Fisher et al., 2010). 
ASXL1 mutations have been identified in 13% of patients with MDSs and 43% of 
patients with CMML, 7% with primary and 47% with secondary AML (Teferi, 2010). 
ASXL1 was identified as the second most mutated gene after TET2 in BPDCN patients, 
reported by Menez et al. They demonstrated that (32%) of a total of 42 BPDCN (sam- 
ples obtained at diagnosis) studied cases were mutated by WES study (Menezes et al., 
2014). 
Taken together this evidence raises the possibility that perturbations in the epi- 
genetic modifying machinery play a crucial role in the pathogenesis of BPDCN and 
similar malignant hematopoietic disorders (Table 1). 
While the genetic causes of cancer have been intensively studied, it is becoming 
evident that a large proportion of cancer susceptibility cannot be atributed to difer- 
ences in protein-coding sequences.  This has been highlighted by genome-wide asso- 
ciation studies in cancer, revealing that more than 80% of cancer-associated single nu- 
cleotide polymorphisms (SNPs) occur in noncoding regions of the genome (Cheetham 
et al., 2013). There is emerging evidence indicating that a significant fraction of the 
genetic etiology of cancer is caused by noncoding regulatory sequences, particularly by 
long noncoding RNAs (lncRNAs). 
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TABLE 1: The role of mutations in epigenetic regulators in myeloid malignancies. 
 
2.2.2.7 Emerging epigenetic players: non-coding RNAs 
The work presented in this doctoral thesis indicates a critical role for lncRNA in BPDCN
pathogenesis. In this seting, I wil introduce and develop the importance of non-coding
RNAs (ncRNAs) in epigenetic regulation and how deregulation of this function can
contribute to cancer progression. 
The discoveries over the past decade have highlighted the evidences suggest- 
ing that there is an emerging category of molecules playing a crucial role in normal 
and neoplastic development (Cheetham et al., 2013).  These discoveries suggested that 
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RNA is not only functional as a messenger between DNA and protein but is also 
involved in the regulation of genome organization and gene expression.  These 
evidences were largely confirmed by analysis that compared transcriptomes with 
genomes  of  mammalian species. These data have established that approximately two-
thirds of genomic DNA is pervasively transcribed, but only <2% of these RNAs are 
ultimately translated into proteins (Djebali et al., 2012). This category of RNA is 
caled non-coding RNA.
ncRNAs comprise a diverse group of transcripts including ’housekeeping’ ncR- 
NAs (ribosomal RNA, transfer RNA, smal nuclear RNA and smal nucleolar RNA) 
and regulatory ncRNAs. Regulatory ncRNAs can be broadly classified according to 
their sizes in to smal ncRNAs (<200 bps, e.g. miRNAs, siRNAs, piRNAs) and large 
ncRNAs (e.g. lincRNAs, macroRNAs) (Pauli et al., 2011) (Table 2). Some ncRNA 
can also originate from various gene regulatory elements (enhancers, promoters, tran- 
scription start site (TSS) and terminators) and exert divers functions essentialy linked 
to gene expression regulation (Pauli et al., 2011). 
 
TABLE 2: Regulatory ncRNAs grouped by size.  
Long non-coding RNA 
Long ncRNAs (lncRNAs) comprise heterogeneous class of ncRNAs that are often polya- 
denylated and devoid of evident open reading frames (ORFs). Many roles are emerging 
for these RNAs in ribonucleo-protein complexes that regulate various stages of gene ex- 
pression. Unlike smal ncRNAs, lncRNAs can fold into complex secondary and higher 
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order structures to provide greater potential and versatility for both protein and target 
recognition (Gutman and Rinn, 2012). Moreover, their flexible and modular scafold 
nature enables them to tether protein factors that would not interact or functionaly co- 
operate if they only relied on protein-protein interactions (Tsai et al., 2010). 
A specific subgroup of lncRNAs is long intervening noncoding RNAs (lincRNAs, 
also caled long “intergenic” noncoding RNAs), which do not overlap exons of either 
protein coding or other non-lincRNA types of genes. LincRNAs are stable RNA poly- 
merase I products, and are nearly always capped and polyadenylated, and frequently 
spliced (Ulitsky and Bartel, 2013). 
Mechanisticaly lncRNAs can be divided in to two distinct functional groups con- 
cerning their sub-celular localization, nuclear and cytoplasmic lncRNAs. Cytoplasmic 
lncRNAs often show sequence complementarity with transcripts that originate from ei- 
ther the same chromosomal locus or independent loci.  These mechanisms permit for 
example the modulation of mRNA stability positively (Kretz et al., 2013) or negatively 
(Gong and Maquat, 2011), or act by competing with endogenous RNAs through their 
miRNA recognition motifs (Cesana et al., 2011).The recognition of the target by base 
pairing alows them specialy to  modulate translational control of protein expression 
(Carieri et al.,  2012, Yoon et al.,  2012). In contrast,  numerous evidences indicate 
that most nuclear lncRNAs function as gene transcription modulators. In the folowing 
section I wil develop more specificaly the functional mechanisms by which nuclear 
lncRNAs regulate gene expression in cels. 
	  
	  
	  
Mechanisms of function of nuclear long non-coding RNA 
	  
	  
Studies of dosage compensation, imprinting, and homeotic gene expression suggest that 
individual lncRNAs can function as the interface or scafold between DNA and specific 
chromatin remodeling factors (Ponting et al.,  2009). Nuclear lncRNA can act in cis, 
or in trans and activate  or repress  gene expression  via the recruitment  of chromatin 
modifying complexes (Figure  11). It  has  been shown that at least  38%  of lncRNAs 
present in several human tissues bind to the polycomb repressive complex 2 or other 
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repressive chromatin-modifying proteins (Khalil et al., 2009) and the rest of them bind 
to trithorax chromatin-activating complexes and/or activated chromatin (Dinger et al., 
2008), some of these mechanisms wil be further described both in physiological and 
pathological context in the next section. 
	  
	  
	  
Physiological roles of lncRNA expression in gene regulation 
	  
	  
X-chromosome inactivation 
	  
	  
Dosage compensation is among the first and best characterized example of lncRNAs 
required for normal development. They are responsible for the formation of silenced 
chromatin and thus the production of monoalelic expression of specific genes in mam- 
mals. 
X chromosome inactivation (XCI) is a compensation mechanism for dosage dif- 
ferences between males and female, it renders al cels functionaly monosomic for the 
X chromosome.  XCI is coordinated  by the  X-inactivation center (Xic),  which con- 
trols most of the steps of this process, including X chromosome counting, random X 
chromosome choice, and the initiation  of silencing along ~1000  genes  of the X. In 
mammals Xist (X-inactive specific transcript) is a lncRNA that is directly involved in 
the formation of repressive chromatin. Xist produces a 17-20 kb RNA that decorates 
the X chromosome during the initiation of XCI (Clemson et al., 1996). Xist RNA di- 
rects chromatin and transcriptional change by binding Polycomb repressive complex 2 
(PRC2), which is the epigenetic complex responsible for trimethylation of histone H3 at 
lysine 27 (H3K27me3) (Figure 11 Aa) from the nucleation center that consists of three 
binding sites for the transcription factor YY1 (Yin Yong 1, transcriptional repressor pro- 
tein), a protein bound only to the Xi (X-inactive) alele. PRC2 spreads initialy to 150 
strong binding sites along the future Xi. As XCI proceeds, the coating of the future Xi 
by Xist RNA corelates with recruitment of 3,000-4,000 moderate polycomb sites. The 
moderate sites cluster around strong sites facilitates the spreading of H3K27me3 in a 
graded concentration relative to strong sites (Lee and Bartolomei, 2013). 
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FIGURE 11: Models for nuclear lncRNA function: Long non-coding RNAs (lncRNAs) 
regulating transcription in cis (part A) and in trans (part B). Aa) cis-acting lncRNA 
examples are;  X-inactive specific transcript (Xist), Kcnq1 overlapping transcript  1 
(Kcnq1ot1) and Airn (antisense Igf2r (insulin-like growth factor  2 receptor) RNA. 
These lncRNAs induce the formation of repressive chromatin through the recruitment 
of DNA methyltransferase 3 (DNMT3), which induces DNA methylation; Polycomb 
repressive complex  2 (PRC2), which produces histone H3 lysine 27 trimethylation 
(H3K27me3); and histone lysine N-methyltransferase EHMT2, which is responsible 
for producing H3K9me2 and H3K9me3 (Lee and Bartolomei, 2013). Ab) HOXA 
distal transcript antisense RNA (HOTTIP) functions through the recruitment of the 
mixed lineage leukemia 1 (MLL1) complex, which drives the formation of the activat- 
ing H3K4me3 mark (Wang et al., 2011). Ba — HOXA transcript antisense RNA (HO- 
TAIR) is a trans-acting regulator of the HOXD genes (Rinn et al., 2007). It is character- 
ized by a modular scaffold structure that alows the recruitment of two distinct repres- 
sive complexes, PRC2 and the H3K4 demethylating complex KDM1A-coREST-REST 
(lysine-specific histone demethylase 1A-REST corepressor 1-RE1-silencing transcrip- 
tion factor) on the same genomic region (Tsai et al., 2010). Bb — The pluripotency 
RNAs lncRNA-ES1 and lncRNA-ES2 associate with both PRC2 and the transcription 
factor sex-determining region  Y-box  2 (SOX2), which suggests that these lncRNAs 
control embryonic stem cel pluripotency by silencing SOX2-bound developmental 
genes (Ng et al., 2012) ; this function is alternative to OCT4 -and SOX2-dependent ac- 
tivation of pluripotency genes. Bc — The lncRNA Jpx (Jpx transcript, Xist activator) 
that binds to the transcriptional repressor CTCF inhibits its binding to the Xist pro- 
moter, thus activating Xist transcription (Sun et al., 2013). From (Fatica and Bozoni, 
Nat Rev Genet, 2014) 
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Xist expression itself is controled by other lncRNAs in both a positive and a neg- 
ative manner. Tsix is one of the best-characterized Xist regulators, which is a natural 
antisense non-coding transcript. Tsix counteracts Xist expression by inducing repressive 
epigenetic modifications at the Xist promoter (Lee and Bartolomei, 2013). Xist activa- 
tion also requires the lncRNA Jpx (Tian et al., 2010), which induces Xist transcription 
through the sequestration of transcriptional repressor CTCF (Figure 11 Bc) (Fatica and 
Bozzoni, 2014). 
	  
	  
	  
Genomic imprinting 
	  
	  
Genomic imprinting is briefly defined as parental-specific gene expression. Imprinted 
genes are  generaly associated in clusters and are epigeneticaly marked in diferent 
and sex-dependent ways during male and female gametogenesis and embryonic devel- 
opment. Similarly,  genomic imprinting is regulated  by cis-acting imprinting control 
regions (ICRs) that influence alelic expression across long distances. 
Imprinted  genes encode various species  of ncRNAs, including lncRNAs (in 
general longer than  100  kb). In many cases, these lncRNAs  bind to imprinted 
regions and are  directly involved in silencing. Two  best-characterized examples are 
the lncRNAs Kcnq1 overlapping transcript  1 (Kcnq1ot1) and Airn (antisense Igf2r 
(insulin-like growth factor 2 receptor) RNA); these lncRNAs are paternaly expressed, 
and function by repressing flanking protein-coding genes in cis (Lee and Bartolomei, 
2013).  During embryonic development, Kcnq1ot1 establishes and  maintains 
repressive DNA methylation  on surounding  genes,  whereas, in the  placenta, it 
functions  by recruiting the repressive  histone  modifiers PRC2 and euchromatic 
histone-lysine  N-methyltransferase 2 (EHMT2) (also known as  G9a)  on  genes that 
are located further away from the im- printed region (Mancini-Dinardo et al., 2006). 
The other example is Airn, which silences the paternal Igf2r alele in cis, whereas 
the  maternal Igf2r alele remains expressed. In embryo,  Airn silences  paternal Igf2r 
through a  mechanism that  does  not require a stable RNA  product but that is  based 
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on continuous Airn transcription, which interferes with the recruitment of RNA poly- 
merase I (Latos et al., 2012), but in placenta, mature Airn recruits EHMT2 to induce 
the formation of repressive chromatin (Sleutels et al., 2002) (Figure 11 Aa). 
	  
	  
	  
Regulation of HOX genes 
	  
	  
In mammals, there are 39 HOX genes that are grouped in four clusters (HOXA, HOXB, 
HOXC and HOXD), which alow precise spatiotemporal expression of evolutionary con- 
served family of transcription factors. In addition to protein-coding genes, these clus- 
ters produce lncRNAs that show similar spatiotemporal windows of expression to their 
flanking  protein-coding  genes and it  has  been shown that they are implicated in the 
regulation of HOX genes (Rinn et al., 2007). 
HOTTIP is the cis-acting antisense transcript of HOXA locus. HOTTIP regulates 
HOXA expression by interacting with the activating H3K4 methyl transferase, mixed 
lineage leukemia 1 (MLL1) complex, and by the formation of chromatin loops that con- 
nect distaly expressed HOTTIP transcripts with various HOXA gene promoters (Wang 
et al., 2011) (Figure 11 Ab). 
HOTAIR (HOXC transcript antisense RNA) was one of the first trans-acting lncR- 
NAs to be identified and it acts as a repressor of the HOXD cluster, which is located on 
a diferent chromosome. HOTAIR acts as a molecular scafold with two known chro- 
matin modification complexes; the 5’ region of this lncRNA binds to the PRC2 complex 
responsible for H3K27 methylation and the 3’ region binds to LSD1, which mediates 
enzymatic demethylation of H3K4 (Tsai et al., 2010) (Figure 11 Ba). 
	  
	  
	  
Long noncoding RNA in cancer development 
	  
	  
As for protein coding genes, ncRNAs contribute to the regulatory networks that par- 
ticipate to cancer development.  Their implication in cancer development has been de- 
tected by various techniques including RNA-sequencing (RNA-seq), next generation 
sequencing, and methylation analysis (Trapnel et al., 2010). These approaches have 
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led to the identification of several lncRNAs whose expression and the epigenetic state 
of their coding genes were associated with cancer cels or tissues. Proteins, controling 
chromatin organization including polycomb repressor complexes, PRC1 and PRC2, and 
members of the trithorax family constitute key players in the molecular pathogenesis of 
cancer. As mentioned before, many evidences suggest that a major role of lncRNAs is 
to guide the site-specific chromatin-modifying complexes to target genes and contribute 
to the epigenetic modification of these genes (Matick and Gagen, 2001). Recent stud- 
ies have linked the miss-expression of wel-characterized lncRNAs to diverse cancers, 
such as HOTAIR in breast cancer,  AINRIL and SChLAP1 in prostate cancer (Gupta 
et al., 2010, Kotake et al., 2011, Prensner et al., 2013). 
HOTAIR is  one  of the first lncRNA discovered to  be involved in tumorigene- 
sis. Its expression is up regulated in primary tumors and up to 2000-fold in metastatic 
breast cancer (Gupta et al., 2010). Overexpression of HOTAIR in epithelial cancer cels 
induces genome-wide re-targeting of PRC2 to an occupancy patern more resembling 
embryonic fibroblasts, resulting to altered histone H3 lysine 27 methylation, gene ex- 
pression, and increased cancer invasiveness and metastasis in a PRC2 dependent man- 
ner (Gupta et al., 2010). 
Prostate cancer is another example in which lncRNAs has been implicated in dis- 
ease development and progression. As an example, SChLAP, a lncRNA identified by 
RNA-seq in prostate cancer, shows high level expression in aggressive forms is predic- 
tive of poor outcomes, and metastasis. SChLAP1 appears to mediate this function by 
antagonizing the genome-wide localization and regulatory functions of the SWI/SNF 
chromatin-modifying complex (Prensner et al.,  2013).  SWI/SNF complexes interact 
with transcription factors, co-activators, and corepressors and are capable  of 
mobilizing  nucleosomes at target  promoters and enhancers to  modulate  gene 
expression (Tolstorukov et al.,  2013).  Loss  of  SWI/SNF complex functionality 
promotes cancer  progression, and it  has  been shown that  multiple  SWI/SNF 
components are somaticaly inactivated in cancer (Reisman et al., 2009). 
AINRIL (antisense  non-coding RNA in the INK4 locus) is a  3.8  kb-long  non- 
coding RNA expressed in the opposite direction from INK4A-ARF-INK4B gene cluster 
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and is important for expression  of the  protein-coding  genes in cis. ANRIL activates 
two polycomb repressor complexes, PRC1 and PRC2 by direct binding to chromobox 
7 (CBX 7) and SUZ12, members of PRC1 and PRC2, respectively (Kotake et al., 2011, 
Yap et al., 2010). This results in silencing the INK4b-ARF-INK4a locus encoding tumor 
suppressors p15INK4b, p14ARF, and p16INK4a, which are usualy altered in an esti- 
mated 30-40% of human tumors.  These genes are implicated in cel cycle inhibition, 
senescence and stress-induced apoptosis. 
Selective  binding  of lncRNAs, such as HOTAIRE, ANRIL and SChLAP1 with 
chromatin modifying complexes and execute histone modifications at specific loci thus 
strongly supports the idea that lncRNAs may function as ideal epigenetic regulators in 
cels (Kotake et al.,  2011). LncRNAs are also implicated in  other celular functions 
such as DNA repair in response to genotoxic stress (Prensner et al., 2014), but to our 
knowledge the main function of lncRNAs curently is the regulation of gene expression, 
therefore it is obvious that their maintained expression remains critical in order to keep 
celular homeostasis and prevent the neoplastic transformation. 
	  
	  
	  
2.2.3 Gene expression profiling of BPDCN - insights to molecular 
pathogenesis 
	  
Besides chromosomal abnormality and mutational analysis, gene expression profiling 
(GEP) provides important insights, which cannot be explored by cytogenetic and mu- 
tational studies. For example Dijkman et al performed GEP analysis on 5 BPDCN and 
3 cutaneous-AML samples and have identified high-level expression of Notch signal- 
ing genes (HES6, RUNX2). Moreover, despite the mono-alelic deletion of FLT3 gene, 
increased expression of FLT3 oncogene was also observed in BPDCN, coincident with 
expression  of  both  myeloid and lymphoid specific  gene expression (Dijkman et al., 
2007). 
In a second study, a  global GEP analysis  on  6  BPDCN cases, in comparison 
with normal pDCs, myeloid and lymphoid precursor cels has demonstrated predom- 
inant expression of myeloid lineage genes and resting pDCs. This work also discov- 
ered evidence of an aberant activation of the NF-κB pathway in BPDCN, which was 
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confirmed by Immunohistochemistry (IHC) by showing the nuclear localization of key 
components of NF-κ	  complex (c-Rel and p50) in BPDCN-derived cel line and BPDCN 
cases, in contrast to normal pDCs, which presented a cytoplasmic staining.  This was 
associated to sensitivity to NF-κB inhibition and thus suggestive of a novel therapeutic 
strategy in BPDCN (Sapienza et al., 2014). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Chapter 3 
	  
	  
Clinical management of BPDCN 
	  
	  
Given BPDCNs rarity and only recent recognition as a distinct clinico-pathological en- 
tity, no standardized therapeutic approach has been established for BPDCN and the op- 
timal therapy remains to be defined. Curent practice considers acute myeloid leukemia- 
like  or acute lymphoblastic leukemia (ALL)-like regimens acceptable for induction 
treatment. 
Patients  usualy respond wel to initial chemotherapy, with complete response 
rates  of  47% to  86%. However, the  disease  often relapses, and the relapsed cases 
are typicaly resistant to the previously used chemotherapeutic agents (Facheti, 2008, 
Feuilard et al., 2002). Outcomes are more favorable in cases that lack cutaneous disease 
at presentation, although a comparison of cutaneous and non-cutaneous cases might be 
confounded  by diferences in treatment regimens. Conversely,  patients with isolated 
cutaneous lesions survive longer (Alayed et al., 2013, Shi and Wang, 2014). 
These short-lived responses, with second remissions that  are difficult to 
achieve, underscore the need to consider hematopoietic cel transplantation early in the 
disease course (Kharfan-Dabaja et al.,  2013) as long lasting remissions have  been 
documented in sporadic cases,  usualy  occuring in  young  patients  who have  been 
treated with acute leukemia-type induction therapy, folowed by alogeneic stem cel 
transplantation in first complete remission (Facheti, 2008). 
	  
	  
53 
Chapter 3. BPDCN clinical management 54 
	  
	  
	  
Durable remissions  have  been observed even in elderly  patients, folowed  by 
allogeneic stem cel transplant from  matched related  or  unrelated  donors after  high-
dose chemotherapy; in a retrospective study  on  39  patients with  BPDCN  who 
underwent alogeneic stem cel transplantation (alo-SCT),  n  =  34,  or autologous 
stem cel trans- plantation (auto-SCT),  n  =  5.  The  3-year cumulative incidence  of 
relapse, disease-free survival, and overal survival  of these  patients was  32%,  33%, 
and 41%, respectively (Roos-Weil et al., 2013). 
It is noteworthy that although the  disease is recognized among acute  myeloid 
leukemias and acute myeloid leukemia-like regimes are often adopted, recent reports 
have suggested a potential role for ALL-like protocols (Pagano et al., 2013, Piccaluga 
et al., 2012, Pileri et al., 2012). Recently, in a case report study, it has been demon- 
strated that using a combined ALL-like and AML-like treatment protocols folowed by 
cord blood stem cel transplant have achieved a complete remission (10 months since 
diagnosis) (Ramanathan et al., 2013). 
Since AML, ALL and lymphoma type therapies actualy are  used for  BPDCN 
treatment, therefore these therapies are explained in the folowing section. 
	  
	  
	  
3.1 Conventional AML type therapy 
	  
	  
Traditionaly AML treatment involves two phases:  1) remission induction therapy, 2) 
consolidation, or post-remission, therapy and then maintenance therapy. Remission in- 
duction is  designed to  bring about complete remission, and consolidation therapy is 
designed to  kil any remaining leukemia cels. AML is  usualy treated with two  or 
three anti-cancer  drugs (combination chemotherapy): the initial treatment applied to 
AML consists of cytosine arabinoside (ara-C or Cytarabine) (is a nucleoside analogue 
that incorporates DNA and induces apoptosis) combined with anthracycline (DNA and 
RNA intercalating that prevents DNA replication and transcription). Consolidation ther- 
apy includes  one to two courses  of  high-dose chemotherapy  using  only ara-C,  or a 
hematopoietic cel (stem cel or bone marow) transplant (Roboz, 2012). 
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Most  patients wil experience a relapse  of their disease  without this additional 
therapy.  Approximately 70%-80% of patients <60 years of age wil achieve complete 
remission, but most ultimately relapse and overal survival is only 40%-45% at 5 years 
(Roboz, 2011). 
	  
	  
	  
3.2 Conventional ALL type therapy 
	  
	  
Glucocorticoids (GCs) particularly prednisone and dexamethasone were among the first 
drugs used in the treatment of acute lymphoblastic leukemia (ALL) and have remained 
essential components of therapy. The most commonly used steroids are dexamethasone 
and  prednisone. ALL  has a  higher incidence rate in children than in adults with a 
median age  of  39  years. Treatment  usualy includes  multi-agent chemotherapy with 
induction, consolidation, and maintenance. 
Although a significant number of ALL patients respond wel to GCs, some re- 
veal  primary GC resistance; approximately  10%  of children with ALL wil respond 
poorly to GCs, and GC resistance is associated with a significantly inferior outcome 
(Bhadri et al.,  2012). In addition, those sensitive to GCs almost exclusively develop 
secondary resistance after prolonged GC therapy (Roychowdhury and Talpaz, 2011). 
Without GC sensitivity the leukemic cels are no longer induced into apoptosis by the 
treatment (Bhadri et al., 2012). Resistance to GCs in ALL has been extensively studied 
but remains very poorly understood at the mechanistic level. (Bhadri et al., 2012). 
	  
	  
	  
3.3 Conventional Lymphoma type therapy 
	  
	  
As BPDCN had been classified as Natural kiler (NK)/T-cel lymphomas and NK-cel 
leukemias, T-cel lymphoma, lymphoma type therapy has been used in BPDCN clinical 
management. These lymphomas are aggressive malignancies in which neoplastic cels 
present surface marks such as CD56+ and with cytoplasmic germ line T-cel receptor 
gene. They occur commonly in the nasal and upper aerodigestive with occasional skin 
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lesions. Concomitant/sequential chemotherapy and radiotherapy is standard treatment; 
L-asparaginase (a hydrolase that catalyzes the L-asparagine to an endogenous amino 
acid necessary for the function of some neoplastic cels and resulting in inhibition of 
RNA and DNA synthesis with the subsequent blastic cel apoptosis) has been incorpo- 
rated into several regimens as it was found to be efective for relapsed/refractory NK/T- 
cel lymphomas.  One of the most intensive regimens used curently against NK/T cel 
lymphoma is a chemotherapy protocol caled “SMILE” that consisted of steroid (dex- 
amethasone), methotrexate, ifosfamide (causing interstrand cross-links (ICLs) and thus 
induces apoptosis), L-asparaginase and etoposide (Tse and Kwong, 2013). 
Etoposide is a potent anti-tumor drug used as an apoptosis-inducing chemother- 
apy agent that belongs to the class of topoisomerase poisons. It has the ability to stabi- 
lize the covalent complex between DNA topoisomerase I (Topo I) and DNA, resulting 
in a high level of DNA damage. Topo I is an essential enzyme that controls the topol- 
ogy of DNA by passing an intact double helix through a transient double-stranded DNA 
break in an ATP-dependent reaction which eventualy leads to apoptosis (Montecucco 
and Biamonti, 2007). 
There are  other lymphoma-type protocols that are  used in  BPDCN containing 
multiagent chemotherapy, such as CHOP (cyclophosphamide, doxorubicin, vincristine, 
and prednisone),  or hyper-CVAD (combination of course A: cyclophosphamide,  vin- 
cristine,  doxorubicin; and course  B: methotrexate and cytarabine, in an alternating 
fashion). These are efective and have been shown to be superior to AML type ther- 
apy (Pagano et al., 2013). 
	  
	  
	  
Glucocorticoids receptor signaling 
	  
	  
Because  of the relevance  of  Glucocorticoid receptor (GCR) signaling to the  present 
work, an overview  of  GCR signaling is given below. It should  be  noted that intense 
eforts are curently underway to derive novel GCR agonists and antagonists and for 
novel synergy particularly with epidrugs. Briefly, Glucocorticoids (GCs) are a class of 
Chapter 3. BPDCN clinical management 57 
	  
	  
	  
steroid hormones that regulate a wide range of physiologic functions and play an impor- 
tant role in the maintenance of basal, stress-related homeostasis and they are involved 
in most of celular regulation networks. It is worth noting that around 20% of the genes 
expressed in human leukocytes are regulated positively or negatively by glucocorticoids 
(Nicolaides et al., 2010). 
The human (h)GCR belongs to the steroid/thyroid/retinoic acid, superfamily of 
transcription factor  proteins and functions as a ligand-dependent transcription factor. 
The hGCR gene is located on chromosome 5(5q31) and consists of nine exons. Two 
highly homologous isoforms of GCR are found, termed α	  and β	  with 97 and 94 kDa, 
molecular weights respectively.  There is conflicting evidence that GCRα	  is the func- 
tional isomer, whereas GCRβ	  does not bind GC, is transcriptionaly inactive and poten- 
tialy functions as a dominant negative inhibitor of GCR activity (Bhadri et al., 2012). 
The human GCR is composed of an N-terminal domain, containing the transactivation 
domain termed activation function (AF)-1, a DNA-binding domain and a hinge region 
and the ligand-binding domain (Figure 12). The transactivation domain plays an impor- 
tant role in the interaction of the receptor with molecules necessary for the initiation of 
transcription, such as co-activators, chromatin modulators and basal transcription fac- 
tors, including RNA-polymerase I, TATA-binding protein (TBP). The DNA-binding 
domain (DBD) contains two zinc finger motifs through which the GCR binds to specific 
DNA sequences (glucocorticoid-response elements (GREs) in the promoter regions of 
target genes. The DBD also contains sequences important for receptor dimerization and 
nuclear translocation. 
	  
The hinge region is a flexible region between the DNA- and ligand-binding do- 
mains, which is involved in its dimerization.  The ligand-binding domain (LBD) of the 
GCR coresponds to amino acids 481-777, binds to glucocorticoids and is implicated 
in the ligand-induced activation of GCR. The LBD also contains a second transactiva- 
tion domain or AF-2, which is important for receptor dimerization, nuclear transloca- 
tion,  binding to the heat shock proteins (Nicolaides et al., 2010). The glucocorticoid 
receptor protein is subjected to post-translational modifications, which impact on the 
glucocorticoid receptor function (McMaster and Ray, 2008) (Figure 12). 
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FIGURE 12: Structure of the glucocorticoid receptor; the coding regions are indi- 
cated by gray boxes encoded within nine exons; is. The N-terminal domain contains 
the major transactivation function domain, AF-1. The DBD consists of two -helices, 
which coordinate two zinc atoms. This domain is important for dimerization, nuclear 
translocation, and binding glucocorticoid-response elements and subsequent transac- 
tivation. The LBD undergoes conformational change when it binds ligand, enabling 
interaction with coregulator proteins. Additional functional domains are indicated by 
the thick horizontal lines marked beneath the structure: the HSP-binding domain; the 
homodimerization domain; the major transactivation domains AF-1 and AF-2; and the 
region that functionaly interacts with AP-1 and NFB. Abbreviations: AF-1, hormone- 
independent transactivation function domain; AF-2, transactivation domain; AP-1, 
adapter protein complex 1; DBD, DNA-binding domain; HSP, heat-shock protein; 
LBD, ligand-binding domain; NFB, nuclear factor B; P, sites of phosphorylation on 
serine or threonine residues; SUMO, sites of SUMOylation (post-translational modifi- 
cation mediated by smal, ubiquitin-related modifier proteins); U, site of ubiquitination 
(post-translational modification mediated by ubiquitin). From (McMaster and Ray, Nat 
Clin Pract Endocrinol Metab, 2008) 
	  
	  
Nucleocytoplasmic translocation of GCR 
	  
	  
In the absence of ligand, GCR can be found mostly in the cytoplasm as part of a hetero- 
oligomeric complex, which contains chaperone heat shock proteins (HSPs) 90, 70 and 
50, immunophilins and other proteins. HSP90 regulates cytoplasmic retention of GCR 
by exposing the ligand-binding site and masking the two nuclear localization sequences 
(NLS), NL1 and NL2, which are located respectively adjacent to the DBD and in the 
LBD of the receptor. Upon ligand-induced activation, the receptor undergoes a confor- 
mational change that results in dissociation from this multiprotein complex and translo- 
cation into the nucleus (Prat, 1993). 
Within the nucleus, the receptor forms a homodimer to GREs in the promoter 
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regions  of target  genes,  or it interacts as a  monomer with  other transcription factors 
protein-1 (AP-1), nuclear factor-κB (NF-κB), p53 and signal transducers and activators 
of transcription (STATs) and regulates gene expression (Nicolaides et al., 2010). Some 
of these factors result in Glucocorticoid dependent-lympholytic actions and that’s the 
reason why they are included in many therapeutic regimens for the treatment of various 
forms of leukemia and lymphoma. As mentioned earlier, significant number of acute 
lymphoblastic leukemia  patients respond wel to GC treatment  during initial  phases, 
although prolonged treatments sometimes results in steroid-resistance (Hilmann et al., 
2000). 
	  
	  
	  
3.4 Emerging therapeutic strategies 
	  
	  
As discussed above, there is curently no consensus on the optimal treatment for BPDCN. 
Radiotherapy or local chemotherapy is ineficient and only patients receiving systemic 
polychemotherapy regimens are likely to achieve complete remission, even if responses 
are short and mostly folowed by drug resistance and relapse in most patients. Molecular 
profiling in BPDCN suggests that a number of novel targeted agents might be useful in 
this disease. 
	  
	  
	  
3.4.1 Inhibitors of signaling pathways 
	  
	  
3.4.1.1 IL3 receptor pathway 
	  
	  
Granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and 
IL-5 are members of a smal family of cytokines that regulate the production and activ- 
ities of many hematopoietic cels.  Their activities are mediated through binding to the 
few but high affinity membrane receptors. 
IL-3 is expressed mostly by activated T lymphocytes and mast cels and is impor- 
tant for the regulation of mast cels function.  One of the biologic activities of IL-3 is 
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exerted at the level of the progenitor compartment, where this cytokine stimulates the 
survival and proliferation of multipotent cels (Hercus et al., 2013). 
It has been observed that interleukin-3 receptor α	  (IL3Rα) (also known as CD123) 
is over expressed in progenitor cels from patients with AML, and blast cels from pa- 
tients with AML proliferate in response to IL-3 (Jordan et al., 2000). IL3Rα	  overex- 
pression is strongly corelated with short  patient survival (Vergez et al.,  2011). High 
IL3Rα	  surface expression is  ubiquitous in  BPDCN  blasts but negligible in  normal 
hematopoietic stem cels and BPDCN blasts in vitro require IL3 supplementation for 
growth and survival (Chaperot et al., 2001, Jordan et al., 2000). 
In a recent study Frankel and coleagues  used SL-401 protein (a recombinant 
fusion  protein composed  of the catalytic and translocation  domains  of  diphtheria 
toxin (DT) fused  via a  Met-His linker to IL3) (Frankel et al.,  2000) as a targeted 
therapy for BPDCN on a cohort of patients (Frankel et al., 2014).  The IL3 domain of 
SL-401, stil capable of binding to its natural receptor, is then internalized, leading to 
translocation of the DT fragment to the cytosol. SL-401 inhibits protein synthesis by 
ADP ribosylation of elongation factor  2. They  demonstrated that  7  of  9 evaluable 
(78%) BPDCN patients had  major responses including  5 complete responses and  2 
partial responses after a single course of SL-401. The median duration of responses 
was 5 months (range, 1- 20+ months) (Frankel et al., 2014). 
	  
	  
3.4.1.2 NF-kB pathway 
	  
	  
Nuclear factor (NF)-κB is a family of transcription factors that comprises diverse mem- 
bers: p50, p65/RelA, c-Rel, p52, and RelB (Wan and Lenardo, 2009). These transcrip- 
tion factors are implicated in the control of many diferent celular mechanisms such 
as the innate- and adaptive-immune responses and programmed cel death (apoptosis). 
They can  both induce and repress  gene expression  by  binding to  promoters and en- 
hancers of DNA sequences known as κB elements. NF-kB is normaly sequestered in 
the cel’s cytoplasm by a protein caled Inhibitor of NF-κB (IκB). Numerous signal- 
ing pathways induce the activation  of NF-κB  during  which IκBs  get  phosphorylated 
and then ubiquitinylated, resulting in IκB degradation by proteasome and the activation 
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of NF-κB. In the absence  of IκBs, NF-κB is free and can translocate to the  nucleus 
(Perkins, 2007). 
	  
As mentioned earlier in a recent study by Sapienza et al., gene expression profiling 
(GEP) and functional tests show a  preclinical rational for NFκB pathway inhibitors 
(Bortezomib) in BPDCN. 
	  
Bortezomib is a wel-known proteasome inhibitor curently employed in the treat- 
ment of multiple myeloma and some non-Hodgkin lymphomas and block proteasome 
degradation and thus prevents the NF-kB activation (Sapienza et al.,  2014).  Borte- 
zomib has been already demonstrated to be very efective and induce rapidly BPDCN 
cel death in ex-vivo experiments (Hirai et al., 2011). 
	  
	  
	  
3.4.2 Epidrugs 
	  
	  
As explained in previous sections, gene mutations impinging on epigenome modifiers 
are recurent in  BPDCN (TET2 mutations, ASXL1 and MLL alterations)  Epigenetic 
therapy can at least in theory counter the ensuing epigenetic disturbances in BPDCN 
and should show some anti-leukemic activity.  Gene  derepression consequent to loss 
of PRC2 function could be countered by HAT (histone acetyl transferase inhibitors) or 
even BET (bromo and extra terminal domain) protein inhibitors while as mentioned ear- 
lier DNMT inhibitors could counter DNA hypermethylation phenotypes associated to 
TET2 mutation. More detailed functional studies including epigenome profiling (ChIP- 
seq and DNA methylation profiling / sequencing) wil be required to determine the best 
strategies and which patients are most likely to benefit from epidrug therapy. 
	  
	  
3.4.2.1 Hypomethylating agent 5-Azacytidine 
	  
	  
As mentioned earlier partial or complete chromosomal losses and mutations are com- 
mon in  myeloid  malignancies.  But loss  of  gene function can also result from 
epigenetic transcriptional silencing through methylation of promoter-associated CpG 
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islands and/or post-translational deacetylation of histones (Haase et al., 2007). Aber- 
rant DNA methylation has been described in cancer cels, and it is hypothesized that 
azanucleoside therapy induces DNA hypomethylation and re-expression of aberantly 
silenced genes particularly tumor suppressor genes in patients with these disorders (Fig- 
ure 13). 
 
	  
	  
FIGURE  13: Proposed mechanism of action of Azanucleosides. From (Quintás- 
Cardama et al., Nat Rev Clin Oncol, 2010) 
	  
	  
Azanucleosides (such as 5-azacitidine and decitabine) are cytidine analogues that 
incorporate into DNA or RNA and form covalent complexes with DNA methyltrans- 
ferases resulting in the depletion of active enzymes. Over the successive rounds of cel 
replication, exposure to hypomethylating agents leads to chromatin decondensation and 
re-expression  of silenced  genes. 5-azacitidine therapies have  been shown,  prolonged 
survival in patients with MDS (Quintas-Cardama et al., 2010). 
Laribi et al. have recently treated two  BPDCN cases with  5-azacytidine,  both 
patients showed excelent responses of their skin lesions after one cycle of chemother- 
apy, and their hematological disease was stabilized, however they passed away for other 
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medical complications (Laribi et al., 2014).  This and similar studies highlight the pos- 
sible  beneficial efects  of  5-Aza as a  part  of the course  of treatment, and  open new 
therapeutic opportunities for BPDCN patients. 
	  
	  
3.4.2.2 BET bromodomain inhibitors 
	  
	  
The studies of epigenetic machinery and its deregulation have led to the development 
and use of a wide range of modulatory molecules directed not only at chromatin en- 
zymes (histone acetyltransferases, histone deacetylases, histone methyltransferases, hi- 
stone demethylases and DNA methyltransferases) but also toward the emerging class of 
chromatin-associated proteins (Filippakopoulos et al., 2010). 
One of these chromatin-associated proteins is the bromodomain and extraterminal 
domain (BET) family  of adaptor  proteins.  This family is comprised  of  Brd2 (~110 
kDa),  Brd3 (~80  kDa),  Brd4 (~152  kDa), and  Brdt (~108 kDa),  which  performs 
diverse roles in regulating the transcription by RNA polymerase I (Pol I). BET family 
proteins are involved in transcription regulation and cel growth and are also implicated 
in cancer. Every  member  of  BET family  proteins  posses two conserved  N-terminal 
bromodomains (BD1 and BD2),  which recognize and interact with acetylated lysine 
residues on histone tails and other nuclear proteins. The recent discovery of potent and 
highly specific inhibitors for the BET proteins has stimulated intensive research activity 
particularly in oncology (Filippakopoulos and Knapp, 2014). 
	  
There are two independent groups of smal-molecule inhibitors of BET bromod- 
omains, caled JQ1 and I-BET, which have a similar chemical structure and mode of 
target inhibition (Filippakopoulos and Knapp, 2014). JQ1 is the first selective inhibitor 
of BET family proteins and can bind the lysine-binding pocket of bromodomain and 
show shape complementarity (Filippakopoulos et al., 2010). 
It has been demonstrated that BET bromodomains play an important role in sup- 
porting the transcription of known oncogenes (MYC and BCL2) in leukemia and lym- 
phoma (Chapuy et al., 2013, Dawson et al., 2011, Zuber et al., 2011). Filippakopoulos 
and coleagues suggested that BET inhibition presented an anti-tumor efect by at least 
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two complementary activities: a specific efect on high BRD4 loaded enhancers (super- 
enhancers) and a more general suppression of transcription at E2F- and MYC-driven 
target genes which are under the control of such enhancers, for example in a difuse large 
B cel lymphoma model.  Thus, the E2F/MYC pathway efect is combined with mas- 
sive depletion of proteins driven by BRD4-overloaded enhancers, preventing cel cycle 
progression and leading to growth arest. These super-enhancers prove particularly sen- 
sitive to bromodomain inhibition, explaining the selective efect of BET inhibitors on 
oncogenic and lineage-specific transcriptional circuits (Chapuy et al., 2013). 
JQ1 displays also antitumor efects in human xenograft models of NUT midline 
carcinoma, inducing cancer cel diferentiation and growth arest in these cels (Fil- 
ippakopoulos et al., 2010).  Using an RNAi screen and JQ1 simultaneously identified 
BRD4 as a strong therapeutic target and associated JQ1 with robust antileukemic ef- 
fects in vitro and in vivo models of AML, accompanied by terminal myeloid diferenti- 
ation and elimination of leukemia stem cels (Zuber et al., 2011). It is noteworthy that 
JQ1-mediated BET inhibition and consequent antitumor activity are partly due to MYC 
suppression through disruption of the ability of BET proteins to bind MYC locus (Zuber 
et al., 2011). 
It has been also been demonstrated that in vitro treatment of lymphoma B cels 
with JQ1, can inhibit the aggressive atitude  of MYC-over-expressing tumors and 
increase the sensitivity  of  human lymphoma  B cels to  Rituximab (Emadali et al., 
2013). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Scientific arguments 
	  
	  
Blastic plasmacytoid  dendritic cel  neoplasm (BPDCN) (also termed  Blastic  natural 
kiler (NK) cel lymphoma or agranular CD4+/CD56+ hematodermic neoplasm) is a 
recently described entity, with the first case reported in 1994 (Adachi et al., 1994). It 
is a rare, clinicaly aggressive hematologic malignancy with a median overal survival 
(OS) of 12-14 months and frequent relapses (Facheti, 2008). Chaperot and coleagues 
were the first to report and recognize that this disease is a malignancy of the pDC lin- 
eage (Chaperot et al., 2001). By performing an immunophenotypic study on 7 BPDCN 
patients, they demonstrated that these tumor cels presented a distinct immunopheno- 
type; lin−, CD123+, CD4+, CD56+, CD3−, CD13−, CD33−, and CD19−.  More 
importantly leukemic cels  upon IL-3 treatment,  BPDCN cels  became powerful 
inducers  of  T-cel proliferation and  produced considerable amounts  of IFN-α	  in 
response to inactivated influenza  virus (Chaperot et al.,  2001).  Based  on this and 
clinical and pathological criteria, BPDCN is classified within Acute Myeloid Leukemia 
(AML) and  myeloid related neoplasms in the  2008 WHO classification  of tumors 
(Facheti, 2008). 
	  
Curently clinical strategies for BPDCN are restricted to conventional AML/ALL 
or lymphoma type chemotherapy. Relapses are frequent and invariably fatal, indicating 
the  necessity for rationalized new therapeutic strategies for this disease. To  date 
neither genetic  nor clonal  origin  of this  disease is known. Patients  display complex 
chromosomal abnormalities afecting in decreasing frequency 5q (5q21 and 5q34), 12p 
(12p13), 13q (13q13 and 13q21), 6q (6q23-ter), 15q and chromosome 9 (Jardin et al., 
2009, Leroux et al., 2002, Petrela et al., 2005). More recently, additional recurent dele- 
tions of chromosomal regions have been identified such as (4q34, 9p13-p11, 9q12-q34 
and 13q12-q31) (Dijkman et al., 2007).  A single translocation t(2;17;8)(p23;q23;p23) 
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case has also been reported lately (Tokuda et al., 2014) and gene mutations afecting 
TP53 (p53), TET2 and ASXL1 have been identified by next generation sequencing ap- 
proaches (Jardin et al., 2009, 2011, Menezes et al., 2014). 
In  order to have a  beter  understanding  of  molecular  mechanisms  underlying 
BPDCN oncogenesis, we have performed molecular and functional analysis of a novel, 
balanced chromosome translocation t(3;5)(q21;q31) observed in a BPDCN patient at 
our center (BPDCN cel line, GEN2.2) (Chaperot et al., 2006, Leroux et al., 2002). Our 
results demonstrated that this translocation targets the NR3C1 gene encoding the gluco- 
corticoid receptor (GCR), (located at 5q31), and a novel nuclear long non-coding RNA 
gene on 3q21, which here is named lincRNA-3q. 
Chromosome 5q deletions are common in AML and myelodysplastic syndromes 
(MDS),  pointing toward the  pathogenic role  of this region in these  diseases (Jerez 
et al.,  2012). Using  both clinical  data and  biological samples from a large cohort 
of  47  BPDCN  patients,  gathered through the “Groupe  Francophone  Cytogénétique 
Hématologiques” and external colaborations (Besancon, France and Leiden, Nether- 
lands), we  demonstrate that NR3C1 gene  deletion is a critical  pathogenetic event in 
BPDCN  pathogenesis, confering  particularly  dismal  prognosis. NR3C1 gene alter- 
ations have been already described in a subset of relapsing B-ALL, (Kuster et al., 2011, 
Mulighan et al., 2008). 
Functional studies revealed the t(3;5) to encode a fusion protein, GCR-FP, which 
interfere with  GCR signaling pathway including response to therapy. Strikingly, al- 
tered GCR signaling was also functionaly linked to misregulation of major epigenetic 
signaling networks in particular polycomb-mediated gene expression repression. 
In the second part of this work, we identified a novel nuclear long intervening non- 
coding RNA (lincRNA), caled here lincRNA-3q. 3q rearangements are known to con- 
fer extremely poor prognosis, at least in AML and MDS (Byrd et al., 2002, Grimwade 
et al., 2010, 2001, Jerez et al., 2012). Given, the emerging role of lincRNAs and the 
growing evidence  of their implication in cancer (Gupta et al.,  2010,  Prensner et al., 
2013, Tokuda et al., 2014, Yap et al., 2010), we investigated whether this RNA could 
be involved in  disease progression,  proposing a regulatory function for epigenetic 
signaling 
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pathways in BPDCN pathogenesis. We demonstrated marked deregulation of lincRNA- 
3q in high risk AML and  BPDCN cel lines and primary patient samples. Our work 
provides evidence of a key role for lincRNA-3q in cel cycle progression at the G1/S 
transition as wel as in the control of hematopoietic and leukemic stem cel signatures 
in  myeloid leukemia. Finaly we showed that epigenetic regulatory factors and  BET 
inhibitors could suppress lincRNA-3q, providing therapeutic opportunities in BPDCN. 
In summary, this work  has led  us to the characterization  of two important tar- 
get genes in leukemogenesis of BPDCN and potentialy other myeloid and lymphoid 
neoplasms sharing similar biological features with this disease. By using functional ge- 
nomic analysis we have identified deviant GCR signaling, and unscheduled activation 
of a novel nuclear lincRNA, driving deregulation of chromatin and transcription factor 
networks in these leukemic cels. And finaly we propose BET bromodomain inhibition 
as a therapeutic strategy in BPDCN. 
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NR3C1 deletion and  a novel, BET inhibitor-sensitive, lincRNA drive disease pathogenesis in 
plasmacytoid dendritic cel neoplasms. 
	  
	  
Anouk Emadali1,2,3*, Neda Hoghoughi1,2*, Samuel Duley1,2*, Azadeh Hajmirza1,2,3, Els Verhoeyen4, 
Philippe Bertrand5, Christophe Roumier6, Anne Roggy7, Martine Chauvet1,2,8, Sarah Bertrand1,2, Sieme 
Hamaidia1,2,3, Sophie Rousseaux1,2, Julie Charles9, Isabele Templier9, Takahiro Maeda10, Juliana 
Bruder-Costa1,2,3, Laurence Chaperot1,2,11, Joel Plumas1,2,11, Marie-Christine Jacob1,2,12, Thierry 
Bonnefoix1,2,3, Sophie Park12, Remy Gressin1,2,13, Cornelis P. Tensen14, Christina Mecucci15, Elizabeth 
Macintyre16, Dominique Leroux1,2,8, Florence Nguyen-Khac17, Isabele Luquet18, Dominique Penther5, 
Christian Bastard5, Fabrice Jardin5, Christine Lefebvre1,2,8, Francine Garnache7, Mary Calanan1,2,8† 
	  
	  
1Université Joseph Fourier, 38000 Grenoble, France ; 2INSERM, U823, Institut Albert Bonniot, 38706 
Grenoble, France ; 3Pôle Recherche, CHU-Grenoble, 38043 Grenoble, France ; 4INSERM, U758, 
Human Virology Laboratory, EVIR, Lyon, France ; 5INSERM, U918, Département d’Hématologie, 
Université de Rouen, Centre Henri Becquerel, 76038 Rouen, France ; 6Institut d’Hématologie, CHRU 
Lile, 59037 Lile, France ; 7UMR INSERM EFS UFC U645, 25020 Besançon, France. 8Plateforme de 
génétique moléculaire des tumeurs, Pôle de biologie, CHU-Grenoble, 38043 Grenoble, France ; 
9Departement de Dermatologie, CHU-Grenoble, 38043 Grenoble, France ; 10Department of Laboratory 
Medicine, Nagasaki University Graduate School of Biomedical Sciences and Central Diagnostic 
Laboratory, Nagasaki University Hospital, Nagasaki, Japan ; 11EFS Rhône-Alpes, Laboratoire R&D, 
Grenoble, France ; 12Laboratoire d’Immunologie, CHU-Grenoble, 38043 Grenoble, France ; 
13Departement d’Hématologie Clinique, CHU-Grenoble, 38043 Grenoble, France ; 14Department of 
Dermatology, Leiden University Medical Center, Leiden, The Netherlands ; 15Department of Medecine, 
Perugia University, Italy ; 16Laboratory of Oncohematology, AP-HP, Hôpital Necker Enfants-Malades, 
University Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades, Institut National de 
Recherche Médicale U1151, Paris, France ; 17Unité Fonctionnele de Cytogénétique Hématologique, 
Groupe Hospitalier Pitié-Salpêtrière, 75651 Paris, France; 18Laboratoire d'Hématologie, Pôle Biologie, 
CHU Toulouse, 31059 Toulouse, France. 
	  
	  
*equal contribution, †coresponding author 
Corespondence: 
Mary Calanan 
Institut Albert Bonniot - Centre de Recherche INSERM U823-Université Joseph Fourier 
Site Santé, BP 170 - La Tronche 
38042 GRENOBLE Cedex 9 - FRANCE 
Tel: +33 (0)4 76 54 95 84 
Fax: +33 (0)4 76 54 94 25 
E-mail: mary.calanan@ujf-grenoble.fr 
	  
	  
	  
Word count : 25085 (manuscript) + 5000 (figures) = 30085 
Results 72 
	  
ABSTRACT 
	  
Blastic plasmacytoid dendritic cel neoplasm (BPDCN) is an incurable malignancy for which disease 
mechanisms are unknown. Here, we identify the NR3C1 gene (5q31), encoding the glucocorticoid 
receptor (GCR), and a long, intergenic, non-coding RNA gene (named here lincRNA-3q), respectively, 
as targets for genetic alteration or transcriptional deregulation in BPDCN. NR3C1 
translocation/deletion was associated to criticaly short survival in BPDCN and to abnormal activity of 
GCR, EZH2, and FOXP3 gene regulatory networks. LincRNA-3q, was found to encode a nuclear, non- 
coding RNA that is ectopicaly activated in BPDCN and high-risk  AML. Depletion of lincRNA-3q in 
myeloid cancer cels induced cel cycle arrest, coincident to suppression of E2F1/Rb and leukemia 
stem cel-specific gene expression signatures. BET bromodomain protein inhibition could selectively 
suppress lincRNA-3q indicating  a treatment strategy for counteracting oncogenic activity of this non- 
coding RNA. Thus, this work defines  a new framework for understanding disease pathogenesis and 
treatment resistance in BPDCN. 
	  
	  
INTRODUCTION 
	  
Blastic plasmacytoid dendritic cel neoplasm (BPDCN) is a rare and clinicaly aggressive disorder that 
shows dismal prognosis whatever the treatment (Facheti, 2008). Median overal survival is less than 2 
years even with high dose chemotherapy, although longer term, albeit short-lived remissions have 
been observed in alo-transplanted patients (Feuilard et al., 2002; Ramanathan et al., 2013; Roos- 
Weil et al., 2013). 
BPDCN is curently classified in the "acute myeloid leukemia (AML) and related precursor 
neoplasms" in the 2008 WHO classification (Swerdlow, 2008). However, the identity of the BPDCN 
cel of origin remains  a mater of investigation (Chaperot et al., 2001; Osaki et al., 2013) and the 
precise pathogenic mechanisms underlying BPDCN are not curently known. Indeed, BPDCN 
presents unusual cytogenetic and molecular features, including co-occurence of chromosomal 
aberations typical of both myeloid and lymphoid disorders (Jardin et al., 2009; Leroux et al., 2002), a 
mutational landscape that is more typical of AML disease (Alayed et al., 2013; Jardin et al., 2011; 
Menezes et al., 2013), while showing predominant expression of lymphoid and pDC-restricted genes 
(Dijkman et  al.,  2007).  Moreover, normal plasmacytoid dendritic cel  development relies on the 
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stepwise, and cel context-specific activity of transcription factor and signaling receptor networks, that 
are dualy implicated in either lymphoid or myeloid lineage development (Belz and Nut, 2012). 
Evolution from pre-existing myelodysplastic syndrome (MDS) or myeloproliferative disorders 
(MPD) has been described in  a subset of BPDCN cases (Facheti, 2008; Pagano et al., 2013). 
Deletion of chromosome 5q, commonly seen in MDS and AML, is frequent in BPDCN, albeit in 
association with ‘lymphoid type’ anomalies (up to 70% of cases with abnormal karyotypes) (Jardin et 
al., 2009; Leroux et al., 2002). This has led to speculation that initiating oncogenic events in BPDCN 
may target an early hematopoietic precursor (Jardin et al., 2009; Leroux et al., 2002). 5q deletion 
(outside of the 5q- syndrome) is associated with increased risk of leukemic transformation in MDS 
(Jerez et al., 2012) and to very poor prognosis in AML (Byrd et al., 2002; Grimwade et al., 2001). This 
is atributed to haploinsuficiency for critical 5q gene(s), that in cooperation with additional signaling 
networks, drives malignant transformation and clonal evolution in these disorders  (Ebert, 2011). 
Similar 5q gene haploinsuficiency mechanisms in are likely to operate in BPDCN since recent 
sequencing eforts, although performed in only  a few patients, have not revealed mutations in genes 
localising to 5q (Menezes et al., 2013). As in myeloid and lymphoid malignancies, mutations in key 
epigenetic modifier-encoding genes have been described in  a proportion of BPDCN cases, thus 
supporting  a role for deregulation of epigenetic signaling pathways in BPDCN pathogenesis (Alayed 
et al., 2013; Jardin et al., 2011; Menezes et al., 2013). 
In an efort to gain insights into the molecular pathogenesis of BPDCN, we have performed 
molecular and functional analysis of  a novel, balanced t(3;5)(q21;q31) observed in  a BPDCN case 
recruited at our centre. We identify NR3C1 as  a critical, pathologicaly relevant 5q target gene in 
BPDCN. Additionaly, we extend previous observations identifying  a potential role for epigenetic 
modifier gene mutations in BPDCN pathogenesis by providing the first evidence of  a key role for 
nuclear lincRNA deregulation in the pathogenesis of this disorder. 
	  
	  
RESULTS AND DISCUSSION 
	  
5q anomalies in BPDCN confer adverse clinical outcome. 
	  
As a first step to uncovering new disease mechanisms in BPDCN, we screened 47 BPDCN patients at 
diagnosis for the presence of 5q alterations/chromosome  5 loss, by conventional metaphase 
karyotyping (n=39), aCGH (n= 25) and/or locus specific FISH (n=22). Overal, 5q alterations, including 
Results 74 
	  
a single case of balanced 5q translocation [(UPN1; t(3;5)(q21;q31) ; Fig. S1A] and one case with 
chromosome 5 loss, were observed in 17/47 patients (Fig. 1A). In cases with available cytogenetics (n 
= 39), with the exception of one case (UPN33), 5q alterations consistently occured in the context of 
complex karyotypes in either founder clones (13 cases) or diagnostic subclones (3 cases) (Table S1). 
In a majority of cases, 5q loss spanned AML/MDS 5q deletion regions, in agreement with our previous 
findings (Jardin et al., 2009; Leroux et al., 2002). Consistent with a role in leukemia initiation and / or 
clonal evolution and disease progression, and as seen in myeloid malignancies, the presence of 5q 
anomalies in BPDCN was associated to extremely poor prognosis (p=0.001) (Fig. 1B, top panel). 
	  
	  
Targeting of NR3C1 by 5q alterations in BPDCN. 
	  
As an entry point to identification of pathogeneticaly relevant 5q genes in BPDCN, we focussed our 
atention on molecular cytogenetic characterisation of the balanced t(3;5)(q21;q32), identified in UPN 1 
(BPDCN cel line GEN2.2) (Table S1, Fig. S1A) (Leroux et al., 2002). Involvement of chromosomal 
arm 3q, was of added interest as 3q aberations are known to confer extremely poor prognosis, at 
least in AML and MDS (Byrd et al., 2002; Grimwade et al., 2010; Grimwade et al., 2001; Jerez et al., 
2012). Remarkably, FISH mapping in GEN2.2 cels revealed the t(3;5) to target the NR3C1 gene, 
located in 5q31 (Fig. 1C). NR3C1 encodes the glucocorticoid receptor (GCR),  a ligand dependent 
transcription factor of the nuclear hormone receptor family (Nicolaides et al., 2010). More detailed 
analysis by aCGH and/or FISH analysis with an NR3C1-specific probe, in our cohort of BPDCN, 
showed NR3C1 deletion to occur in 13 of 17 5q-rearanged cases (76%) of which 3 in subclones (Fig. 
1A, Table S1). No further NR3C1 translocations were identified. Strikingly, one case with normal 
cytogenetics (UPN33) presented  a focal, morphologicaly cryptic, NR3C1 deletion (coordinates 
5:141,529,340 to 143,696,321), thus defining  a minimaly deleted 5q region in our BPDCN patient 
series. Focal deletions of NR3C1 have previously been implicated in  B cel acute lymphoblastic 
leukemia (Kuster et al., 2011; Mulighan et al., 2008) but not in myeloid malignancies.  NR3C1 
deletions were mono alelic and sequencing, when performed (UPN  1 to 9), did not detect NR3C1 
mutations, suggesting that haploinsuficiency for NR3C1 is at least one pathogenicaly relevant  event 
in 5q/NR3C1 deletion/alteration in BPDCN. In keeping with this, NR3C1-deleted BPDCN showed 
lower NR3C1 expression compared to non-(5q)-deleted cases, as assessed by gene expression 
profiling in primary BPDCN bone marow or skin samples (Fig. 1D). NR3C1 deletion was associated to 
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criticaly short survival, compared to BPDCN cases with 5q alterations that did not target NR3C1 (Fig. 
1B, lower panel). Taken together, our findings point to the existence of common pathogenetic 
mechanisms, centering on NR3C1, in BPDCN and  B-ALL and suggest that screening for NR3C1 
alterations could serve to identify very high risk BPDCN patients. 
	  
	  
Molecular characterisation of  a novel t(3;5) in BPDCN reveals fusion of the NR3C1 gene to  a 
lincRNA gene in 3q21. 
To further explore the pathological relevance of NR3C1 rearangement in BPDCN, we performed 
detailed molecular and functional characterisation of the t(3;5) observed in UPN1 (Fig. 2). RACE-PCR 
and sequencing revealed the t(3;5) to encode a single chimeric transcript comprising exons 1 and 2 of 
the NR3C1 gene fused to an antisense sequence deriving from a novel lincRNA gene located in 3q21 
(named here, lincRNA-3q) (Fig. 2A, Fig S1 and S5). LD-PCR genomic breakpoint cloning identified 
this transcript to result from fusion of NR3C1 intron 2 (chr5:142,732,115) to lincRNA-3q intron 3 on the 
der(3) chromosome (chr3:129,837,689) (Fig. S1D). The NR3C1-lincRNA-3q fusion transcript thus 
likely derives from a splicing event between NR3C1 exon 2 and a cryptic splice acceptor site located in 
the antisense orientation in lincRNA-3q exon  2 (chr3:129,832,478) (Fig. 2A, Fig. S1C). No further 
abnormal transcripts were detectable by Northern bloting across the NR3C1 gene, thus ruling out 
NR3C1 reciprocal fusion transcripts deriving from the der(5) chromosome (Fig. S1B). The NR3C1- 
lincRNA-3q fusion transcript was detected only in the t(3;5)-positive GEN2.2 cels and not in the t(3;5)- 
negative cel lines (Fig. S1B and C). Sequencing predicted the NR3C1-lincRNA-3q fusion transcript to 
encode a truncated GCR fusion protein (GCR-FP) comprising the GCR N-terminal activation domain, 
AF1 (amino acids 1 to 393), fused to 18 amino acids derived from transcriptional read through into the 
lincRNA-3q locus (Fig. 2B, left panel). In keeping with this, western bloting in t(3;5)-positive cels, 
using an anti-N terminal GCR antibody, detected  a single abnormal GCR protein isoform 
(approximately 52kD, hereafter refered to as GCR-FP), in addition to the wildtype GCR (90kD) (Fig. 
2B, right panel). 
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The t(3;5)-encoded GCR fusion protein drives altered GCR signaling and drug resistance in 
BPDCN. 
NR3C1 gene alterations have been described in  a subset of relapsing  B-ALL, suggesting  a role in 
therapy resistance (Kuster et al., 2011; Mulighan et al., 2008). We thus investigated responses to 
drug therapy folowing stable overexpression of  a GFP-tagged isoform of GCR-FP in CAL-1 BPDCN 
cels, compared to CAL-1 cels expressing GFP alone (Fig. 2C, Fig. S2A-B). Strikingly, responses to 
combination therapy with high dose dexamethasone (10 µM) and etoposide (10 µM) were markedly 
reduced in CAL-1 GCR-FP-overexpressing cels, compared to controls (Fig. 2C). Cel death folowing 
dexamethasone (10 µM) or etoposide (10 µM) treatment alone was unchanged, at least under these 
conditions. We next asked whether GCR-FP overexpression might dominantly interfere or result in 
functional haploinsuficiency for wild type GCR alpha transcriptional transactivation activity. To test 
this, GCR activity luciferase reporter assays were performed by transient co-transfection assays in 
Cos cels expressing wildtype GCR alpha and increasing amounts of GCR-FP, in the presence or 
absence (DMSO) of dexamethasone,  a synthetic GCR ligand (Fig. 3A ; 6h, 100nM). This revealed 
dose-dependent inhibition of  GCR transcriptional transactivation activity indicative of functional 
interference. We next investigated the impact of the t(3;5)-encoded GCR-FP on global, ligand- 
dependent GCR signaling. For this, as  a model system, we used CAL-1 GCR-FP-overexpressing 
cels, treated for 6 hours with low dose dexamethasone (100 nM) or vehicle (DMSO), (Fig. 3B, C). Low 
as opposed to high dose dexamethasone was used in order to simulate the conditions in which 
NR3C1 alterations might be expected to undergone clonal selection in treatment naïve leukemia cels 
in vivo (i.e. physiological glucocorticoid concentrations). Strikingly, this analysis revealed specific, 
hormone-dependent deregulation, by GCR-FP, of a discrete subset of genes (83 genes; 74 up and 9 
down), including known GCR target genes such as C-FOS, and genes encoding nuclear factors that 
have been implicated in either normal or leukemic lymphoid (BCL6) (Bunting and Melnick, 2013), 
myeloid (c-MYB) (Clappier et al., 2007; Lahortiga et al., 2007) or dendritic cel lineage development 
(RELB) (Belz and Nut, 2012) (Fig. 3B). 
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Deregulation of GCR, EZH2 and FOXP3 gene regulatory circuits is a halmark of 5q alterations 
targeting NR3C1 in BPDCN. 
To further explore the pathological relevance 5q alterations targeting NR3C1 in BPDCN, we used 
GSEA to identify, in an unbiased manner, dexamethasone-dependent gene signatures that are 
abnormaly modulated upon overexpression of the t(3;5)-encoded GCR-FP in BPDCN cels. 
Consistent with our functional studies (Fig. 2C), this analysis revealed enrichment of  a prednisone 
resistance gene signature previously described in  B-ALL (Holeman et al., 2004), in dexamethasone- 
treated, CAL-1-GCR-FP-expressing cels, compared to control-treated cels (Fig. 2D), in addition to 
enrichment for signatures related to EZH2 loss of function in cancer cels (Kondo et al., 2008; Takeda 
et al., 2006) (Fig. 3C and Fig. S3A). Additionaly,  a significant proportion of the genes that were 
abnormaly modulated upon hormone treatment in CAL-1-GCR-FP-expressing cels, compared to 
controls, was found to corespond to FOXP3-bound genes, as identified by ChIP-seq studies in CD4- 
positive T helper cels (Zheng et al., 2007) (Fig. 3C). These genes included among others, a number 
that encode chromatin modifiers or nuclear factors such as BCL11B which is essential for early T cel 
lineage commitment, specificaly for suppression of alternate myeloid or NK cel fates (Ikawa et al., 
2010) and that is implicated in T cel malignancies (Gutierez et al., 2011). Interestingly, FOXP3-bound 
genes that are upregulated in developing CD4 positive  T lymphocytes in the thymus, including the 
NR3C1 gene itself, appeared to be specificaly afected upon hormone treatment of our model GCR- 
FP-overexpressing BPDCN cel line, compared to control treated cels, suggestive of compromised 
FOXP3 repressor activity (Fig. 3C). In view of this, we hypothesised that BPDCN with NR3C1 deletion 
and thus possible haploinsuficiency for GCR function, might display similar deregulation phenotypes. 
To test this, gene expression profiling (GEP) was performed in RNA derived from the bone marrow of 
11 BPDCN cases (3 with and 9 without 5q/NR3C1 deletion). Additionaly we reanalysed data from the 
skin biopsies of 5 BPDCN patients (2 with and 3 without 5q/NR3C1 deletion) (Dijkman et al., 2007). In 
keeping with our starting hypothesis GSEA of these GEP data sets, revealed specific enrichment of 
the EZH2 loss of function and FOXP3 regulatory signatures in the 5q/NR3C1 deleted versus non- 
deleted cases, thus arguing in favour of the pathological relevance of functional deregulation of these 
pathways in 5q/NR3C1-deleted BPDCN (Fig. 3C and Fig. S3B). To investigate this further we focused 
on EZH2,  a member of the PRC2 repressor complex, that is  a frequent target for deregulation in 
myeloid cancers, including BPDCN (Menezes et al., 2013; Shih et al., 2012) and that is required for 
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FOXP3 transcriptional repressor functions, at least in regulatory  T cels (Arvey et al., 2014). Also, 
FOXP3 transcripts, albeit at very low levels, are detectable in normal, sorted human pDC cels and in 
bone marow and skin biopsies from BPDCN patients (Fig. S4 ; expression analysis from GEO data 
sets GSE28490 (Alantaz et al., 2012) and GSE32719 (Pang et al., 2011) and data obtained or 
reanalysed in this study. We selected the CAL-1 GCR-FP-overexpressing cel line as a suitable model 
system to assess the impact of altered GCR signaling on global H3K27me3 levels (Fig. 3). Strikingly, 
this revealed evidence of  a global decrease in H3K27me3 levels in CAL-1 GCR-FP-overexpressing 
cels treated with low dose dexamethasone (100nM or 500nM for  6 or 24h), compared to control 
treated cels (Fig. 3D, Fig. S2C). Coincident to this, reduced H3K27me3 levels were also observed at 
the HOXA locus,  a major downstream target of EZH2 in the hematopoietic lineage, as assessed by 
site specific ChIP at the HOXA5, HOXA9 and HOXA11B gene promoters (Fig. 3E). Taken together, 
these data indicate that altered GCR signaling thresholds, in addition to driving treatment resistance, 
can also directly contribute to leukemogenesis and clonal evolution, through interference with gene 
regulatory circuits requiring, at least in BPDCN, EZH2 and/or FOXP3 activity. Functional interference 
by GCR (‘transrepression’) of the activity of numerous transcription factors, by either direct binding or 
through chromatin dependent mechanisms is wel documented (John et al., 2011; Nixon et al., 2013). 
Our findings raise the possibility that this facet of GCR function may play a role in leukemia. 
	  
	  
LincRNA-3q is overexpressed in BPDCN and AML and encodes a nuclear non-coding RNA that 
regulates cel proliferation and leukemic stem cel gene expression signatures. 
We next wished to assess the pathological relevance of the lincRNA gene target identified at the 3q21 
breakpoint in the t(3;5) observed BPDCN. For this, we first measured expression levels of lincRNA-3q 
in normal pDC, BPDCN cel lines and primary BPDCN leukemia samples by RT-qPCR (Fig. 1E). This 
revealed evidence of ilegitimate lincRNA-3q activation in 7/10 primary BPDCN cases, compared to 
normal pDC (Fig. 1E). Evidence of lincRNA-3q deregulation was also evident in AML with intermediate 
or poor risk cytogenetics, particularly those AML cases with 3q abnormalities [inv/translocation (3q)] 
(Fig. 1E). This is of interest, since the lincRNA-3q locus is located approximately 1Mb telomeric of the 
inv/translocation 3q super enhancer region/RPN1 recently identified as responsible for long range 
deregulation of the EVI1 gene in AML (Groschel et al., 2014). LincRNA-3q overexpression appeared 
to occur independently of 3q genetic aberations in BPDCN. Taken together these findings evoked a 
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potentialy key pathological role for lincRNA-3q overexpression in the pathogenesis of BPDCN and 
AML. Additional RT-qPCR screening revealed broad expression  across  a wide  range of normal 
tissues, with highest expression being observed in bone marow, brain and kidney (Fig. S6A). Further 
screening hinted at deregulation in lymphoid and solid cancers as wel, particularly in lymphoma, lung 
and liver cancer lines (Fig. S6B and C). Linc-RNAs can be either nuclear where they can operate as 
epigenetic regulators through RNA-dependent recruitment of chromatin modifier complexes to 
chromatin or cytoplasmic where they can operate as miRNA decoys (Ulitsky and Bartel, 2013). We 
thus assessed the subcelular localisation of lincRNA-3q  by cel fractionation  analysis  in CAL-1, 
GEN2.2 and U937 AML cels, folowed by RT-qPCR analysis of RNA extracted from whole cels, and 
cytoplasmic  and nuclear fractions (Fig. 4A). Strikingly, lincRNA-3q was found to be predominantly 
nuclear (Fig. 4A), suggestive of  a nuclear function, most probably related to chromatin signaling. To 
probe this further, we performed short hairpin RNA knockdown by using U937 as model cel line 
(overexpresses lincRNA-3q and is amenable to lentiviral transduction). Quite strikingly, lincRNA-3q 
knockdown (Fig. 4B) induced  a G1/S arest in these cels (Fig. 4C) without inducing cel death or 
evidence of diferentiation at least at the morphological level (Fig. S7A and data not shown). In view of 
this phenotype, gene expression profiling, folowed by GSEA, was performed in lincRNA-3q 
knockdown compared to control U937 cels, transduced with  a non-targeting hairpin. Short hairpin- 
mediated lincRNA-3q depletion was associated to diferential expression of 904 genes of which 428 
were up and 476 down-regulated, thus suggestive of a role in both gene activation and repression. Of 
these, were multiple leukemia-relevant genes including MYC, EZH2 and genes encoding E2F family 
members (E2F7 and E2F8) known to negatively regulate transcriptional activatory E2F members 
(Chen et al., 2009). Consistent with this and our data showing G1/S arrest in lincRNA-3q-depleted 
leukemia cels, GSEA revealed reduced expression of numerous E2F target genes upon lincRNA-3q 
depletion in U937 cels compared to controls (Fig. 4D). Additionaly, knockdown of lincRNA-3q in U937 
AML cels was also found to downregulate normal and leukemic hematopoietic stem cell gene 
expression programmes (Georgantas et al., 2004; Wang et al., 2010), compared to controls (Fig. 4D) 
suggestive of  a role in the hematopoietic stem cel compartment which is consistent with high level 
lincRNA-3q expression in normal bone marrow samples (Fig. 1E). Thus, lincRNA-3q displays features 
of a bona fide leukemic driver that warants further functional analysis and assessment for therapeutic 
intervention. 
Results 80 
	  
Numerous cancer genes have been shown to criticaly depend for their expression on the 
activity of bromodomain proteins of the Bromo and Extra Terminal (BET) domain family (Emadali et 
al., 2013; Groschel et al., 2014; Loven et al., 2013). Since we suspected epigenetic mechanisms to be 
the root cause of linc-RNA-3q deregulation in leukemia cels we tested the efects of one such BET 
inhibitor (JQ1) on expression levels of lincRNA-3q in BPDCN and AML cel lines (CAL-1 and U937, 
respectively). Quite strikingly, linc-RNA-3q levels were significantly suppressed in  a dose and time- 
dependent manner in CAL-1 BPDCN cels and U937 cels (Fig. 4E) in paralel to MYC suppression 
(Fig. S7B). Thus BET bromodomain inhibition would be expected to counteract at least some of the 
oncogenic signaling properties of lincRNA-3q in BPDCN and AML. 
In conclusion, our personalised, functional genomics analysis has identified deviant GCR 
signaling, and unscheduled activation of  a novel nuclear lincRNA, to drive deregulation of chromatin 
and transcription factor networks of relevance to treatment resistance and malignant reprogramming in 
the dendritic cel lineage. Further studies wil be required to fuly leverage these findings for treatment 
innovation in BPDCN and potentialy other myeloid and lymphoid cancers that share  biological 
features with this disease. One avenue of investigation is BET protein inhibition. 
	  
	  
MATERIALS AND METHODS 
	  
BPDCN patients investigated in this study were selected from  2 previously published French cohorts 
(Jardin et al., 2009; Leroux et al., 2002),  1 Dutch study (Dijkman et al., 2007) and via colaborations 
with the GFCH (Groupe Francophone de Cytogénétique Hématologique) and the French BPDCN 
network (Table S1 ; n= 47; median age: 66y, range: 7-82 ). Two human BPDCN cel lines GEN2.2 and 
CAL-1 derived from primary human BPDCN cels (Chaperot et al., 2006; Maeda et al., 2005) were 
included in the study and are referred to as UPN 1 and 2, respectively, in Table S1. Cel lines, were 
cultured in RPMI medium supplemented with 10% FCS (Chaperot et al., 2006; Maeda et al., 2005). 
Murine stromal cell support (MS5) was provided for GEN2.2 cels, as described (Chaperot et al., 
2006).  R-banded karyotyping, FISH analyses and aray CGH were performed by standard methods, 
as previously described (Fournier et al., 2010; Jardin et al., 2009). BAC and fosmid probes used for 
FISH are listed in Table S2. Long distance (LD)-PCR cloning of the t(3;5) genomic breakpoint was 
performed using the Roche LD Expand kit and LD-PCR primers (Table S3). For RACE-PCR, RT- 
qPCR, northern bloting and Afymetrix gene expression analysis, total RNA was prepared by Trizol 
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reagent, according to the manufacturer’s instructions and processed as described (Emadali et al., 
2013). RACE-PCR (5’ and 3’) was used to clone the t(3;5)-encoded fusion transcript and was 
performed using BD Biosciences Clontech SMART RACE cDNA amplification kit, according to the 
manufacturer’s instructions. RACE primers, are listed in Table S4. For functional studies, GCR fusion- 
protein cDNA was cloned into pcDNA3.1 or pEGP-C1 or as  a GFP-tagged isoform into  a modified 
pHIV-SFFV-mRFP-WPRE lentiviral vector, using primers described in Table S5. CAL-1 cel lines 
stably expressing GFP alone or GFP-tagged GCR fusion protein were obtained by lentiviral 
transduction and cel sorting (FACS ARIA, BD). Successful transduction was confirmed by flow 
cytometry and western bloting using anti N- and C-terminal GCR (respectively clones E-20 and P-20, 
Santa Cruz) and anti-GFP (clone B2, Santa Cruz) antibodies. Transient transfection assays, using the 
glucocorticoid response element Luciferase reporter plasmid (gift from J. Cidlowski) were performed 
with lipofectamine reagent in COS-7 cels. For gene expression profiling, control and GFP-tagged, 
GCR-FP-expressing, CAL-1 cel lines were treated with vehicle (DMSO) or dexamethasone (100nM) 
for 6h and total RNA extracted for hybridization to Afymetrix U133 2.0 chips, according to the 
manufacturer’s instructions (Afymetrix, Santa Clara, CA, USA). For lincRNA-3q knockdown, short 
hairpin targeting sequences were cloned into pLKO and packaged for lentiviral transduction into CAL- 
1 cels. Selection was by puromycin for 10 days. Cel cycle analysis and Afymetrix gene expression 
profiling were performed as described (Emadali et al., 2013). For detailed experimental methods and 
description of bioinformatics analyses, see supplemental methods. 
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FIGURE LEGENDS 
	  
Figure 1: Targeting of the NR3C1 gene by 5q deletions/translocation in BPDCN. 
	  
A. Schematic representation of 5q alteration in BPDCN patients (n= 17), as indicated. B. Kaplan-Meier 
cumulative survival curves in BPDCN according to 5q alteration status (for simplicity this is labeled 
del(5q) [UPN1, 2, 8,12, 14, 21, 22, 24, 26, 27, 29, 31, 35 and 45] and non-del(5q) [UPN3, 9, 10, 16-19, 
25, 28, 36, 37, 40-42] (upper panel) and NR3C1 deletion status [UPN1, 8, 14, 22, 24, 26, 27, 31, 35 
and 45] (lower panel ; determined by FISH or aCGH; ΔNR3C1), p values from log-rank test. C. FISH 
analysis of the t(3;5)(q21;q35) translocation in the BPDCN cel line, GEN2.2 with chromosome 5q 
probes CTB-88J14 (green) and RP11- 278J6 (red) (Table S2). Note  a split signal for RP11-278J6 
(NR3C1) on the der(3) and der(5) chromosomes. D. Afymetrix-derived NR3C1 expression in BPDCN 
patients presenting del(5q) targeting NR3C1 or not. E. RT-qPCR-derived lincRNA-3q expression 
profiles in normal bone marow (BM), normal pDC, BPDCN (CAL-1, GEN2.2) and AML cel lines 
(U937) and in BPDCN and AML patient samples. AML patients are classified according to cytogenetic 
risk group (Fav: favorable, Interm: Intermediate, Adv: Averse). Cases presenting chromosome 3q 
abnormalities are identified in blue. 
	  
	  
Figure 2: The t(3;5)-encoded GCR-lincRNA-3q fusion is associated with glucocortioid 
resistance. 
A. Schematic representation of the genomic organization surounding the normal 3q  and der(3) 
breakpoint region and the resulting fusion transcript NR3C1-lincRNA-3q. cen: centromere ; tel: 
telomere ; blue filed circle: GATA2 super enhancer ; genes as indicated ; TSS: transcription start site ; 
ex: exon. B. Schematic representation of the structure of wild-type GCR (left panel, top) and predicted 
GCR fusion protein (left panel, botom). NTD:  N-terminal domain, DBD: DNA binding domain, LBD: 
ligand binding domain, AF: activation function domain, ZnF: zinc finger domain, (right) GCR western 
blot analysis showing expression of an abnormal GCR isoform (GCR-FP) exclusively in GEN2.2 cels, 
compared to t(3;5)-negative cel lines, as indicated. C. Evaluation of drug sensitivity of CAL-1 cels 
overexpressing GCR-FP compared to control CAL-1 cels, folowing 16h treatment with 10 µM 
etoposide (Eto), 72h treatment with 10 µM dexamethasone (Dex) or a combination of both treatments. 
Specific cel death was calculated as folows: 100 - [experimental cel death (%) - spontaneous cel 
death (%)/100% - spontaneous cel death (%)]. n=3,  p value from  a Wilcoxon test. D. Gene Set 
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Enrichment Analysis (GSEA) enrichment plots obtained using the ratio Dex/DMSO in CAL-1-GCR-FP 
(GCR-FP(+)) over the ratio Dex/DMSO in CAL-1 control cels (GCR-FP(-). 
	  
	  
Figure 3: Misregulated GCR and EZH2 signaling as  a consequence of NR3C1 alterations in 
BPDCN. 
A. Luciferase reporter assay for glucocorticoid transcriptional transactivation activity in Cos cels 
transduced with empty pcDNA3.1 vector, pcDNA3.1-GCR and pcDNA3.1-GCR-FP, as indicated, after 
a 6h treatment with either DMSO or 100 nM dexamethasone. B. Heat-map representation of the 
diferentialy expressed genes between CAL-1-GCR-FP [GCR-FP(+)] and CAL-1 control cels [GCR- 
FP(-)] treated with 100 nM dexamethasone for 6h. Black arows: genes cited in text. C. Gene Set 
Enrichment Analysis (GSEA) enrichment plots showing gene regulatory circuits that are diferentialy 
expressed between dexamethasone treated CAL-1-GCR-FP compared to control CAL-1 control cels 
(CAL-1-GFP) and between BPDCN patients presenting or not del(5q) targeting NR3C1 (bone marow 
or skin, as indicated). D. Western blot analysis of global H3K27me3 in CAL-1-GCR-FP [GCR-FP(+), 
upper panel] and CAL-1 control cels [GCR-FP(-), lower panel] treated with 100 nM dexamethasone 
for 6h and 24h. E. ChIP for H3K27me3 folowed by qPCR analysis for enrichment on HOXA gene 
promoters, as indicated, in CAL-1-GCR-FP [GCR-FP(+)] and CAL-1 control cels [GCR-FP(-)] treated 
with 100 nM dexamethasone for 24h. 
	  
	  
Figure 4: lincRNA-3q overexpression in BPDCN and AML drives G1/S and leukemia stem cel 
gene expression signatures and can be suppressed BET inhibition. 
A. RT-qPCR and RT-PCR analysis of lincRNA-3q and GAPDH (control) expression levels in CAL-1 
BPDCN cels in RNA extracted from whole cel and subcelular fractions ; total, whole cel extract ; cyt : 
cytosolic fraction, nuc: nuclear fraction (n=2). B. RT-qPCR-derived lincRNA-3q expression in U937 
cels transduced with control (Ctrl) or lincRNA-3q targeting sh contructs (shA, B and C). C. Cel cycle 
analysis of U937 transduced with control (Ctrl) or lincRNA-3q sh (shA,  B and C) contructs, (upper 
panel) histogram representation of  % cels in cel cycle phases, (lower panel) (n=4). D. Gene Set 
Enrichment Analysis (GSEA) enrichment plots obtained by comparing gene expression profiles of 
U937 cels transduced with control (shCtrl) or lincRNA-3q targeting sh (shlincRNA-3q) and associated 
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heat-map. Genes mentioned in the text are marked with an arow. E. RT-qPCR-derived lincRNA-3q 
	  
expression in U937 and CAL-1 cels treated with JQ1 at the time and doses indicated (n=3). 
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SUPPLEMENTAL METHODS 
FISH 
FISH analyses were performed by standard methods, as described (Fournier et al., 2010). BACs 
probes used for FISH are listed in Table S2 and were selected through the UCSC or  ENSEMBL 
genome browsers. 
	  
	  
Long distance (LD)-PCR 
	  
LD-PCR products were generated from 0.5 µg total DNA using the Expand Long Template PCR 
System (Roche) and the folowing conditions for amplification: initial denaturation 94°C,  2 min; 94°C, 
10s – 57°C, 30s – 68°C, 20 min (x10); 94°C, 15s – 57°C, 30s - 68°C, 20 min + 20s per cycle (x24); 
final extension, 68°C, 7min. PCR products were then gel-purified, cloned into pGEM-T Easy vector 
(Promega) and sequenced in both directions. LD primers are listed in Table S3. 
	  
	  
RNA extraction 
	  
Total RNA was extracted from cel lines, tissues or sorted  B cels by TRIzol reagent (Invitrogen) and 
quantified by NanoDrop (Thermo Fisher Scientific). 
	  
	  
RACE-PCR 
	  
Nested RACE PCR reactions were performed from  1 µg RNA using the SMART RACE cDNA 
Amplification kit (BD) with NR3C1 exon  2 specific forward (3’ RACE) and reverse primers (5’ RACE) 
together with 5’ and 3’ RACE SMART primers, in order to identify NR3C1 exon  2 flanking sequence 
(see Table S4), using the manufacturer’s instructions. RACE products were purified on agarose gels, 
cloned and sequenced in both directions. 
	  
	  
RT-qPCR gene expression analysis 
	  
Total RNA was reverse transcribed using the SuperScript® II First-Strand Synthesis SuperMix 
(Invitrogen), according to manufacturer’s instructions. qPCR was performed using SYBR® Green PCR 
master mix (Applied Biosystems) and primers shown in Table S4, according to the manufacturer’s 
instructions. The ABL gene was used as  a control for normalization of gene expression data. qPCR 
was performed on a MX3000P machine (Stratagene). 
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Fusion transcript cloning 
	  
For functional studies, GCR fusion-protein cDNA was cloned into pcDNA3.1 and then subcloned in 
pEGP-C1.  N-terminal GFP-tagged GCR fusion protein cDNA was then subcloned as  a 2117bp 
fragment BamH1(ATG)/Xho-1(TGA) into the pHIV-SFFV-mRFP-WPRE vector using primers described 
in Table S5. 
	  
	  
Northern Bloting 
	  
20 µg RNA was electrophoresed on 1% denaturing gels, transfered onto Hybond N+ membrane and 
hybridized using NR3C1 cDNA probes obtained by RT-PCR amplification using primers listed in Table 
S6. 
	  
	  
Lentiviral Transduction 
	  
N-terminal GFP-tagged GCR fusion protein cDNA was then subcloned as a BamH1(ATG)/Xho-1(TGA) 
2117bp fragment into the pHIV-SFFV-mRFP-WPRE vector using primers described in Table S6. Non- 
targeting or lincRNA-3q targeting short hairpin (sh) RNA sequences were designed using the DSIR 
algorithm (htp:/biodev.cea.fr/DSIR/DSIR.html) (Vert et al., 2006). Sequences provided in Table S7, 
were cloned into the pLKO-1 lentiviral vector (Addgene). Lentiviral particles were packaged, as 
described previously (Levy et al., 2010). Cels were transduced with lentiviral particles at  a MOI 
(multiplicity of infection) of 10. GFP expressing cels were sorted using flow cytometry (FACS ARIA, 
BD). Cel lines stably expressing shlincRNA-3q were established under puromycin selection. 
	  
	  
Western Bloting 
	  
Protein lysates were  resolved by SDS-PAGE and transfered  onto nitrocelulose membranes for 
bloting with anti  N- and  C-terminal GCR (respectively clones  E-20 and  P-20, Santa Cruz), anti-GFP 
(clone B2, Santa Cruz), anti-H3K27me3 (Milipore), anti-H3 (Upstate) and anti-ACTIN (Sigma) 
antibodies. After treatment with blocking solution (1X  PBS, 8% skimmed milk, 0.1% Tween 20), 
membranes were incubated with primary antibody (GCR, 0.4 µg/ml, H3K27me3, H3 and actin 0.5 
µg/ml in PBS 3% skimmed milk 0.1% Tween 20), washed and incubated with anti-rabbit or mouse 
IgG-HRP  (Thermo  Fisher  Scientific)  before  incubation  in  ECL  SuperSignal  West  Pico 
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Chemiluminescent Substrate (Thermo Fisher Scientific). Images were captured using autoradiography 
films. 
	  
	  
GRE reporter assay 
	  
Transient transfection assays using the glucocorticoid response element Luciferase reporter plasmid 
(gift from  J Cidlowski) were performed in COS7 cels using Lipofectamine (Invitrogen) according to 
manufacturer’s instructions. 
	  
	  
ChIP on native chromatin 
	  
ChIP experiments were performed as described in (Fournier et al., 2010). Briefly, al  Q-ChIP assays 
were performed in triplicate in at least two independent chromatin preparations. For qPCR analyses of 
immunoprecipitated chromatin fractions at sequences of interest,  a SYBR Green PCR kit (Applied 
Biosystems) was used. qPCR was performed on 20 ng of ChIP DNA or DNA from input chromatin 
fractions, using the folowing conditions; 40 cycles at 95°C for 15 s, 60°C for  1 min. Primer pairs are 
listed in Table S8. qPCR data obtained on immunoprecipitated fractions were  normalized to input 
chromatin (IP/Input = 2ΔCt = 2[Ct(IP)-Ct(Input)]). Background precipitation was evaluated with a mock IP. 
	  
	  
Cel fractionation 
	  
Nuclear fractions were prepared by incubating cels in 0.2% NP40, 0.3M sucrose, 15mM Tris pH8, 
60mM KCl, 15mM NaCl, 5mM MgCl2, 0.1mM EDTA pH8 and protease inhibitors (Complete®, Roche) 
for 10 min on ice. Eficient cel lysis without nuclear disruption was verified by trypan blue staining prior 
to nuclear fraction separation by centrifugation at 500g, for 10 min at 4°C. 
	  
	  
Afymetrix gene expression analysis 
	  
Afymetrix microarays were processed in the Microaray Core Facility of the Institute of Research on 
Biotherapy, CHRU-INSERM-UM1 Montpelier (htp:/irb.chu-montpelier.fr/). RNA was amplified using 
the kit GeneChip IVT express and hybridized to HG U133 Plus 2.0 microarays according to 
manufacturer’s instructions (Afymetrix). Fluorescence intensities were quantified using the GCOS 1.2 
software. Gene expression data were normalized with RMA algorithm and analyzed using GeneSpring 
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software package (Agilent). Data are being deposited in the NCBI Gene Expression Omnibus (pending 
accession number). 
	  
	  
GSEA analysis 
	  
Gene Set Enrichment Analysis (GSEA) is a computational method that determines whether an a priori 
defined set of genes shows statisticaly significant, concordant diferences between two biological 
states (Subramanian et al., 2005). We first generated  a pre-ranked list obtained by calculation of the 
ratio: fold change in CAL-1 cels transduced with GCR-FP upon dexamethasone treatment on fold 
change in control CAL-1 cels upon dexamethasone treatment. This strategy was defined to identify 
gene signatures specificaly associated with the presence of GCR-FP upon dexamethasone treatment. 
Analysis was performed using GSEA v2.07 software to compare this pre-ranked list against the c2 
gene sets from the Broad Institute Molecular Signature Database 
(htp:/www.broadinstitute.org/gsea/msigdb/). For shlincRNA-3q data analysis, GSEA was run using 
default parameters against the c2 and c3 gene sets from the Broad Institute Molecular Signature 
Database. Genes are ordered on the  x axis by their rank in the list (each vertical line representing  a 
gene).  A detailed description of GSEA methodology and interpretation is provided online 
(htp:/www.broadinstitute.org/gsea/doc/GSEAUserGui-deFrame.html). In brief, the normalized 
enrichment score (NES) provides “the degree to which  a gene set is overepresented at the top or 
botom of  a ranked list of genes”. The false discovery rate q-value (FDR q-val) is “the estimated 
probability that a gene set with a given NES represents a false positive finding”. 
	  
	  
Statistics 
	  
Excel® 2010 (Microsoft), J.M.P.® 10.0.0 (SAS Institute) and GraphPad (Prism) softwares were used for 
graphical representations and to perform statistical analysis across al experiments. The Wilcoxon 
non-parametric method or the two-sided Student t tests were used for statistical analysisas indicated. 
Histograms represent the average for each group and erors bars represent standard deviation. 
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SUPPLEMENTAL FIGURE LEGENDS 
	  
Figure S1: Molecular characterization of the t(3;5) translocation in the BPDCN line GEN2.2. 
	  
A. Partial karyotype of the t(3;5)(q21;q31) from GEN2.2 cel line (UPN1). B. NR3C1 northern blot 
analysis in  a panel of leukemia and lymphoma cel lines, as indicated, showing expression of an 
abnormal GCR transcript (2 kb), exclusively in GEN2.2 cels using probe 1 (see Table S6: primers for 
NR3C1 cDNA probe amplification). C. Sequence and schematic representation of the NR3C1- 
lincRNA-3q fusion transcript breakpoint junction (upper and middle panels), and RT-PCR fusion 
transcript detection in t(3;5)-negative CAL-1 cels compared to t(3;5)-positive GEN2.2 cels (lower 
panel, green arow), using primers depicted in green (see also Table S4). D. Sequence and schematic 
representation of the der(3) genomic breakpoint (upper and middle panels). Long-distance (LD)-PCR 
amplification of the breakpoint junction in t(3;5)-positive GEN2.2 cels compared to control CAL-1 cels 
(lower panel), using primers depicted in blue (see also Table S3). A 16.2kb fragment can be amplified 
only in GEN2.2/UPN1 harbouring the t(3;5)(q21;q31) translocation. *non-specific band. 
	  
	  
Figure S2: Stable expression of GFP-tagged GCR-FP in the BPDCN line CAL-1. 
	  
A. Western blot using both anti-GCR (upper panel) and anti-GFP (lower panel) antibodies in the 
parent CAL-1 cel line (WT) compared to CAL-1 cels transduced with empty GFP vector (n=2, GFP1 
and GFP2) or with the GFP-tagged, GCR-FP (n=2, GCR-FP1 and GCR-FP2) expression vector, as 
indicated. B. Flow cytometric analysis of GFP and GFP-GCR-FP expressing CAL-1 cels after GFP 
flow cytometric cel sorting and cel line amplification in vitro. C. Western blot analysis of global 
H3K27me3 in CAL-1-GCR-FP [GCR-FP(+), upper panel] and CAL-1 control cels [GCR-FP(-), lower 
panel] treated with 500 nM dexamethasone for 6h and 24h. 
	  
	  
Figure S3: Gene signatures abnormaly induced by dexamethasone  treatment of   GCR-FP- 
expressing CAL-1 cels compared to control GFP-expressing cels. 
A. Gene Set Enrichment Analysis (GSEA) enrichment plots obtained using the ratio Dex/DMSO in 
CAL-1-GCR-FP over the ratio Dex/DMSO in CAL-1 control cels. GSEA enrichment plots thus 
represent gene signatures specificaly associated with the presence of GCR-FP upon dexamethasone 
treatment (left). B.  Gene Set  Enrichment Analysis (GSEA) enrichment plots obtained folowing 
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comparison of non-del(5q) and del(5q) primary BPDCN cels (source : skin biopsies or bone marow – 
BM, as indicated). 
	  
	  
Figure S4 FOXP3 transcript levels in human dendritic and CD4 T cel compared to BPDCN. 
FOXP3 mRNA expression levels in hematopoietic stem cels (HSC, negative control), sorted, normal 
CD4 single positive thymic T cels, normal pDC and in BPDCN (patient bone marow and skin samples 
and cel lines, this study), as indicated. Gene expression data for normal CD4 and pDC cels were 
derived from the GEO data set GSE28490. Data for normal HSC were derived from GEO data set 
GSE32719. 
	  
	  
Figure S5: Genomic organisation of the lincRNA-3q locus. 
	  
A. Schematic representation of the lincRNA-3q genomic locus, showing lincRNA and TUCP transcripts 
from RNA-seq data, and activating and repressive histone marks, and RNA PolI binding sites at the 
predicted lincRNA-3q gene promoter, in K562 cels (ENCODE data, UCSC genome browser). 
Transcript expression levels across various tissues and sequence conservation across species 
(botom, as indicated). Primers used for lincRNA-3q RT-qPCR and sh target sequences are also 
indicated (top). 
	  
	  
Figure S6: LincRNA-3q expression profiles in normal and cancer cels. 
	  
RT-qPCR-derived lincRNA-3q expression profiles in normal tissues (A.), leukemia and lymphoma cell 
lines (B.) and non-hematological cancer cel lines (C.), as indicated. 
	  
	  
Figure S7: Knockdown of lincRNA-3q and BET inhibitor treatment in U937 cels. 
	  
A. Evaluation of U937 cel viability in non-transduced cels (NT), cels transduced with a non-targeting 
shRNA (shCtrl), or cels transduced with three diferent lincRNA-3q targeting shRNA (shA,  B and C), 
respectively (left panel). Typical flow cytometry results, using Annexin V/propidium iodide for U937 
cels transduced with non-targeting shRNA (shCtrl), or cels transduced with lincRNA-3q targeting 
shRNA  B (right panel). B. RT-qPCR-derived MYC expression in U937 and CAL-1 cels treated with 
JQ1 at the time and doses indicated. 
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Table 51: Clinical characteristics, cytogenetic/FISH and molecular investigations in 47 cases of BPDCN 
	  
	  
UPN   
Age(y)  Clinical  Survival 
/sex status  (months) 
	  
74/M DOD 
	  
	  
Hematological 
disease 
	  
PB, BM 
	  
Extra- 
hematological 
sites 
Skin 
	  
Prlor Hlstory 
(time before 
diagnosis) 
None 
Source of  % 
cels for  Blasts Karyotype 
karyotype  (BM)1 
PB 100    49,XY, add(6)(q21 ),-8,2mar, 
	  
aCGHIFSH 
NR3C12'3 
Split 
rl6]149,idem,t(15;16)(?q21;?q21)16]/49,idem,t(3;   (subclone) 
5)(7q21;7q31)15]ish wcp M-FISH 49,XY, 
6,t(6;8)(p21;q24),r(12), 
20149,idem,inv(15)(q1?4q2?3),t(16;16) 
(q?;q?)/49,idem,t(3;5)(q?21;q?31)113] 
	  
76/M 
	  
	  
	  
	  
	  
	  
	  
	  
	  
72/M 
	  
	  
41/M 
	  
69/M 
	  
DOD 
	  
	  
	  
	  
	  
	  
	  
DOD 
	  
	  
DOD 
DOD 
	  
PB, BM, LN, 
spleen 
	  
	  
	  
	  
	  
	  
	  
26 BM 
	  
	  
18 BM. LN 
BM 
	  
Skin Skin, LN, spleen 
lesions (1m) 
	  
	  
	  
	  
	  
	  
	  
Skin None 
	  
	  
None None 
	  
Skin None 
	  
BM 100  45,X,- 
Y,add(1)(q43),add(5)(q3 74),t(6;8)(p21 ;q24), 
del(6)(q23q25),add(11)(q22),+12, 
add(12)(p12),der(13;20)(q1O;q10), 
add(16)(p13),add(18)(q21),add(19)(p13), 
der(21)t(7;21)(q11;p12),der(22)[22qter- 
>22p12 :8q11->8q24::6p21->6pter][20] 
BM 86  49,XY,t(6;8)(p21;q24),+11,+16,+18[19]1 
46,XY [1] 
BM >50%  46,XY,t(6;8 )(p21;q24) 
PB >50% 46,XY [15] 
	  
Normal 
	  
	  
	  
	  
	  
	  
	  
	  
	  
Normal 
	  
	  
Normal 
Normal 
78/M DOD 
	  
74/M Alive 
29 BM 
	  
34 BM, LN 
Skin None 
	  
Skin None 
PB >50% 46.XY (14] 
	  
NA >50%  ND 
Normal 
Normal 
64/F 
	  
26/M 
DOD 
DOD 
PB, BM, LN 
	  
19 BM, LN 
Skin None 
	  
Skin None 
NA >50%  ND 
LN 70   43,XY,del(2)(q31),+4,del(6)(q15q23),-8,-9, 
t( 13;22)(p12;q11 ),-22,+mar[2]146,XY[18] 
Deletion 
Normal 
	  
10 51/M Alive 
	  
	  
11 64/M Alive 
	  
60 PB. BM, LN, 
spleen 
	  
63 BM 
	  
Skin None 
	  
	  
RAEB1 (2y) 
	  
BM 48   46,XY,d el(6)(q21q34)(,i(7)(q10), 
del(9)(q11q13).del(10)(q23q25)19]/46.XY [1] 
	  
BM 47   46.XY [20] 
	  
Normal 
	  
	  
Normal 
	  
12 62/F 
	  
DOD 
	  
29 PB, BM,LN, 
spleen 
	  
Skin None 
	  
BM 91   47,XX,1(1;5)(p13 ;p14),del(5)(q13q15),+12, 
del(13)(q14)(14]146,XXl3] 
	  
Normal 
13 58/M Alive BM Skin None BM  44   46,XY[20] Normal 
	  
14 67/M DOD 
	  
PB,BM, LN 
	  
Skin, CNS 
	  
None 
	  
BM 89   46,XY,der(5)[5pter:Sp14 ->5q21 :5q34 :12p11- 
>12p12],der(12)(5p15::5q31:12p12- 
>12qter][13]1 
44,sl,der(3)t(3;9)(p12;q32),der(3)[8qter- 
>8q23:?3p24 
>3qter],de1(4)(q21 ),der(6)t(6;11)(q22;q11], 
t(7;9)(q11;p11),der(8)add(8 )(p23) 
add(8)(q23),-9,-1O,del(11)(q11),del(13)(q13), 
del(15)(q22),add(22)(q12)[cp16]146,XY[7] 
	  
Deletion 
	  
15 43/F DOD 
	  
10 PB, BM 
	  
Skin None 
	  
BM  40   46,XX[20] 
	  
Normal 
	  
16 75/M  Alive 
	  
BM Skin None 
	  
BM 91     43,Y,?der(X)t(X;15)(p21;q 14).1(3;12)(p21;q24).ad 
d(4)(q11),add(7)(p13),der(9)t(1;9) 
(q12;p13),-10,-13,-15[17]146,XY[5] 
	  
Normal 
	  
17 71/M Alive 
	  
	  
	  
	  
	  
18 63/M  Alive 
	  
13 PB, BM 
	  
	  
	  
	  
	  
PB, BM 
	  
Skin None 
	  
	  
	  
	  
	  
None None 
	  
BM 97    47,XY,del (6)(q13q26),der(8)(8pter->8q24:6q21- 
>6q26:20p13- 
>20pter).del(12)(p12),der(20)t(8;20)(q24;p13) 
[cp16]146,XY[4] 
	  
BM 95    47.XY,add(7)(p11),+20[8]146,XY[1].ish 
i(7)(q1O)(wcp7+),+20(wcp20+) 
	  
Normal 
	  
	  
	  
	  
	  
Normal 
	  
19 11/F 
	  
	  
20 82/M 
	  
21 67/M 
DO
D 
	  
	  
DOD 
DOD 
	  
83  PB, BM.spleen 
	  
	  
None 
	  
11 PB,BM, LN 
	  
Skin None 
	  
	  
Skin None 
	  
Skin None 
	  
BM 90     46,XX ,del(1)(q31),-3,del(6q),add(12)(p13),- 
13,+2mar<2>/46,XX<18> 
	  
BM 40   46,XY [20] 
	  
BM 82  43,XY,?del(5)(q21q22),add(12)(p1 1),- 
13,?der(14)ins(14;?)(q24;?),-15,add(17)(p1 2),- 
20[12]143,sl,- 
add(12),der(12;15))(q1O;q10)(5]/43,sdl1, 
del(13)(q21q31)[2]146,XYl1] 
	  
Normal 
	  
	  
Normal 
Normal 
	  
22 20/M Alive 
	  
PB, BM 
	  
Skin None 
	  
BM 45   45,XY,- Deletion 
4,add(S)(p15),del(5)(q14q33),del(6)(q16q23)  ,ad 
d(8)(q274),-9,der(13)ins(13;7)(q14;7),7-14,- 
15,+21,+mars(3]/46,XY117] 
	  
23  74/M DOD 
	  
10 PB, BM 
	  
Skin RAEB1 (10y) 
	  
BM 20   46,XY[20].ish 8q24(MYCx2 ).11q23(MLLx2) 
	  
Normal 
	  
24 72/M 
	  
DOD 
	  
PB, BM 
	  
None 
	  
MPN (Sy) 
	  
BM 87  43,XY,t(2;6)(p21;q26),add(7)(q3?4) , 
der(12  ;18)(q10;q1O),del(13)(q13q21),- 
15,der(16)t(16;17)(q2?2;q12),-17[15]/ 
	  
Deletion 
(subclone ) 
Results  
	  
	  
	  
	  
	  
UPN 
Extra- 
Age{y)  Clnlcal  Survlval   Hematologlcal  
hematological
 
Prior History 
(time before 
	  
Source of % 
cels for  Blasts 
	  
	  
Karyotype 
	  
aCGH/FISH 
/sex status  (months) disease sites diagnosis) karyotype   (BM)' NR3C1
2'3 
25 62/M Alive 18 PB,BM Skin None BM 87 47.XY ,+8[7)/47,sl.1(7;14 )(p14;q22)[17)/46,XY[1]. 
ish t(7;14)(wcp14+,IGH+;wcp14+,IGH-) 
Normal 
26 65/M DDD 	   BM Skin None BM 74 41-46,XY ,-3,-4,add(7)(p1  ?),-10,-12,-13,- Deletion 
	   	   	   	   	   	   	   	   	  
17,+2-Bmars,dmin[ cp12]/45,XY ,- (subclone) 
	   	   	   	   	   	   	   	   	  
4,de12)t(4;12)(q1?3;p1?2),dmin[6]/46,XY[7] 
	  
27 82/F Alive 	   PB,BM None None BM 88 45,XX,add(1)(q23),-5,-6,-7,-9,-13,+4mar[9] Deletion 
28 71/F Alive 10 PB,BM,LN, 
spleen 
Skin None BM 94 43-44,XX ,der(6)t(6;12)(q22;q13),-9,-t 2,- t 3[12].+1- 
2mars[cp t 5]/46,XX[7] 
Normal 
29 12/F Alive 42 BM,LN Skin None BM 50 46,XX,t(3;8)(q28;q12)inv(8)(q12q24), Normal 
	   	   	   	   	   	   	   	   	  
t(5;12)(q23;p13),der(1O)t(3 ;10)(q21;q25) 
	  
	   	   	   	   	   	   	   	   	  
t(3;8)inv(8)[4)/49,sl,+i(5)(p10),- 
	  
	   	   	   	   	   	   	   	   	  
der(10),+1O,der(14)t(3 ;14)(q21;p11)1(3;8) 
	  
	   	   	   	   	   	   	   	   	  
inv(8),+der(14),der(15)t(3;15)(q21;p11)  (3;8) 
	  
	   	   	   	   	   	   	   	   	  
inv(8),+der(15)[6]/50 ,sdl1,+20[2]/46,XX[8] 
	  
30 82/M DOD 	   PB,BM. LN Skin None BM 50 46,XY[20] Normal 
31 38/M DOD 18 PB,BM Skin None BM 60 44,X,-Y,del(9)(q11q31),- Deletion 
	   	   	   	   	   	   	   	   	  
13[2]144,idem,add(4q?),add(5q?) [3]/46,XY[14] 
	  
32 75/F MD MD PB,BM Skin None BM 90 45,XX ,del(5)(q13q34),inv(11)(p11q21), Deletion 
	   	   	   	   	   	   	   	   	  
der(15)t(15;18)(?;?),-18 
	  
33 82/M MD MD PB, BM, LN Skin None BM 84 46,XY [20] Deletion 
34 69/M 000 	   BM,LN Skin Colon cancer BM 95 46,XY[20] Normal 
35 74/M DOD 18 PB,BM Skin Skinlesions BM 75 ND Deletion 
36 60/M DOD 11 PB,BM. LN Skin None BM 70 44,X ,-Y,t(4;12)(?;?),-9,-13,+ma  9Y46,XY[18) Normal 
37 70/M Alive 72 PB,BM Skin CMML BM 85 44.X ,-Y.del(6)(q23q25-27)x2.add(8)(q24). 
inv(9)(p11q13)c,1(12;15)(p10;p10),- 
13[18]/46,XY,inv(9)(p11q13)c[2] 
Normal 
38 59/M DOD 15 PB.BM. LN Skin None BM 95 46,XY[20] Normal 
39 61/M DOD 	   PB,BM Skin None BM 82 46,XY[20] Normal 
40 51/M Alive 83 PB,BM, LN Skin None BM 71 46,XY,del(6)(q11q22),del(9)(q11q13), 
del(1O)(q12q13)[1]/46,XY ,idem.i(7) 
Normal 
	   	   	   	   	   	   	   	   	  
(q10}[18]/46,XY[1] 
	  
41 15/M Alive 54 PB. BM. LN Skin None BM 62 43,XY ,1(3;6),der(7)t(7;19},-9, der(12)t(5;12), 13,- Normal 
	   	   	   	   	   	   	   	   	  
19/86,idemx:2 
	  
42 66/M Alive 24 PB.BM. LN Skin None BM 74 46,XY[20] Normal 
43 67/F DOD 	   None Skin, breast None NA NA NA Normal 
44 74/M DOD 12 None Skin None NA NA NA Normal 
45 60/M DOD 22 BM Skin None NA NA NA Deletion 
46 56/M DOD 29 None Skin None NA NA NA Normal 
47 7/F Alive 20 None Skin None NA NA NA Deletion 
	  
	  
DOD : dead of disease 
PB : Peripheral blood, LN: lymph node, BM: bone marrow, CNS; central nervous system 
RAEB: Refractory anemia with excess blasts, MPN: Myeloproliferative neoplasm,CMML: chronic myelomonocytic leukemia 
NA = Not applicable. ND = Not done. MD= Missing data 
	  
bold: abnormal5q 
	  
	  
1 estimated at  >50% by aCGH for UPN4-8 
2 NR3C1 FlSH peformed in UPN 10-30 
3 aCGH performed in UPN 1-9 and 31-47 (UPN 43-47 in skin biopsies, Dijkman, 2008) 
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Table 52 : BACs used for FISH experiment 
	  
	  
BAC Chr.location Gene Genome coordinates length (kb) 
RP11-114A13 5q31.2 
	  
	  
	  
	  
VAT"..;.P?N""'-•ç-"'ro chr5:138,618,787-138,764,501 146 
RP11-94G20 5q31.2 
	  
	  
	  
"'-VM'l'1lM'Al""""-"2""' chr5:138,508,691-138,688,954 180 
RP11-114B22 5q31.2 
	  
	  
CYSTMlPFDNlHBEGF chr5:139,536,924-139,713,162 176 
RP11-261B11 5q31.2 NRG2 chr5:139,272,101-139,436,755 165 
RP11-277D10 5q31.2 ,.......,..,.,.,.,......, chr5:139,666,321-139,860,054 194 
RP11-301F04 5q31.2 
	  
NRG21PURAllGJP chr5:139,403,026-139,589,459 186 
RP11-78P13 5q31.2 PSD2/NRG2 chr5:139,218,325-139,388,032 170 
RP11-323J18 5q31.3 
	  
	  
S!.C2'5A2'rAF 7JPCDHB1 chr5:140,664,083-140 ,827,682 164 
RP11-429E 15 5q31.3 
	  
	  
PCDHB1  A PCDHB(j chr5:140,400,738-140,549,204 148 
CTD-202417 5q31.3 
	  
	  
	  
l'CL.Wüfp,Vl'PHUHV C3 chr5:140,844,770-141,030,663 186 
CTD-2040G12 5q31.3 
	  
FCHS01/ARAP3 chr5:141,030,664-141,111,527 81 
CTB-88J14 5q31.3 	   chr5:141,740,973-141,883,180 142 
CTD-2185H17 5q31.3 
	  
	  
ARHGAP26 / NR3C1 chr5:142,525,913-142,761,634 236 
RP11-278J6* 5q31.3 NR3C1 chr5:142,680,739-142,816,857 136 
CTB-163B16 5q32 PREL/02 chr5:144,861,294-144,945,294 84 
CTD-2277F12 5q32 
	  
	  
SP!NK5 / SPINK14 chr5:147,515,884-147,570,458 55 
RP11-331K21 5q32 ABLIM 3 chr5:148,461,756-148,580,284 119 
RP11-34P1 5q33.3 
	  
FABP6!CCNJL chr5:159,651,182-159,796,906 146 
RP11-117L6 5q35.1 NPM1/FGF18 chr5:170,829,745-170,882,555 53 
• :split signal 	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Table 53: Long distance PCR primers for breakpoint mapping and cloning 
	  
Primer name Forward primer Genome coordinates 
5q primers 	   	  
LD-NR3C1-F1 GGCAATGATGATGCGGCTCT chr5: 142,777,288-142 ,777,269 
LD-NR3C1-F2 CACCCGAGAGGTGGGGCTCT chr5:142,772,700-142,772 ,681 
LD-NR3C1-F3 TCCCCAGCAGCATGGAGAGC chr5: 142,768,779-142,768,760 
LD-NR3C1-F4 TGCCTCCCCCTCCCTCAGTT chr5: 142,768,739-142,768,720 
LD-NR3C1-F5 GCAGAGCCACCAGGGCAGAG chr5:142,764,291-142 ,764,272 
LD-NR3C1-F6 CCTGGCCCCCAATTTCATCC chr5:142,757,539-142 ,757,520 
LD-NR3C1-F7 TCCAGTCCTCCACCGCACCT chr5: 142,756,462-142 ,756,43 
LD-NR3C1-F8 TGCTCGCTGGATGCCCTTTC chr5: 142,753,382-142 ,753,363 
LD-NR3C1-F9 TCAGCTGTGGCCCCTTGACC chr5: 142,748,435-142 ,748,416 
LD-NR3C1-F1O* TTGCCCCTTTCCGCTCCTTC chr5: 142,743,537-142,743,518 
LD-NR3C1-F11 
LD-NR3C1-F12* 
TTGGGGTGGTGAACGGGAAG 
CCAGTTGGCTTCAGGCAGCA 
chr5: 142,737,741-142 ,737,722 
chr5: 142,735,491-142,735,472 
LD-NR3C1-F13 CATGCCACAACACAAAAGGGACA chr5:142,731,163-142  ,731,141 
LD-NR3C1-F14 CCCAAGGCCTGGGTGTGGAT chr5: 142,729,104-142,729,085 
LD-NR3C1-F15 GCCGAAACCCAGGGAAGCTG chr5:142,722,865-142 ,722 ,846 
LD-NR3C1-F16 AGCCATGGGGCCATTTACCG chr5: 142,720,920-142 ,720,901 
LD-NR3C1-F17 TGGAAGGGCCTCGGCATGTA chr5: 142,714,766-142,714,747 
LD-NR3C1-F18 TGGAAAGGGCGCAAGAACCA chr5: 142,712,692-142 ,712 ,673 
LD-NR3C1-F19 CCCCTGCCAGGCAACAGTCA chr5:142,705,789 -142 ,705,770 
LD-NR3C1-F20 TCATGATTGGAGGCAGGCACA chr5: 142,702,041-142,702 ,021 
LD-NR3C1-F21 GCCCGTATGACCGCATCCAG chr5:142,696,110-142 ,696,091 
LD-NR3C1-F22 CCGCATCCAGGGGTGATGAT chr5: 142,696,100-142,696,081 
Primer name Reverse primer Genome coordinates 
3q primer 	   	  
3q-R1 CCAGGGATGGGTCTGGGTGA chr3: 129,832,386-129 ,832,405 
* : breakpoint amplification 	   	  
used for breakpoint cloning 	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Table 54: RACE-PCR and RT-qPCR primers 
	  
	  
RACE-PCR 
Primer name Primer sequence 
	  
	  
Localisation 
NR3C1-3'RACE 
NR3C1-5'RACE 
TCTGGTTTTGTCAAGCCCCAGT 
TCCTGCTGTTGAGAAAGGGATGCTG 
NR3C1 exon 2 
NR3C1 exon 2 
	  
RT-PCR (fusion transcript isolation) 
Primer name 
	  
	  
Primer sequence 
NR3C1-Forw 
3Q-R1-Rev 
ATGGACTCCAAAGAATC 
TCAACGGTTTCTGGGTCTG 
	  
RT-qPCR (quantitative PCR) 
Primer name 
	  
	  
Primer sequence 
3Q-F1 
3Q-R1 
3Q-F2 
3Q-R2 
GGGCACTGCTTTGCTTTTGCTGT 
CTGAACCAACCTAGATTAATATTTTAGTATA 
AAATTGCCTGTTTGCTCCAC 
CAGAGTTTCTGAGGCCTTGC 
Results  
	  
	  
Table 55: PCR primers for fusion transcri pt molecular cloning and sequencing 
	  
	  
pcDNA3.1(+) Fusion Transcript cloning primers 
Primer name Primer sequence Restriction site 
ATG-NR3C1-F1 
3Q-R1 
(TAGCGGA TCCACC)A TGGACTCCAAAGAA  TC 
(TAGCGAATTCA)TCAACGGTTTCTGGGTCTG 
BamH1 
EcoR1 
	  
pEGFP-C1 Fusion Transcript cloning primers 
Primer name sequence Restriction site 
Ntag-NR3C1-F1 
3Q-R1 
(TAGCGGATCC)GACTCCAAAGAA  TC 
(TAGCGAATTCA)TCAACGGTTTCTGGGTCTG 
BamH1 
EcoR1 
	  
PCR pSFFV-HIV-(mRFP)-wPRE GFP-Fusion Transcri pt cloning primers 
Primer name sequence Restriction site 
BamHl-ATG-EGFP-FT-F1   (TAGCGGA TCCACC)A TGGTGAGCAAGGGC 
Xho1-TGA-EGFP-FT-R1 (CTCGAGAATTCA)TCAACGGTTTCTGGGTCTGAG 
BamH1 
Xhol 
	  
Sequencing primers for pSFFV-HIV-GFP-Fusion Transcript vector 
Primer name sequence 
GFP-TAAseq-F1 
GFP-ATGseq-R1 
HIV-SFFV-seq-R1 
AAGATCCGCCACAACATCG 
CTTCTCGTTGGGGTCTTTGC 
AATGAAAGCCATACGGGAAG 
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Table 56: PCR primers for Northern Blot probes amplifcation 
	  
Primer name 
	  
NR3C1_S_1 / NR3C1_AS_1* 
NR3C1_S_2 / NR3C1_AS_2 
NR3C1_S_3 / NR3C1_AS_3 
NR3C1_S_4 / NR3C1_AS_4 
* :anormal transcript detected 
Forward primer 
	  
GCCAGAGTTGATATTCACTG 
CTGTTCATGGTGTGAGTACC 
GCTGTATGTTTCCTCTGAG 
GACTGCCTTAATAAGAATGG 
Reverse primer 
	  
GGTACTCACACCATGAACAG 
CTCAGAGGAAACATACAGC 
CCATTCTTATTAAGGCAGTC 
GCCATATAGCCATTGCAAAAATAG 
Results  
	  
	  
Table 57: Sequence of short-hairpin 3q cloned in pLK0.1 vector (Addgene) 
	  
	  
Designed using DSIR algorithm (http ://biodev.cea.fr/DSIR website)   
Primer name Hairpin sequence (Agel -> EcoRI cloning) 
Sh-A sens            CCGGTCGGGTCTGAGATGTTGCATACAACTGCAGATGTATGCAACATCTCAGACCCTTTTTG 
Sh-A AS                AATTCAAAAAGGGT CTGAGATGTTGCATACAACTGCAGAT GTATGCAACATCTCAGACCCGA 
Sh-B sens       CCGGTCGCCTTTGGAGTGTCACCAAACACTGCAGAGTTTGGTGACACTCCAAAGGCT TTTTG 
Sh-B AS                AATTCAAAAAGCCTTTGGAGT GTCACCAAACACTGCAGAGTTTGGT GACACTCCAAAGGCG A 
Sh-C sens       CCGGTCGGAGCAGTCCATCAAGAATGAACTGCAGATCATTCTTGAT GGACTGCTCCTTTTTG Sh-
CAS             AATTCAAAAAGGAGCAGTCCA TCAAGAATGAACTGCAGATCATTCTTGATGGACTGCTCCGA 
	  
	  
Source :mRNA chosweyby.cApr07 
Loop (Pstl) :CTGCAG 
Results 119 
	  
	  
	  
Table 58: PCR primers for qChlP 
	  
	  
Gene promoter Forward primer Reverse primer 
HOXA5 
HOXA9 
HOXA11B 
GAGAGACTGGGCTCTGTTGG AGGGGGTCTAAGAGCTGGAG 
GCGAATGTCCCCTAATCAGA AGACAAGGCCTCGGTTATGA 
GAGTTTGAAGCCGTGGATGT TCGGAAGTGACCATGAATGA 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
General discussion and perspectives 
	  
	  
In a clinicaly  guided approach focused  on functional  genomic characterization  of a 
novel t(3;5)(q21;q32) translocation we have uncovered novel disease mechanisms cen- 
tering on the glucocorticoid receptor and a novel BET-inhibitor sensitive, long,  non- 
coding RNA in the pathogenesis of BPDCN. 
NR3C1 deletion is associated with poor prognosis and drives abnormal EZH2 sig- 
naling in BPDCN 
Our initial interest in our BPDCN case presenting a t(3;5) translocation stemmed 
from its high potential for discovery, by functional genomic analysis, of 5q-linked dis- 
ease mechanisms in BPDCN. Chromosome 5q deletions, outside of the 5q- syndrome, 
have been demonstrated to be associated with increased risk of leukemic transforma- 
tion in MDS and with very poor prognosis in AML (Byrd et al., 2002, Grimwade et al., 
2001).  Chromosome 5q loss is also prevalent in MDS and AML arising after previous 
cancer treatment with alkylating agents or radiotherapy (Bhadri et al., 2012, Pedersen- 
Bjergaard et al., 1990) suggesting strongly an important role for afected genes in 5q 
locus in leukemogenesis and leukemia  progression.  This hypothesis is supported  by 
numerous studies including the recent identification of a TRAF6-mediated NF-κB sig- 
naling survival network driven by 5q deletion in AML / MDS (Fang et al., 2014). 
Chromosome 5q deletion is one of the most recurent chromosomal abnormali- 
ties observed in BPDCN (Jardin et al., 2009, Leroux et al., 2002, Petrela et al., 2005). 
The  genes and gene-networks involved in  del(5q) in  BPDCN have  not  been investi- 
gated until this work.  Our molecular cytogenetic and gene cloning eforts of the t(3;5) 
pointed to NR3C1, as an important target gene in 5(q)-linked BPDCN pathogenesis. 
121 
Results 122 
	  
	  
	  
Indeed, the NR3C1 gene underwent recurent homozygous deletion in 13 of 17 (76%) 
5q-rearanged BPDCN cases. This included 1 case with focal NR3C1 deletion in addi- 
tion to the index case of reciprocal chromosomal translocation.  The later resulted in 
expression of a truncated GCR isoform, lacking the DNA and ligand binding domains. 
Importantly, our clinical data demonstrated that the loss of this gene is associated with 
a very poor outcome in BPDCN patients. In this work we demonstrated that glucocor- 
ticoid receptor expression levels are decreased in primary BPDCN samples presenting 
del(5q), compared to controls , suggesting a haploinsufficiency mechanism for GCR in 
del (5q) cases. 
Luciferase reporter assays of GCR activity, in the presence of the GCR fusion 
protein (GCRFP) resulted in reduced activity  of GCR transcriptional transactivation, 
suggestive of functional interference and a mechanism mimicking NR3C1 haploinsuf- 
ficiency in these cels. In vitro and in vivo, NR3C1 knock-down experiments to GCR 
levels similar to those found in del(5q) cases (i.e. 50%) are in process to further confirm 
these observations. 
Perturbed GCR signaling induces treatment resistance in BPDCN 
	  
	  
Cortico-resistance is a common feature in leukemic  disorders and it  has  been 
demonstrated that this can manifest as early cortico-resistance or cortico-resistance fol- 
lowing prolonged treatments  ultimately leading to relapse. NR3C1 deletion has  been 
associated to acquired corticoresistance in B-ALL (Mulighan et al., 2008) We assessed 
the biological consequence of truncated GCR to treatment response and discovered that 
it confers resistance to combination therapy with dexamethasone and etoposide. Consis- 
tent with this, gene set enrichment analysis (GESA) on dexamethasone treated CAL-1 
BPDCN GCR-FP-overexpressing cels compared to controls demonstrated a perturbed 
GCR signaling, accompanied with cortico-resistance signatures in B-ALL (Holeman 
et al., 2004). 
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Perturbed EZH2 and FOXP3 regulatory networks, a halmark of 5q alterations 
targeting NR3C1 gene in BPDCN 
A striking finding in  our  gene expression  profiling analysis in dexamethasone 
treated CAL-1 GCR-FP-overexpressing cels compared to controls was the discovery 
that functional  deficiencies in the  GCR signaling pathway provoked an EZH2 loss 
of function phenotype (Kondo et al., 2008, Takeda et al., 2006).  This was confirmed 
experimentaly  by  direct  demonstration  of  global loss  of  H3K27 trimethylation in 
the afected cels.  Furthermore, this was associated to loss  of  H3K27me3 at 
promoters of genes within the HOXA locus which is critical to hematopoiesis (Khan 
et al.,  2013) and frequently deregulated in  myeloid  malignancies consequent to 
mutations afecting components  of the  PRC2 complex (Abdel-Wahab et al.,  2012, 
Lawrence et al.,  1996). Importantly the EZH2 loss  of function signature was also 
evident in  primary  BPDCN patient transcriptomic  data  when classed according to 
NR3C1 deletion status. 
Further functional investigations, such as co-immunoprecipitation experiments 
would be needed to elucidate the precise molecular mechanisms responsible. 
A second striking finding was identification  of altered FOXP3 network signa- 
tures in our experimental system for NR3C1 deletion and in primary BPDCN patients 
with NR3C1 deletion versus non-deletion. Interestingly FOXP3 repressor functions 
appeared to be specificaly compromised. It has been demonstrated that transcription 
factor Foxp3 (forkhead  box  P3), is restricted in its expression to a specialized 
regulatory  CD4+ T- cel subset (TR)  which  maintain immune tolerance, suppress 
fatal inflammation, and controls TR lineage development and commitment through 
suppression of alternative lineage choices (Arvey et al., 2014, Fontenot and Rudensky, 
2005, Zheng et al., 2007). Recently FOXP3 expression was  demonstrated  not to  be 
restricted to the lymphocyte lineage and it has demonstrated to be expressed by some 
non-lymphoid  normal and cancerous cels (Martin et al.,  2010). Interestingly we 
observed expression of FOXP3 in  normal  pDC and BPDCN cel lines (Gen2.2 and 
CAL-1) and primary BPDCN samples, albeit at low levels. This suggests a regulatory 
function for FOXP3 in pDCs and that it is deregulated in leukemic samples. 
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FOXP3-bound sites in CD4 T helper cels have been demonstrated to present di- 
minished chromatin accessibility and selective deposition of histone H3 trimethylated 
at Lys27 (H3K27me3), and this is atributed to the capacity of FOXP3 to directly inter- 
act and recruit EZH2 to cognate sites (Arvey et al., 2014).  Thus loss of the repressive 
function  of FOXP3  might  occur as a consequence  of a feed forward inhibitory loop 
driven by NR3C1 / GCR haploinsufficiency in BPDCN. 
lincRNA-3q a novel leukemia driver in BPDCN and AML ? 
	  
	  
A second major finding from our clinicaly guided approach to BPDCN pathogen- 
esis was the discovery of a novel, nuclear lincRNA gene with potent anti-proliferative 
activities in BPDCN and AML. 
This lincRNA named here, lincRNA-3q, was ectopicaly expressed in of our BPD- 
CN primary cases and in high-risk AML, particularly those with 3q abnormalities (in- 
versions  or translocations).  This is  of keen interest  because AML with inv(3)/t(3;3) 
is known to  be associated with aberant expression  of the stem-cel regulator  gene 
Ecotropic viral integration site 1 (EVI1) located in 3q26.  This gene encodes a mem- 
ber of the SET/PR domain transcription factors.  Chromosomal rearangements afect- 
ing chromosome 3q26 activate EVI1 expression especialy in acute myeloid leukemia 
(AML) and myelodysplastic syndrome (MDS) (Goyama et al.,  2008). It  has  been 
demonstrated that this occurs consequent to repositioning of a distal GATA2 enhancer to 
the EV1 gene resulting in its ectopic activation (Groschel et al., 2014). This observation 
is of interest, since this “super enhancer” is located approximately 1Mb centromeric 
of lincRNA-3q and therefore in cases with  3q rearangements, the GATA2 enhancer 
could also impact the lincRNA-3q expression.  Further analysis would be necessary to 
verify this hypothesis by treatment with BET inhibitors which can decommission the 
GATA2 super enhancer also show marked suppression  of lincRNA-3q. Short  hairpin 
RNA (shRNA)  of lincRNA-3q caused a significant  G1/S cel cycle arest in  U937 
AML cels (U937). GEP analysis on KD and control cels folowed by GSEA revealed 
this to be linked to suppression of multiple proliferation genes many of which are driven 
by E2F-dependent promoters and to upregulation of E2F7/8, an inhibitory E2F family 
member. 
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The  E2F transcription factors function in cel cycle control and are intimately 
regulated  by RB (Chen et al.,  2009). In mammals, the E2F family comprises eight 
genes (E2F1–8),  which give rise to  nine  distinct  proteins. Deregulated  E2F activity 
is observed in the vast majority of human tumors and occurs through several diferent 
mechanisms. These proteins are categorized into subfamilies on the basis of their tran- 
scriptional activity, structure and interaction with Rb family members.  The “activator 
E2Fs” including E2F1, E2F2 and E2F3A, implicated mainly as gene expression acti- 
vators and interact only with  RB.  E2F4–8 largely function in the repression  of  gene 
expression and are generaly refered to as the “repressor E2Fs”. In the subfamily of re- 
pressor E2Fs, E2F4 and E2F5 repress gene expression in an RB family-dependent man- 
ner, whereas E2F6–8 exert transcriptional repression through distinct, Rb-independent, 
mechanisms.  Generaly speaking, activity  of the activator  E2Fs is required for cel 
proliferation, whereas the repressor E2Fs function in cel cycle exit and diferentiation 
(Figure 14) (Polager and Ginsberg, 2009). 
 
	  
	  
FIGURE 14: In quiescent (G0) cels, the ubiquitously expressed E2F4 and E2F5 as- 
sociate with pocket proteins and other corepressors to maintain repression of E2F- 
responsive genes (line labeled E2F target) that promote entry into the G1 phase of 
the cel cycle. Upon mitogenic stimulation, the sequential phosphorylation of RB by 
activated cyclin-dependent kinases results in the loss of RB function, release of E2F 
repressors and the accumulation of newly synthesized free E2F1, E2F2 and E2F3 late 
in G1 phase. Together, these events initiate a transcriptional program driving cels into 
S phase (dashed line labeled DNA replication). This G1/S-specific transcriptome is 
then atenuated upon completion of S phase in G2 by the action of the repressors E2F6, 
E2F7 and E2F8, which are thought to function independently of RB and RB-related 
proteins. From (Chen et al. 2009, Nat Rev Cancer) 
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This suggests that lincRNA-3q might control the transcriptional activity of E2F- 
bound genes. In order to confirm this, E2F-luciferase reporter assays in the presence or 
absence of a recombinant E2F and smal interfering RNA (siRNA) targeting lincRNA- 
3q are underway. Likewise, in vivo leukemia growth assays are planned to determine 
the impact of this lincRNA in leukemia progression in vivo. 
A major chalenge in the future wil be molecular dissection of how lincRNA-3q 
might influence E2F activity.  The first  possibility is that lincRNA-3q  directly binds 
E2F family members and either regulates their activity or stability. Indeed, previous 
studies have suggested that nuclear lncRNAs are associated with chromatin modifying 
complexes such as PRC2 (Khalil et al., 2009) and MLL (Wang et al., 2011). For exam- 
ple, HOTAIR, which is known for its role in promoting tumor metastasis (Gupta et al., 
2010), binds to EZH2/PRC2 and LSD1 to coordinate their function in epigeneticaly 
regulating gene expression (Tsai et al., 2010) and HOTTIP, regulates HOXA expression 
by interacting with the activating H3K4 methyl transferase, MLL1 complex on HOXA 
gene  promoters (Wang et al.,  2011). Hu et al  by  performing a  genome-wide survey 
on somatic copy-number alterations (SCNAs) of long noncoding RNA (lncRNA), iden- 
tified an oncogene, focaly amplified lncRNA on chromosome 1 (FAL1),  whose copy 
number and expression are corelated with outcomes in ovarian cancer. FAL1 binds to 
epigenetic repressor BMI1 and regulates its stability, controling the expression  of a 
number of genes including CDKN1A (Hu et al., 2014). 
Since our lincRNA-3q KD resulted in the repression of E2F target genes, we pro- 
pose the folowing model forlincRNA-3q in leukemogenesis. Under physiological con- 
ditions lincRNA-3q is expressed at low levels, which would favor normal G1/S progres- 
sion through balanced activity of activatory and inhibitory E2F members. In contrast, in 
leukemia, overproduction of lincRNA-3q might drive favor uncontroled G1/S progres- 
sion by constraining activity of inhibitory E2F members such as E2F7/8 (Figure 15). 
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FIGURE 15:  A proposed model of the functional consequence of lincRNA-3q expres- 
sion in leukemic cels 
	  
	  
Overview of experimental strategies for assessing nuclear lncRNA function 
	  
	  
The above direct interaction model could be assessed by performing RNA pul 
down assays, using in vitro transcribed biotinylated lincRNA-3q or RNA immunopre- 
cipitation assay (RIP)  using an anti-E2F antibody for example.  RIP is an antibody- 
based technique used to map RNA–protein interactions in vivo by immunoprecipitating 
the RNA binding protein (RBP) of interest together with its associated RNA and quan- 
tifying interaction with the transcript of interest versus control. 
The genome is regulated by trans-acting factors that bind to specific loci in chro- 
matin and in addition to proteins, as mentioned in the introduction, long non-coding 
RNAs can act on chromatin at sites distant from where they are transcribed (Simon, 
2013).  Numerous techniques that alow the identification “sans a  priori”  of the  pro- 
tein partners and chromatin-bound sequences of uncharacterized lncRNAs, such as our 
lincRNA-3q have emerged in recent years. These include RAP (RNA antisense purifica- 
tion) (Figure 16), CHART (capture hybridization analysis of RNA targets) (Figure 17) 
and ChIRP (chromatin isolation by RNA purification) (Figure 18), techniques. 
These techniques are al  based  on the same  principle,  which is to  use biotiny- 
lated oligonucleotides complementary to the RNA of interest, and pul down associated 
proteins, or more accurately, chromatin-bound RNA. This is then folowed by or mass 
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spectrometry and/or NGS to identify respectively the proteins associated with the RNA 
and the genomic locations at which those interactions occured (Engreitz et al., 2013). 
 
	  
	  
FIGURE 16: Schematic diagram of RAP. Biotinylated probes (blue) are hybridized to 
the target RNA (red) crosslinked to proteins and DNA. Gray inset: 120-mer antisense 
capture probes are designed to tile across the entire target RNA. From (Engreitz et al. 
2013, Science) 
	  
	  
An alternative technique encompassing many features  of the techniques men- 
tioned above is  domain-specific chromatin isolation  by RNA purification (dChIRP), 
which is a scalable technique that wil dissect pairwise RNA-RNA, RNA-protein and 
RNA-chromatin interactions at the level of individual RNA domains in living cels (Fig- 
ure 18) (Quinn et al., 2014). 
dChIRP can reveal lncRNA architecture and function with high precision and sen- 
sitivity (Quinn et al., 2014).  Therefore in order to characterize the chromatin-binding 
patern and interacting protein factors of lincRNA-3q, dChIRP would be a highly infor- 
mative technique. 
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FIGURE 17: CHART is a hybridization-based strategy that uses complementary 
oligonucleotides to purify the RNA together with its targets from reversibly cross- 
linked extracts. The cartoon here shows the scenario where the RNA is bound in direct 
contact with the DNA together with proteins,  but other configurations are also pos- 
sible. CHART-enriched material can be analyzed in various ways; the two examples 
depicted here are (Left) sequencing the DNA to determine genomic loci where the 
RNA is bound and (Right) analyzing the protein content by Western blot analysis. 
From (Simon et al, Proc Natl Acad Sci, 2011) 
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FIGURE 18: dChIRP uses antisense oligonucleotides to purify specific RNA domains 
and associated RNAs, proteins and chromatin. (a) dChIRP oligonucleotide design 
strategy. Biotinylated antisense oligonucleotide pools (OPs) are designed to tile spe- 
cific regions of the target RNA. (b) dChIRP workflow. To prepare chromatin, whole 
cels are cross-linked to preserve protein–nucleic acid interactions. Sonication is used 
to solubilize the nuclear fraction and shear nucleic acids. Next, the chromatin is sub- 
divided into equal samples. OPs are added to each sample, which hybridize to the 
targeted RNA fragments. The biotinylated oligonucleotides, RNA targets and cross- 
linked biomolecules are then purified on magnetic streptavidin beads, and unbound 
material is washed away. (c) RNA-, protein- and DNA-sensitive modalities of dChIRP. 
RNA, protein and DNA fractions are extracted from each dChIRP sample. Intra- or in- 
termolecular RNA-RNA, RNA-protein and RNA-DNA interactions may be measured 
by RT-qPCR, immunobloting, and qPCR or sequencing, respectively. From (Quinn et 
al. 2014, Nat Biotechnol) 
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lincRNA-3q BET-inhibitor sensitivity 
	  
	  
Molecular profiling approaches have revealed multiple abnormalities in the genes 
afecting DNA methylation and chromatin remodeling complexes in cancer cels. To- 
day epigenetic regulators represent a  promising new class  of therapeutic targets for 
cancer (Xu et al., 2012). In order to propose a drug capable of targeting lincRNA-3q, 
we assessed the inhibitory efect of JQ1, a BET inhibitor molecule on lincRNA-3q ex- 
pression levels. JQ1 treatment resulted in suppression of lincRNA-3q in a dose and time 
dependent manner in BPDCN (CAL-1) and AML (U937) cel lines. It is noteworthy 
that JQ1-mediated BET inhibition might partly be due to MYC suppression through dis- 
ruption of the ability of BET proteins to bind MYC locus (Zuber et al., 2011).  Since 
the suppressive efect on lincRNA-3q appeared as soon as 4 hours after beginning the 
treatment, we assumed a direct inhibitory efect of JQ1 on the expression of this gene. 
Although characterization of the precise mechanism involved requires further investi- 
gation (BET protein binding to the lincRNA-3q locus itself?), these results suggest a 
new-targeted therapeutic strategy that could be applied to BPDCN. 
In conclusion the molecular characterization and cytogenetic analysis of our BPD- 
CN cohort have permited the identification of two important genes in leukemogenesis 
of  BPDCN.  Our functional and  genomics analysis  highlighted the deviant GCR sig- 
naling, and unscheduled activation of lincRNA-3q, driving in part the deregulation of 
chromatin and transcription factor networks controling treatment resistance and ma- 
lignant reprogramming in the dendritic cel lineage.  Further studies wil be needed to 
fuly leverage these findings for treatment innovation in BPDCN and other myeloid and 
lymphoid cancers that share biological features with this disease. 
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